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ABSTRACT 
 Due to rapid growth in computing power, the collection of high dimensional and 
complex datasets is increasingly feasible. To reap their full benefit, novel analytic 
strategies may be required. Application of such methods remains limited in certain 
epidemiologic research areas. The overarching aim of this dissertation was to apply novel 
analytic strategies with close ties to causal inference and statistical learning theory to gain 
new insights into well-studied areas of perinatal epidemiology. In Study 1, we explored 
whether the association between short interpregnancy intervals (i.e., the end of one 
pregnancy to the start of the next) and increased risk of preterm birth may be due to 
residual confounding in three populations (n=693 American Indian and n=728 white 
women from the Northern Plains, U.S., and n=783 mixed ancestry women from the 
Western Cape, South Africa). Using data from the prospective Safe Passage cohort 
(2007-2015), we applied propensity score methods to control for a variety of 
sociodemographic and reproductive factors. A third-to-half of women with <6 months 
intervals had propensity scores that largely did not overlap with those of women with 18-
23 months intervals. Since the propensity score models included factors related to both 
 
 x 
interpregnancy interval and preterm birth, these findings suggest the possibility of strong 
confounding in all three populations. The pooled associational estimate with preterm 
birth was attenuated in the propensity score trimmed and weighted data (risk ratio 1.4, 
95% CI 0.75-2.6) compared with the crude results (risk ratio 1.7, 95% CI 1.1-2.7). 
However, the sample size and precision were reduced after propensity score trimming, 
and several covariates remained imbalanced. The data demonstrated the complexity of 
the processes leading to interpregnancy interval length. These issues may have been 
difficult to identify without comprehensive confounder data and with other methods, such 
as traditional regression adjustment. In Study 2, we examined the relative importance of 
timing (first trimester versus second/third trimesters) and degree of gestational weight 
gain in relation to infant size at birth (small-and-large-for-gestational age) among women 
with obesity using data from a medical records-based case-cohort study (Pittsburgh, PA, 
1998-2010). We operationalized serial antenatal weight measurements as above, below, 
or within the current recommended ranges for U.S. pregnancies, i.e., 0.2-2.0 kg total gain 
in the first trimester and 0.17-0.27 kg per week in the second and third trimesters (based 
on group based trajectory modeling). Data were analyzed by obesity class (n=1290 in the 
class I subcohort, n=1247 class II, n=1198 class III). Our findings supported the current 
clinical guidelines, except for women with class III obesity. Among women with class III 
obesity, lower than recommended gain in the second and third trimesters was associated 
with decreased risk of having a large-for-gestational age infant (adjusted risk ratio 0.76, 
95% CI 0.51-1.1), while not increasing small-for-gestational age (SGA) risk (adjusted 
risk ratio 1.0, 95% CI 0.63-1.7). Our results were in agreement with findings from several 
 
 xi 
other studies of women with obesity using other methodologies to operationalize 
gestational weight gain. In Study 3, we used hierarchical clustering to explore latent 
groups of placental pathology features. We also investigated whether the placental 
clusters, in addition to birthweight percentiles, were beneficial to explain the variability 
of select adverse pregnancy outcomes. Data were from the Safe Passage Study (same as 
Study 1, n=2005). We identified one cluster with low prevalence of abnormalities 
(60.9%) and three clusters that mapped well to the expert consensus-based Amsterdam 
criteria: severe maternal vascular malperfusion (5.8%), fetal vascular malperfusion 
(11.1%), and inflammation (22.1%). The clusters were weakly-to-moderately associated 
with certain antenatal risk factors, pregnancy complications, and neonatal outcomes. 
Birthweight percentiles plus the placental clusters was better able to explain the variance 
of select adverse outcomes, compared with using small-for-gestational age only. This 
study serves as proof-of-concept that machine learning methods, and placental data, may 
aid in the identification and etiologic study of certain adverse pregnancy outcomes. In 
sum, all three studies support that the application of novel analytic methods to high-
dimensional datasets may expand our understanding of certain causal questions, even 
ones that have been broached before, although, as seen in Study 2, such research may not 
always yield novel insights.   
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CHAPTER 1: Introduction 
 Over the past 50+ years, there have been increases in formalized and 
mathematized causal inference in epidemiology.1 By the mid-20th century, the types of 
research questions being addressed widened from a singular focus on infectious disease 
to include chronic, non-communicable diseases.1 This shift coincided with the expansion 
of the National Institutes of Health to conduct not only basic science research but also 
clinical studies.2 Under the biomedical model, there was increased focus in understanding 
the etiology of disease occurrence.2 Such questions required formalized assumptions and 
statistical models to study cause and effect.3 More recently, rapid growth in computing 
power have increased feasibility of the collection of high dimensional and complex 
datasets and their analysis using novel methodologies.4, 5  
It is believed that the methodological toolkit with which doctoral-trained 
epidemiologists are equipped will enable them to assess the complexity of causes of 
population health, and potentially obtain better answers to etiologic research questions.6 
For this reason, we chose to center on the application of novel methods in the present 
dissertation work. We specifically focused on topics in perinatal epidemiology with wide-
spanning prior research so there would be a wealth of literature to compare to our studies 
for comment. The remainder of the introduction summarizes the research questions and 





Study 1: Short Interpregnancy Intervals and Preterm Birth Risk: An Exploration of 
Confounding in Three Populations 
Adverse neonatal outcomes are more likely following short interpregnancy 
intervals.7, 8 Yet, it remains unclear whether these associations are causal.9, 10 It is 
unlikely a single biologic mechanism explains all observations and only minimal 
empirical data support proposed hypotheses (including nutrition and folate depletion, 
increased cervical insufficiency, and immune suppression).11 Interpregnancy interval 
length results from many factors, including fecundity, prior pregnancy/infant outcomes, 
health/childcare policies and access, and financial stability. Such data are minimal in vital 
statistics, on which most U.S. research is based. In Study 1, we explored whether the 
association between short interpregnancy intervals (often defined as <6 months between 
successive pregnancies) and increased risk of preterm birth may be due to confounding. 
Using data from the prospective Safe Passage cohort (2007-2015), we applied propensity 
score methods to control for a variety of sociodemographic and reproductive factors in 
three populations (i.e., American Indian and white women from the Northern Plains, 
U.S., women of mixed ancestry from the Western Cape, South Africa). Propensity scores 
were applied because we aimed to control for a larger number of covariates than 
traditional regression adjustment will allow.12 Propensity scores are the conditional 
predicted probabilities of exposure assignment (here, short versus reference 
interpregnancy interval length) based on measured covariate values.13 Various methods 
can be applied (e.g., matching, weighting) to control for the net bias from all of the 




index and reference groups should appear similar to one another with respect to measured 
covariates, similar to the covariate balance achieved through randomization in controlled 
trials. We know of only one other study of interpregnancy intervals that applied 
propensity scores.15 In that study, the propensity score-adjusted results were slightly 
attenuated compared with what was observed using more traditional approaches. 
However, in their study interpregnancy intervals were dichotomized at 9 months, making 
their results challenging to compare to prior research, where the primary index and 
reference groups are usually <6 months and 18-23 months. Further, in their study, the 
propensity score was treated as an additional covariate in adjusted regression models. 
This assumes a linear relationship between the propensity score and risk of the outcome, 
which may not be correct. To avoid this, in our study we applied a propensity score 
weighting approach, which does not require this assumption. 
 
Study 2: Timing and Amount of Gestational Weight Gain and Risks for Small-and Large-
for-Gestational Age among Women with Prepregnancy Obesity 
Given the recent increases in prepregnancy obesity, there is urgent need to 
understand how to optimize pregnancy outcomes among women with obesity.16 
Gestational weight gain—that is, weight gain during pregnancy—is a potentially 
modifiable risk factor for several adverse outcomes. Pregnancy weight gain may be 
affected by prepregnancy body-mass-index (BMI) and also contribute to long-term BMI, 
as not all weight may be shed postpartum.17 Unfortunately, for much of the prior research 




gestational weight gain was modeled. Total gestational weight gain (the simplest 
approach) may be biased when models are adjusted for gestational age at delivery, as 
women with shorter duration pregnancies have less time to gain weight. In Study 2, we 
examined the relative importance of timing (first versus second/third trimester) and 
degree of gestational weight gain in relation to infant size at birth (specifically, small-and 
large-for-gestational age) among women with obesity using data from a medical records-
based case-cohort study (Pittsburgh, PA, 1998-2010). For first trimester weight gain (start 
of pregnancy through 13 6/7 weeks’), we categorized total gain as below, within, or 
above the current U.S. recommendations of 0.2-2.0 kg. For second and third trimester 
weight gain (14 0/7 weeks’ through delivery), we used group-based trajectory modeling18 
to derive trajectories of gain per week, aiming to find at least one trajectory that 
approximated the current U.S. recommendations (0.17-0.27 kg per week). Latent class 
models, such as group-based trajectory modeling, have not been explored much in 
gestational weight gain research and can capitalize on serial antenatal measurements 
across pregnancy and may be less prone to bias associated with length of pregnancy and 
random measurement errors. 
 
Study 3: Placental Pathology Clusters, Growth, and Neonatal Outcomes 
 In the last study, we explored clusters of placental pathology in relation to infant 
size at birth. Fetal growth restriction is a complex condition where the fetus does not 
reach its innate growth potential, which can lead to problems in infancy and childhood.19  




challenging to study. The suspected primary cause of fetal growth restriction is placental 
insufficiency.20, 21  In Study 3, we used hierarchical clustering to explore latent clusters of 
placental pathology features and investigated whether the placental clusters, in additional 
to the full spectrum of infant weight percentiles (not strictly birthweight <10th percentile), 
may be beneficial to explain the variability of certain adverse pregnancy outcomes. Data 
were from the Safe Passage Study (same as Study 1).  Our study used similar 
methodology as research conducted by Stanek et al.22-24 However, in our study, we 
grouped together pregnancies with similar patterns across various placental features to 
create new participant categories for further analysis, whereas the Stanek et al. approach 
was purely descriptive in nature. 
 
Chapters 2-4 summarize each of the three aforementioned studies in detail. 
Chapter 5 provides a brief summary of the findings and a reflective comment with respect 
to the research questions, methods and their limitations, and implications for future 




CHAPTER 2: Short Interpregnancy Intervals and Preterm Birth Risk: An 
Exploration of Confounding in Three Populations 
INTRODUCTION 
Interpregnancy interval is the timing between the end of one pregnancy and the 
start of the next. Short interpregnancy intervals have been associated with obstetric 
complications25, 26 and adverse perinatal outcomes,7, 8 including preterm birth. Stronger 
associations have been observed in socioeconomically disadvantaged populations27 and 
among women with a history of preterm birth.28 A meta-analysis published in 2006 
reported a summary adjusted odds ratio (OR) of 1.4 [95% confidence interval (CI) 1.2-
1.6] for preterm birth, comparing intervals of <6 to 18-23 months.7 Similar strength 
associations were observed in an updated systematic review restricted to women from 
high resource settings [summary adjusted OR 1.5 (95% CI 1.4, 1.7)].8, 29  
Several hypothesized biological mechanisms have been proposed to explain these 
associations, including nutrition and folate depletion, increased cervical insufficiency, 
and immune suppression.11 Most hypotheses center on the notion that pregnancy puts 
stress on a mother’s body and becoming pregnant again after a short interval leaves 
insufficient time for her body to recover. This, in turn, increases the risks for adverse 
outcomes in the next pregnancy. Still, there does not seem to be a single biological 
mechanism that could explain the associations with all of the outcomes that have been 
observed, and empirical data to support any given hypothesis are limited. Preliminary 
data exists to support folate depletion—or nutritional depletion, in general—in the 




defects in the next pregnancy.30 These findings are bolstered by strong evidence, 
including randomized trials, supporting reductions in risks for some malformations, most 
notably neural tube defects, with folic acid intake.31, 32 However, whether (and which) 
nutritional factors play a role in the etiologic pathway(s) leading to preterm birth is not 
nearly as well established. Some observational research suggests some protection against 
preterm birth with supplementation,33 but randomized trials do not.34, 35 Observational 
studies are more susceptible than trials to bias from residual confounding. Specifically, 
women who supplement may tend to have healthier lifestyles, putting them at lower risk 
for preterm birth. Such lifestyle patterns may not be fully captured by the limited number 
of measured covariates available in some observational databases.   
In recent years, some investigators have called into question whether there is truly 
a biological mechanism between short interpregnancy intervals and certain outcomes, 
including preterm birth, or whether the association may be explained by social factors 
that are strongly related to birth spacing and adverse pregnancy outcomes.9, 10 This is an 
important question, because if birth spacing does not have a causal effect, interventions 
aimed at preventing short birth spacing (e.g., changes to clinical practice or postpartum 
contraception policies) will be ineffective in actually reducing rates of adverse outcomes 
in the population, and may result in unnecessary delay in childbearing for women of 
advanced maternal age. Currently, the American College of Obstetricians and 
Gynecologists (ACOG) strongly advises that women avoid interpregnancy intervals of <6 
months and also advises clinicians to counsel their patients on the risks associated with 




before attempting the next pregnancy, except when the prior pregnancy resulted in 
spontaneous or induced abortion, in which case women should wait at least 6 months.37  
Most U.S.-based studies have used vital records or registries and commonly 
adjusted for demographic characteristics, such as maternal age and race, available aspects 
of reproductive history, and behavioral factors like smoking status. Recent sibling case-
crossover designs, which may have better control for non-time-varying social factors, 
found attenuated associations, with adjusted ORs ranging from 0.85-1.2 for comparisons 
of <6 months to 18-23 months intervals.38-41 However, these designs have their own 
limitations (e.g., generalizability and inability to control for birth order as it will always 
differ between the first and second pregnancies).42 Further, there is still potential for 
residual confounding by uncontrolled factors that are likely to change from pregnancy-to-
pregnancy.42 Experts have ruled that the sibling case-crossover research is still not 
compelling enough to rule out the potential for a biological association, and that better 
confounding control in conventional cohort studies is needed to inform policy 
recommendations.8, 43  
An expert panel arranged by the U.S. Office for Population Affairs published best 
practices for this research area.42 They emphasized the importance of explicitly stating 
the hypothesized causal structure via directed acyclic graphs when the goal is to 
understand etiological relationships. Confounding by socioeconomic status, pregnancy 
intention and prior outcome (e.g., stillbirth, neonatal death), which have been linked to 
both birth spacing44, 45 and future pregnancy outcomes,46 should be considered, along 




Using data from the Safe Passage Study, a prospective pregnancy cohort 
(Northern Plains, U.S., and Western Cape, South Africa, 2007-2015), we examined the 
relation between short interpregnancy intervals and subsequent preterm birth, comparing 
traditional regression adjustment controlling for a selection of typically measured 
confounders to a propensity score method controlling for a wider array of social and 
reproductive factors. We hypothesized that, using traditional regression adjustment, we 
would observe a modest (~50%) increase in preterm birth risk associated with 
interpregnancy intervals of <6 months versus 18-23 months intervals, as has been 
observed in prior cohort studies. In contrast, we hypothesized the observed association 
would be attenuated or even absent in the propensity score adjusted models, suggesting 
that the biological mechanism is weaker than previously thought, and other reproductive 
and social factors are the predominant force that puts subsequent pregnancies with short 




The Safe Passage Study (2007-2015) was a prospective pregnancy cohort 
originally designed to evaluate the associations between drinking and smoking during 
pregnancy and risks of stillbirth and sudden infant death syndrome (SIDS).47, 48 Women 
from North and South Dakota, U.S., and the Western Cape, South Africa, were 
prospectively enrolled during pregnancy as early as 6 weeks’ gestation and followed 




participants identified as one of three racial groups: in the U.S., white (23%) or American 
Indian (17%) and in South Africa, mixed ancestry (58%). The American Indian and 
mixed ancestry populations were specifically targeted because they tend to have higher 
rates of prenatal drinking and smoking and SIDS.49, 50 They also were disproportionately 
composed of women of lower income and educational attainment. The white study 
participants, on the other hand, represented a group that was more generalizable to the 
general U.S. population of white women.  
Enrolled women completed up to 4 in-person study visits during pregnancy, 
which comprised standardized questionnaires, mental health batteries, and physiological 
assessments of the mother and fetus, in addition to their standard clinical antenatal visits. 
The questionnaires collected data on demographic characteristics, reproductive and 
medical history, and lifestyle and behaviors. In addition, data were collected through 
delivery via medical chart abstraction. The research was approved by affiliated 
institutional review boards (IRBs) and, in the U.S., by local tribal research review 
boards.51  
 
Consent and Eligibility 
Women were approached at antenatal clinics. Those who were willing provided 
written informed consent and were further screened to confirm eligibility. The eligibility 
criteria are detailed elsewhere.47 In brief, women had to be at least 16 years of age, 
pregnant with no more than two fetuses, and able to speak English or Afrikaans, with no 




ranged from 54% to 99% depending on the clinical site. Consent rates were lowest 
among sites that were predominantly white and highest among those that were 
predominantly American Indian. The most common reasons for refusal were ‘not 
interested’ and ‘lack of time’.  
This analysis was restricted to multiparous participants whose most recent 
pregnancy lasted at least 20 weeks’ gestation and whose interpregnancy interval was 23 
months or less. We excluded women whose prior pregnancy lasted <20 weeks’ because 
short interpregnancy intervals following miscarriage or termination have not been 
associated with increased risk of preterm birth in the next pregnancy.52, 53 This may be 
because a pregnancy duration of <20 weeks’ is not substantial enough for the biological 
mechanism, if present, to have an effect. Longer interval comparisons of ≥24 months 
were not of primary interest for our research question and may be due to another 
mechanism (e.g., decrease in fecundability associated with advancing maternal age). We 
also excluded women who were pregnant with more than one fetus during the study 
pregnancy, as associations may be different for twin pregnancies. 
 
Interpregnancy Interval 
The 20-24 weeks’ maternal interview included recall of complete reproductive 
history, including the timing of all live births, stillbirths, ectopic pregnancies, and 
spontaneous and induced abortions. When the day of the prior delivery was missing but 
the month and year were recorded (6%), we replaced the missing day with the 15th day of 




and days (continuous) or as a category (full term ≥37 weeks’, 32-36 weeks’, 20-31 
weeks’, <20 weeks’). Less than 1% of women were missing information on duration of 
the prior pregnancy. For the subset of women without the interview data or with missing 
month or year of the previous pregnancies (~3%), dates of delivery outcomes were 
abstracted from the medical record. We assumed that all deliveries captured in the chart 
abstractions lasted at least 20 weeks’ because the abstractors were instructed to not record 
dates of elective or spontaneous abortions. We restricted to women whose prior 
pregnancy lasted at least 20 weeks’ gestation. Interpregnancy interval was defined as 
time between the prior delivery and estimated start of the study pregnancy (see Preterm 
Birth section). We excluded women whose interpregnancy interval computation resulted 
in a negative value (<1%). The analysis used a categorical version of interpregnancy 
interval in months (i.e., <6, 6-11, 12-17, 18-23) with the primary comparison being <6 
months versus 18-23 months. We selected these cut points for the interpregnancy interval 
categories and this primary comparison to be comparable to prior studies.7, 8  
 
Preterm Birth 
The estimated start of the study pregnancy was defined as the delivery date (from 
the medical record) minus the estimated gestational length (in days). Gestational age was 
determined at study enrollment and estimated based on standard local clinical practice 
(i.e., obstetric ultrasound in South Africa; clinical evaluation based on clinical 
examination, obstetric ultrasound, and last menstrual period in the U.S.). We excluded 




was preterm birth, i.e., delivery of the study pregnancy before 37 completed weeks’ 
gestation. Study personnel were verbally notified of each delivery in real time by the 
local medical facilities, so that they could complete the study procedures (e.g., specimen 
collection). The date, outcome, and details of each delivery were later confirmed during 
medical record abstraction. The secondary outcome was spontaneous preterm birth, 
defined as preterm birth among deliveries with spontaneous onset of labor or spontaneous 
rupture of membranes as indicated in the medical record. 
 
Covariates 
The Safe Passage Study collected data on a wide range of sociodemographic, 
economic, and lifestyle factors and reproductive and medical history. We identified 
potential confounders of association between short interpregnancy intervals and preterm 
birth based on a priori knowledge and hypothesized causal structure (Figure 2.1). 
Demographic and social factors included maternal age at the time of the prior delivery 
(<20, 20-24, 25-29, ≥30 years), partner status (living together versus not, since civil 
marriage is not as common in some of these populations), self-identified race (American 
Indian, white, mixed ancestry) and ethnicity (Hispanic, U.S. only), maternal and paternal 
education (did not complete high school, high school graduate, some college or 
professional school), maternal and paternal employment (yes/no), number of hours 
worked per week, monthly household income (originally collected in seven categories, 
converted to quartiles), number of people contributing to and supported by the income, 




recipient of government support during the study pregnancy [i.e., in the U.S.: food 
stamps, Women Infants and Children (WIC) assistance, Temporary Assistance for Needy 
Families (TANF); in South Africa: “All Pay” (formerly “180”)  or child support grant], 
recipient of alimony/child support, recipient of another form of financial support, 
residential type, crowding index, household amenities (electricity, phone/cell service, 
running water, toilet), and one (or more) residential moves in the year prior to the study 
pregnancy. Reproductive factors included gravidity prior to the study pregnancy (number 
of pregnancies occurring prior to the study pregnancy, modeled as 1 or >1),  parity 
(number of pregnancies lasting at least 20 weeks’ prior to the study pregnancy, modeled 
as 1 or >1), any history of miscarriage or stillbirth, and any history of preterm birth, as 
well as features of the prior pregnancy, including outcome (live birth versus stillbirth or 
neonatal death), year of delivery, duration (20-31 weeks’, 32-36 weeks’, ≥37 weeks’), 
and any complications (gestational diabetes, preeclampsia, placenta previa, placental 
abruption, preterm premature rupture of membranes). A proxy of intention for the study 
pregnancy was defined as women who reported that they recognized the pregnancy 
within the first 6 weeks’, started prenatal care during the first trimester (based on the 
medical record), and did not report using oral contraceptives or spermicides during the 
periconceptional period.54, 55 Subfertility was evaluated by use of fertility treatment noted 
in the medical record, as no information was collected on time-to-pregnancy. Lifestyle 
and behavioral factors included any multivitamin or folic acid supplementation during the 
periconceptional period, estimated dietary folate equivalents based on food frequency 




smoking in the year prior to the study pregnancy, any illicit drug use in the year prior to 
the study pregnancy, and a measure of secondhand smoke (i.e., presence of other 
individuals who smoked inside the household or workplace). Maternal medical history 
included diagnosis of the following conditions prior to the study pregnancy: diabetes 
mellitus (type I or II, not gestational), chronic hypertension (not pregnancy-related), 
anemia, depression, anxiety or other mental disorder, and more rare conditions (heart 
disease, hyperthyroid, hypothyroid, cancer). We adjusted for the aforementioned 
behavioral and lifestyle factors and medical history because they may be important 
confounders, given their relationships with interpregnancy interval length and increased 
risk of preterm birth. However, we recognize that these factors may also biologically 
interact with and exacerbate the biological effects of short interpregnancy intervals, if 
present (see Limitations section). We anticipated that medical conditions would tend to 
be under-diagnosed in South Africa as there is no standard screening for many of these 
conditions. All of the social, reproductive, and lifestyle factors, unless otherwise noted, 
were defined based on maternal report during the standardized questionnaires. History of 
medical conditions was based on a combination of maternal report and comorbidities 
indicated in the medical record. Lastly, we also considered control for study center (5 in 
U.S., 1 in South Africa), as it may be a proxy for other measured factors common to each 
catchment area (e.g., local policies, clinical practices, healthcare access). Some variable 
subcategories not specified above (such as, maternal age 30-34 and ≥35 years) were 






First, we conducted a descriptive analysis, evaluating the distributions of the 
interpregnancy intervals, gestational ages at study delivery, and aforementioned 
covariates. A priori we hypothesized that there would not be major heterogeneity of the 
biological association between interpregnancy interval and preterm birth risk by 
race/study setting, if present. However, the three groups had very different exposure, 
outcome, and covariate distributions, supporting that these are three distinct populations, 
and may have their own unique confounding structures. Thus, we decided to impute 
missing data and develop the propensity scores separately by race/study setting because it 
seemed important in order to accomplish the primary goal of our study (i.e., to control for 
confounding).   
 
Imputation for Missing Data 
Minimal missing data were expected since most of these covariates were 
ascertained during the 20-24 weeks’ interview (and most participants were enrolled by 
then) or from the medical record (which was available on nearly all participants). 
However, when covariate data were missing, we used multiple imputation to replace 
missing values. Imputation was done separately by each race/study setting group. We 
generated 10 imputed datasets and took the mean (or most frequent) value. This approach 
was selected since it is less computationally intensive, and allowed us to investigate the 
steps for data reduction prior to building our propensity score models, although may be 








Propensity scores are the conditional predicted probabilities of exposure 
assignment (here, short versus reference interpregnancy interval category) based on 
measured covariate values, and range from 0 to 1.13 We decided to apply propensity 
scores because propensity scores should allow us to control for more factors than 
traditional regression covariate adjustment, which is prone to model convergence issues, 
notably in stratified analysis.12 Further, propensity score weighting estimates the marginal 
associational effect, which theoretically should more closely approximate the 
confounding control achieved through randomization.13, 59 In comparison, traditional 
regression covariate adjustment estimates the conditional effect (i.e., the association 
averaged across all the combinations of covariates included in the model). 
 
Data Reduction 
We conducted a data reduction process to determine which of the aforementioned 
covariates would be included in the propensity score models to avoid unnecessarily large 
variances.60 We generated contingency tables of the covariate distributions by 
interpregnancy interval and by preterm to visually assess the distribution of the data. To 
avoid issues with model convergence and overfit, we excluded variables that were rare 




confounders, which by our definition were factors associated with both the exposure and 
outcome, antecedent to the outcome (ruling out the possibility of being a common effect), 
and not on the causal pathway.61 Inclusion of instrumental variables (i.e., covariates 
associated with the exposure but not the outcome) can increase variance62, 63 and bias in 
the presence of unmeasured confounding.63-66 To determine which variables were 
associated with both the exposure and outcome, in addition to applying a priori causal 
knowledge,67 we estimated standardized differences between each predictor and 
interpregnancy interval and preterm birth. We only selected variables whose standardized 
differences for both the exposure and outcome were >0.20. This cutoff was chosen as it 
represents a small but not necessarily trivial difference.68, 69 Lastly, to avoid highly 
collinear data, we did a visual inspection of contingency tables and via Pearson 
correlation coefficients between combinations of the candidate covariates. Collinearity 
did not appear to be a major issue once we had reduced down the candidate variables, so 
we did not perform formal diagnostic testing with statistical thresholds for collinearity.   
 
Propensity Score Models 
To create the propensity scores, we first created subgrouping for each of the three 
interpregnancy contrasts (<6 versus 18-23 months, 6-11 versus 18-23 months, 12-17 
versus 18-23 months). Following, we used multivariable logistic regression to generate 
predicted probabilities for being in each index group, versus the reference group, based 
on a given woman’s covariate values. This process yielded one propensity score for each 




woman in the reference group (18-23 months), representing the predicted probabilities for 
the three respective index groups. The sample from the reference group and the weight 
assigned differed for each comparison, because the propensity score creation, trimming, 
and weighting (as detailed below) was done separately for each of the three contrasts (<6 
versus 18-23 months, 6-11 versus 18-23 months, and 12-17 versus 18-23 months). 
 
Model Fit 
We evaluated model discrimination—that is how well the propensity score 
models were able to distinguish between women in each of the exposure contrasts—
based on the C-statistic. It should be noted that we did not use the C-statistic to detect if 
an important confounder was missing or if a certain covariate should be included in the 
model, as it does not provide such information.70 We also reviewed standardized betas to 
assess the relative influence of each covariate on the predicted probabilities. Standardized 
betas >0.2 were considered notable predictors. 
 
Propensity Score Weighting 
 There are two primary methods to control for confounding using propensity 
scores: matching and weighting. Initially, we considered using 1:1 matching on the 
propensity scores because matching has been shown to be superior to the weighting based 
on stratification by 5 strata.71, 72 However, we ultimately chose a weighting method based 
on the standardized mortality ratio (SMR), also known as “weighting by the odds,”73, 74 




is rare.75 This element was important for our analysis because <6 months intervals were 
rare (<10% of the data) among women of mixed ancestry, even when the sample 
comprised only women with <6 months or 18-23 months intervals. Specifically, the 
weights assigned were:76 
 index group = 1 
 reference group = the propensity score / (1 – the propensity score)  
For instance, a woman in the reference group with a propensity score of 0.78 would be 
up-weighted (weight=3.55) because the woman appears more like women in the index 
group based on the covariates included in the propensity score model (hence the higher 
propensity score). In comparison, women in the reference group with a lower propensity 
score of 0.21 would be down-weighted (weight=0.27) because they look less like women 
in the index group.  
 
Trimming 
We generated statistics to assess the distribution of the propensity scores for each 
exposure contrast. If the maximum value for the index group exceeded the maximum 
value for the reference group, or if the minimum value for the reference group was lower 
than the minimum value for the index group, we excluded women in these extreme non-
overlapping regions of the propensity score distributions. This process is known as 
‘trimming’ and tends to discard women with deterministic propensity scores (close to 1 
or 0). In addition, trimming should theoretically result in excluding women who have no 




scores above the highest value for any women with intervals of 18-23 months, these 
women would be trimmed because there is no one in the 18-23 month group that could 
represent what would have happened to those with <6 months intervals had they instead, 
contrary to fact, had 18-23 months intervals. The trimming process should improve the 
internal validity of propensity score adjusted estimates, although statistical efficiency 
may be harmed due to reduced sample size.14  
We also trimmed to avoid extreme weights (≥6 or ≤0.16), so that no woman in the 
reference group could stand in for more than 5 women in the index group or be down-
weighted to represent <0.16 of a woman. Extreme weighting can be problematic. If a 
woman has a weight of 6, it means that her data will be duplicated 6 times in the 
weighted sample. Such extreme up-weighting can be problematic if those individuals 
have outlier values. Very low weights, on the other hand, mean that the data are 
contributing very little. Low extreme weights can be problematic when the outcome is 
rare (as is the case for preterm birth and spontaneous preterm birth within some of our 
groups under study) because several outcomes would need to occur before they would be 
counted as one event. Note that there is a newer method to down-weight all extreme 
weights without completely trimming them off.77 However, we did not employ this 
method.  
After trimming, the index and reference groups should be more similar with 
respect to the distributions of the covariates included in the propensity score models, and 
after applying the weights, covariate distributions should be nearly identical. Thus, 




between these factors and the exposure should be removed. To evaluate covariate balance 
qualitatively, we visually compared the propensity score and covariate distributions in the 
entire cohort, after trimming, and after trimming and weighting. We also evaluated 
covariate balance quantitatively by calculating and comparing standardized differences 
between the index and reference groups for all covariates before and after applying the 
propensity score trimming and weights.76  Note that imbalanced covariates that are not 
(strong) risk factors for preterm birth may be acceptable.78  
 
Associational Estimates with Preterm Birth 
We estimated crude and adjusted associations between interpregnancy interval 
length and preterm birth risk stratified by race/study setting, as well as overall, pooled 
across the three race/study setting groups. To quantify the associations, we used modified 
Poisson regression to estimate risk ratios (RRs) and associated 95% CIs.79, 80 We 
estimated risk ratios rather than rate ratios to be comparable to prior studies. We used a 
Poisson regression approach because it tends to encounter fewer issues with convergence 
in adjusted models, compared with log binomial regression,81 and performs better in the 
presence of outliers82 and model misspecification.83 The “modified” refers to using a 
robust error variance approach, known as sandwich estimation, to estimate the 95% CIs,84 
which is supposed to yield correct coverage with Poisson regression. Without 
modification, the error would be overestimated.85 The method we used also accounted for 
the non-independence between observations due to the up-weighting of participants in the 




fewer than 3 events in the index or reference group or if the models did not converge.  
We generated crude and adjusted estimates controlling for a traditional subset of 
confounders. The covariates selected for the multivariable models included maternal age 
at prior delivery, outcome of prior pregnancy (stillbirth or neonatal death), parity (>1 
versus 1, prior to the study pregnancy), and smoking status. In a prior systematic review 
of short intervals and adverse neonatal outcomes in high resource settings,8 these four 
covariates were the most commonly adjusted variables in 9 cohort studies that were 
identified evaluating associations between <6 versus 18-23 months intervals and preterm 
birth. In stratified and pooled analyses, we also controlled for self-reported racial group 
(through stratification and multivariable regression adjustment, respectively). We 
compared the RR point estimates and whether the regions of the 95% CIs were similar 
across the crude and adjusted traditional regression models, the propensity score trimmed 
models, and the propensity score trimmed and weighted models.  
 
Sensitivity Analyses 
Propensity Score Methods 
In sensitivity analyses, we assessed how the propensity scores and propensity 
score-adjusted estimates changed when all covariates were included in the propensity 
score models. We also assessed whether retaining women with extreme down-weights 
(<0.16) affected the estimates. In addition, we assessed whether there were differences 
applying fine stratification-based weights with 20 strata instead of the SMR weighting 




a potential confounder in the relation between short interpregnancy intervals and preterm 
birth. Ideally, one would measure BMI at the end of the prior pregnancy to control for 
confounding. BMI can change between pregnancies, and change in BMI has been found 
to be associated with the length of the interpregnancy interval and subsequent pregnancy 
complications and outcomes.86-88 We had complete data on BMI at study enrollment and 
incomplete self-reported data on BMI at the start of the study pregnancy but no data on 
BMI at the end of the prior pregnancy. Due to concerns regarding this timing issue as 
well as the potential of controlling for a causal intermediate, we adjusted for BMI in 
sensitivity analyses only.  
 
Eligibility Criteria 
The primary analysis was restricted to study pregnancies that resulted in live 
birth. However, there is controversy regarding whether or not stillbirths should be 
included in estimates of preterm birth, notably for impoverished countries with higher 
rates of neonatal loss.89, 90 Thus, in sensitivity analysis of the South Africa data, stillbirths 
(occurring at ≥20 weeks’) were also included. Lastly, while most women enrolled prior to 
24 weeks’ gestation, some enrolled later in gestation. This was more common in South 
Africa. This timing issue could have resulted in left truncation where women with 
preterm birth, notably early preterm birth, might be less likely to be included in the 
observed sample.91 To try to assess the impact of this possible bias, we restricted the 





Collapsed Interpregnancy Interval Categories 
In our last sensitivity analysis, we collapsed the two shortest interval groups (<6 months 
and 6-11 months) to be one group (<12 months) and evaluated how our interpretation of 
the findings would change.  
 
RESULTS 
Of the 11,892 women enrolled in the Safe Passage Study, 1.5% had unknown 
gravidity (4.7% American Indian, 2.0% white, 0.4% mixed ancestry,), and 31.3% had 
never been pregnant before (20.8% American Indian, 28.9% white, 35.4% mixed 
ancestry). Of the remaining women, 4.9% lacked sufficient data to calculate 
interpregnancy interval (2.9% American Indian, 1.9% white, 6.8% mixed ancestry). Upon 
excluding the 15.3% whose prior pregnancy ended in miscarriage or early termination, 
there were 1310 American Indian, 1438 white, and 3636 mixed ancestry women whose 
prior pregnancy lasted at least 20 weeks’ (Figure 2.2). Short intervals of <6 months 
occurred in 14.8%, 4.0%, and 1.2% of American Indian, white, and mixed ancestry 
women, respectively. Lastly, we excluded women whose intervals were ≥24 months 
(43.7% American Indian, 47.6% white, 77.9% mixed ancestry), 1.3% twin pregnancies, 
0.9% with unknown gestational age delivery, 1.0% of other or unknown race, and 0.9% 
that resulted in miscarriage in the study pregnancy. An additional 0.9% resulted in 
stillbirth and were excluded from the primary analysis (0.9% American Indian, 1.4% 
mixed ancestry, and 0.6% white). The final analytic sample for the primary analysis 




mixed ancestry, and 728 (33.0%) were white. 
 
Analytic Sample Description 
The distribution of interpregnancy interval categories differed by race/study 
setting. Short interpregnancy intervals were the most common among the American 
Indian women (26.5% <6 months, 30.3% 6-11 months, 25.9% 12-17 months, and 17.4% 
18-23 months). For white women, the most frequent category was 12-17 months (7.5% 
<6 months, 28.0% 6-11 months, 34.9% 12-17 months, and 29.6% 18-23 months). 
Women of mixed ancestry tended to have the longest intervals (5.2% <6 months, 15.1% 
6-11 months, 37.2% 12-17 months, and 42.6% 18-23 months).  
The median gestational age at delivery was 39 0/7 weeks’ for both American 
Indian and mixed ancestry women and 39 2/7 weeks’ for white women (minimum 20 2/7 
weeks’; maximum 45 1/7 weeks’). Preterm birth occurred in 12.7%, 7.1%, and 13.4% of 
American Indian, white, and mixed ancestry women, respectively. Of these, 81.8%, 
67.3%, and 81.9% were spontaneous. In other words, preterm birth was almost twice as 
common among American Indian and mixed ancestry women, compared with white 
women, and a third of the preterm deliveries among white women were due to medical 
intervention.  
The American Indian and mixed ancestry women tended to be younger in their 
prior pregnancy (62.7% and 58.2% ≤24 years, respectively, compared with 26.8% among 
white women). They were also less likely to be living with their partner (61.0% and 




more likely to live in crowded conditions (crowding index >1, 50.8% and 77.3% versus 
4.3%). For the U.S. samples, the American Indian women had lower income compared 
with white women and were more likely to receive forms of government support (e.g., 
WIC 85.0% versus 22.3%).  
American Indian and mixed ancestry women had higher gravidity (>1 prior to 
study pregnancy 72.3% and 63.5% versus 53.7%) and were less likely to have a planned 
study pregnancy (based on our proxy) (38.5% and 13.0% versus 87.9%). Having a 
stillbirth or neonatal death in the prior pregnancy was more common among women of 
mixed ancestry (10.0%) than American Indian and white women (2.3% and 2.1%, 
respectively).  
Cigarette smoking during the prior year was more common among American 
Indian and mixed ancestry women (64.9% and 69.7%) than white women (17.3%). 
Exposure to secondhand smoke was also more common among these two groups. 
Conversely, any alcohol consumption in the year prior to the study pregnancy was more 
common among white women (86.7%) compared with American Indian and mixed 
ancestry women (70.1% and 61.7%). Maternal BMI was lowest among women of mixed 
ancestry (65.2% underweight or normal weight); the most frequent BMI category among 
white women was normal weight (39.9%); and American Indian women tended to have 





Differences in Covariates by Interpregnancy Interval Categories 
The characteristics of women with shorter intervals differed from those with 
longer intervals (Table 2.1). The most pronounced differences were observed for white 
women with intervals of <6 months versus 18-23 months, with 28/51 characteristics 
having absolute standardized differences >0.20 (Table 2.2). Specifically, white women 
with intervals of <6 months had lower partner education, were less likely to be employed, 
had lower income, were more likely to receive government financial support (including 
WIC and food stamps), and were less likely to have private (versus public) insurance, to 
have moved within the prior year, and to have consumed alcohol in the year before the 
study pregnancy (standardized differences >0.5). In addition, mothers with <6 months 
intervals tended to have lower education, worked fewer hours, and had more people in 
contributing to the household income (perhaps because of higher parity or because some 
of the younger mothers lived with parents or other relatives). They also were more likely 
to have an unplanned pregnancy, to have the prior pregnancy resulting in a stillbirth or 
neonatal death, and to have a history of anxiety, and were more likely to smoke. 
Standardized differences for these characteristics were 0.3-0.5.  
Although less pronounced, differences were also noted for American Indian 
women with <6 months intervals versus those with 18-23 months intervals, with 18/51 
characteristics having standardized differences >0.20 (Tables 2.1 and 2.2). The observed 
patterns tended to be similar to those observed among white women, although the 
differences tended to be less extreme, perhaps because the American Indian sample was 




Indian women with short intervals tended to be older, to have higher gravidity, and to 
have more people supported by the household income and living in the home, and were 
more likely to have a history of miscarriage or stillbirth. Lastly, they tended to have less 
education, were less likely to work and tended to work fewer hours. Standardized 
differences for these characteristics were 0.3-0.5.  
Among women of mixed ancestry, 20/47 characteristics had standardized 
differences >0.20 for comparisons of <6 to 18-23 months intervals (Tables 2.1 and 2.2). 
The largest differences were observed for reproductive characteristics. Specifically, 
women with <6 month intervals were more likely have a prior pregnancy resulting in 
stillbirth or neonatal death, to have a history of miscarriage or stillbirth, and to have the 
prior delivery be preterm (standardized differences >0.5). In addition, women with <6 
months intervals had different patterns of partner education than women with 18-23 
months intervals and were more likely to have moved in the past year. Unlike the U.S., 
South African women with <6 months intervals were less likely to receive financial 
support from the government, tended to have lower crowding indices, and were more 
likely to have consumed alcohol in the prior year. Standardized differences for these 
characteristics were 0.3-0.5. 
All racial groups had notable differences in year of prior delivery depending on 
the interpregnancy interval. This difference was likely by design, due to the fact that the 
study period was fairly short (10 years). It would not have been possible to have a short 
interpregnancy interval for earlier years (because the pregnancy would have occurred 




would have been not be possible to have a longer interval for later years (because these 
pregnancies would have occurred after the enrollment period had ended). In addition, for 
the U.S. women, there were differences by study center, which may be a proxy for 
differences in state policies, urban versus rural (or reservation versus non-reservation) 
settings, access, and provider practices.  
For 6-11 months and 12-17 months versus 18-23 months interval comparisons, 
there were fewer covariate differences (Tables 2.1 and 2.2). For 6-11 versus 18-23 
months, American Indian women had 16/51 covariates, white women had 14/51 
covariates, and mixed ancestry women had 5/47 covariates with standardized differences 
>0.20. For 12-17 versus 18-23 months, American Indian women had 10/51 covariates, 
white women had 6/51 covariates, and mixed ancestry women had 1 covariate with 
standardized differences >0.20.  
 
Propensity Score Creation 
After exclusion for rare covariates, factors unrelated to both short intervals and 
preterm birth, and highly collinear variables, the following factors were retained for the 
propensity score models: for American Indian women (12 covariates), maternal age, 
maternal education, maternal employment, number of people living inside the home, 
other financial support, insurance type, planned pregnancy, history of miscarriage or 
stillbirth, cigarette and alcohol frequency in the year prior to pregnancy, environmental 
smoking exposure, and study center; for white women (10 covariates), maternal age, 




the mother, planned pregnancy, history of preterm birth, cigarette or alcohol use 
frequency in the year prior to pregnancy, and prior delivery year; and for mixed ancestry 
women (9 covariates): maternal age, paternal education, maternal employment status, 
phone service, prior pregnancy outcome, prior delivery preterm, history of miscarriage or 
stillbirth, prior delivery year, and alcohol use frequency in the year prior to pregnancy.  
Across all racial groups, the propensity score models for women with <6 months 
versus 18-23 months intervals had strong discrimination for American Indian and white 
women (c-statistic=0.80 and 0.83, respectively) and good discrimination for mixed 
ancestry women (c-statistic=0.75). Discrimination was good for the models of women 
with 6-11 months versus 18-23 months intervals (c-statistic=0.72, 0.71 and 0.72 for 
American Indian, white, and mixed ancestry, respectively). Lastly, discrimination was 
good for the models of women with 12-17 months versus 18-23 months intervals for 
American Indian women (c-statistic=0.71), but not as good for white and mixed ancestry 
women (c-statistic=0.68 and 0.0.61, respectively). Factors that had the highest and lowest 
standardized beta coefficients and Wald chi-square p-values from the propensity score 
models tended to be those expected based on the standardized differences.  
A substantial proportion of participants in the <6 to 18-23 months comparisons 
were excluded during trimming (Figure 2.3). Specifically, 18% of American Indian 
women with <6 months intervals and 5% of American Indian women with 18-23 months 
intervals were excluded due to non-overlap. An additional 16% of American Indian 
women with <6 months intervals and 8% with 18-23 months intervals, respectively, were 




and 18-23 months intervals, respectively, were excluded due to non-overlap, and an 
additional 20% and 59% of women with <6 and 18-23 months intervals were excluded 
due to extreme weights. Lastly, among mixed ancestry women, 3% and 20% of women 
with <6 and 18-23 months intervals, respectively, were excluded due to non-overlap, and 
49% and 67% due to extreme weights.  
Trimming and extreme weights tended to exclude a smaller proportion of 
participants for the 6-11 and 12-17 versus 18-23 months comparisons. Specifically, for 6-
11 versus 18-23 months comparisons, among American Indian women, 24% of women 
with 6-11 months intervals and 15% of 18-23 months intervals were excluded due to 
trimming and weighting combined; among white women, 8% of women with 6-11 
months intervals and 10% of women with 18-23 months intervals were excluded; and 
among mixed ancestry women, 13% of women with 6-11 months intervals and 33% of 
women with 18-23 months intervals were excluded. Lastly, for 12-17 versus 18-23 
months comparisons, among American Indian women, 29% of women with 12-17 
months intervals and 13% of women with 18-23 months intervals were excluded due to 
trimming and weighting combined; among white women, 6% of women with 12-17 
months intervals and 2% of women with 18-23 months intervals were excluded; and 
among mixed ancestry women, 2% of women with 12-17 months intervals and no women 
with 18-23 months intervals were excluded.  
Ultimately, after trimming there were 123 and 103 American Indian women, 39 
and 65 white women, and 17 and 41 mixed ancestry women for the <6 versus 18-23 




women, 187 and 196 white women, and 104 and 225 mixed ancestry women for the 6-11 
versus 18-23 months interval contrasts, respectively. There were 157 and 115 American 
Indian women, 238 and 213 white women, and 287 and 337 mixed ancestry women for 
the 12-17 versus 18-23 months interval contrasts, respectively. Within each racial 
group/study setting, the propensity score values for each comparison were nearly 
identical in weighted data (Figure 2.3).  
 
Covariate Balance after Applying Propensity Scores 
When we reviewed standardized differences, balance for all covariates (not only 
those included in the propensity score models) generally improved after propensity score 
trimming and weighting, although some imbalances remained (Table 2.2). For <6 
months versus 18-23 months intervals among American Indian women, 10 of the 51 
original covariates had standardized differences >0.20. Three of these covariates were 
related to risk of preterm birth in the next pregnancy in the weighted data: receipt of 
WIC, history of diabetes, and history of hyperthyroidism. None of these factors were 
included in the propensity score model. Given the rarity of the comorbidities, the 
observed differences may have been due to chance. For white women, 20 of the 51 
original covariates remained imbalanced. Half of these covariates were related to preterm 
birth in the weighted data: partnered and living together, partner education, number of 
people contributing to the income, study center, prior delivery outcome, history of 
miscarriage or stillbirth, complications in the prior pregnancy, history of heart disease, 




in covariate balance were women of mixed ancestry. In the trimmed data without 
weighting 20 of the 47 covariates had standardized differences > 0.20. Covariate balance 
was arguably worsened by weighting, as more covariates (26 in total) became 
imbalanced. Most of these covariates were associated with preterm birth in the weighted 
data. The sample size was dramatically reduced in the trimmed sample, so some of the 
imbalance may have been due to confounding by chance.  
In all three racial/setting groups, few of the ≥47 covariates were imbalanced for 
the other two interval comparisons. Imbalanced characteristics that were also associated 
with preterm birth included: among American Indian women with 6-11 months versus 
18-23 months intervals, living with their partner, running water and toilet inside the 
home, history of diabetes, and history of hyperthyroidism; among white women 6-11 
months versus 18-23 months intervals, Hispanic ethnicity and prior pregnancy outcome; 
among white women 12-17 months versus 18-23 months intervals, living with their 
partner and paternal employment status; and among mixed ancestry women 6-11 months 
versus 18-23 months intervals, smoking during the year before the study pregnancy.  
By far, the largest determinants of differences in interpregnancy interval length, 
preterm birth risk, and covariate values in the overall cohort were racial group and study 
center (standardized differences=1.2). By conducting the propensity score trimming and 
weighting process within these subgroups, these factors were now balanced in the overall 
sample, and the aforementioned covariate variations in the stratified and weighted data 
may have been due to chance related to the drop in sample size, which was already 




weights were applied, all covariate standardized differences were within ±0.20, except 5 
covariates for the <6 versus 18-23 months interval comparison and 1 covariate for the 6-
11 versus 18-23 months comparison. Further, none of these factors were strongly 
associated with interpregnancy interval (standardized differences ≤0.3). This suggested 
that the pooled and weighted results may not be as prone as the stratified weighted data to 
random confounding. Random confounding occurs due to chance imbalances between 
groups, rather than true biological associations.92 Pooled associational estimates may be 
appropriate to report if the strength of the biological association, if present, is consistent 
across these three populations, and there are not major differences in the distribution of 
effect modifiers within the samples. Under these assumptions, the pooled and weighted 
associational estimates with preterm birth are also provided, in addition to the stratified 
results. 
 
Associations with Preterm Birth 
Stratified Results  
The crude risk of preterm birth was higher among women with intervals <18 
months among American Indian women (<6 months 12.4%, 6-11 months 14.7%, 12-17 
months 14.1%, versus 18-23 months 7.6%). For white women and women of mixed 
ancestry, the crude risk of preterm birth was highest among women with intervals <6 
months and similar for women with intervals 6-23 months (white: <6 months 13.0%, 6-
11 months 7.4%, 12-17 months 6.3%, and 18-23 months 6.4%; mixed ancestry: <6 




 According to the crude RRs, women with intervals of <6 months from the end of 
one pregnancy to the start of the next had 60% to 100% increased risk of preterm birth in 
the next pregnancy compared with women who had 18 to 23 months between their 
pregnancies (American Indian RR 1.6, 95% CI 0.78 to 3.4; white RR 2.0 95% CI 0.86 to 
4.8; mixed ancestry RR 1.6, 95% CI 0.78 to 3.3; refer to Figure 2.4). Upon adjustment 
for the traditional set of covariates (i.e., maternal age, prior pregnancy outcome, parity, 
and smoking), the RR point estimates attenuated by 8% for American Indian women and 
21% for mixed ancestry women, but did not attenuate for white women (American Indian 
RR 1.5 95% CI 0.72 to 3.1, white RR 2.1 95% CI 0.79 to 5.7, mixed ancestry RR 1.3 
95% CI 0.54 to 3.0). In the trimmed sample before weighting, imprecision increased 
substantially, with RR confidence interval widths increasing by 27% to 154%. The RR 
point estimate for American Indian women was attenuated (RR 1.3, 95% CI 0.53 to 3.0) 
compared with the crude and traditional regression adjusted estimates. The RR point 
estimate was similar among white women (RR 2.0 95% CI 0.65 to 6.1) but less precise. 
The RR estimate for mixed ancestry women (RR 1.9 95% CI 0.59 to 6.3) was higher 
compared with the crude and traditional regression adjusted estimates and far more 
imprecise. The trimmed and weighted RR point estimates were lower for American 
Indian and mixed ancestry women (American Indian RR 1.2, 95% CI 0.47 to 3.2; mixed 
ancestry RR 1.1, 95% CI 0.28 to 4.0) but not computed for white women due to cell 
counts less than 3 in the weighted data.  
For 6-11 months versus 18-23 months interval comparisons, the crude RR point 




Indian RR 1.9, 95% CI 0.96 to 3.9) but was only slightly above the null for white and 
mixed ancestry women (white RR 1.2, 95% CI 0.57 to 2.3; mixed ancestry RR 1.1, 95% 
CI 0.63 to 1.8; Figure 2.4). Upon traditional regression adjustment, point estimates 
shifted downward by 10% to 25% for white and mixed ancestry women but was not 
computed for American Indian women because the model would not converge (white RR 
0.86, 95% CI 0.41 to 1.8; mixed ancestry RR 1.0, 95% CI 0.58 to 1.9). In the trimmed 
sample, the RR point estimates were between the crude and regression adjusted for white 
and mixed ancestry women (white RR 0.97, 95% CI 0.47 to 2.0; mixed ancestry RR 1.0, 
95% CI 0.58 to 1.9), and similar to the crude for American Indian women (RR 1.9, 95% 
CI 0.89 to 4.1). For all groups, RR point estimates were lowest in the trimmed and 
weighted samples, with the estimate consistent with the null for mixed ancestry women, 
just below the null for white women, and above the null for American Indian women 
(American Indian RR 1.3, 95% CI 0.59 to 3.0; white RR 0.94, 95% CI 0.21 to 1.4; mixed 
ancestry RR 1.0, 95% CI 0.54 to 1.9).  
For 12-17 versus 18-23 months interval comparisons, the crude RR point 
estimates were moderate for American Indian women (RR 1.9, 95% CI 0.90 to 3.9) and 
consistent with the null for white and mixed ancestry women (white RR 0.98, 95% CI 
0.49 to 2.0; mixed ancestry RR 1.1, 95% CI 0.73 to 1.6; Figure 2.4). Upon traditional 
regression adjustment, the RR point estimates were the same for mixed ancestry women 
(RR 1.1, 95% CI 0.73 to 1.6), slightly lower for white women (RR 0.92, 95% CI 0.45 to 
1.8) and not computed for American Indian women due to convergence issues. In the 




setting groups (American Indian RR 1.8, 95% CI 0.86 to 3.7; white RR 0.96, 95% CI 
0.46 to 2.0; mixed ancestry RR 1.1, 95% CI 0.75 to 1.7). Upon trimming and weighting, 
the RR point estimates were similar to the previously reported estimates for mixed 
ancestry women and attenuated for American Indian and white women (American Indian 
RR 1.4, 95% CI 0.62 to 3.2; white RR 0.92, 95% CI 0.41 to 2.1; mixed ancestry RR 1.1, 
95% CI 0.73 to 1.7).  
For both 6-11 and 12-17 versus 18-23 months comparisons, confidence intervals 
were fairly similar in all models by race/setting. Intervals for the trimmed and weighted 
samples tended to be the widest. 
 
Pooled Results 
When all race/study setting groups were pooled together, the crude models 
consistently provided the most exaggerated estimates, the traditional regression adjusted 
and the trimmed estimates were slightly attenuated, and the propensity score weighted 
estimates were closest to the null. With respect to the magnitude of these associations, all 
models supported a modest association (~40-70% increased risk) for preterm birth with 
<6 months intervals versus 18-23 months intervals. The models for 6-17 months intervals 
supported weak or null associations. 
 
Secondary Analysis with Spontaneous Preterm Birth 
Several models restricted to spontaneous preterm birth outcomes did not converge 




noted for associations that could be estimated (Figure 2.5). The pattern of results from 
model to model were similar, although slightly stronger, compared to those with all 
preterm birth outcomes for American Indian and mixed ancestry women. The 
associations for white women were less strong than those when all preterm births were 
included. Lastly, the pooled estimates were similar, although slightly lower, than those 
with all preterm births.  
 
Sensitivity Analyses  
Change to Eligibility Criteria for South Africa 
Restricting the South African sample to women enrolled by 37 weeks’ gestation 
had essentially no impact on the study findings (data not shown). Inclusion of stillbirths 
to define preterm and term deliveries increased the RR associations for intervals of <6 
months to be closer to 2.0 in the adjusted models, but the findings for 6-17 months 
intervals were unchanged (data not shown).  
 
Changes to the Propensity Score Models 
Including (rather than excluding) women with extremely low weights (applicable 
to the comparisons of <6 months versus 18-23 months for white and mixed ancestry 
women) resulted in similar propensity score trimmed and weighted RR point estimates. 
When using all 47+ covariates in the propensity score models, the propensity score 
overlap (or lack thereof) for <6 months versus 18-23 months intervals was similar (or 




following propensity score weighting was similarly poor (data not shown). When using 
only the traditional covariates (age, parity, prior delivery outcome, and smoking) in the 
propensity score models, the distributions of propensity scores of women with <6 months 
versus 18-23 months intervals were much more similar (data not shown). Had these been 
the only covariates included in the propensity scores for the main analysis, it would have 
given the impression that complete confounding (that is, the propensity score regions 
where there is no overlap) is far less prevalent than it appeared based on the more 
comprehensive set of factors. Lastly, using fine stratification resulted in similar point 
estimates and precision as compared to the SMR-based approach (data not shown).  
 
Collapsing Short Intervals <12 Months 
When we collapsed interpregnancy interval categories <6 months and 6-11 
months to be one category <12 months, the results were generally consistent with the null 
(except for American Indian women) and more precise (data not shown). This seems to 
be driven by the fact that intervals of <6 months were rare among white and mixed 
ancestry women and the results for 6-11 months intervals were more consistent with the 
null. The heightened risk we observed with short intervals of <6 months intervals was 







We evaluated the associations between short interpregnancy intervals and risk of 
preterm birth in The Safe Passage Study, an international cohort which had data on a 
larger array of covariates than typically available to evaluate confounding. We evaluated 
the availability of counterfactual women to study the effect of the treatment (short 
interpregnancy intervals versus 18-23 months intervals) on the treated. Propensity scores 
aided our ability to assess if there were women with 18-23 months intervals who were 
similar enough with respect to predictors of short intervals and risk factors for preterm 
birth such that their outcome experiences could represent what would have happened to 
women with short intervals had they instead, contrary to fact, had longer intervals. We 
found some degree of non-overlap in the propensity scores of women with <6 months 
intervals versus those with 18-23 months intervals, suggesting some degree of complete 
confounding. Here, we refer to “complete confounding” as a situation where some 
participants in the index group had entirely different characteristics from those in the 
reference group, making it difficult to tell if the observed association was due to the 
effect of the exposure or these other covariates. Some degree of complete confounding 
was found in all three populations, even though there were slight differences in the 
strength of certain risk factors, as well as differences in the prevalence of short intervals 
and preterm birth. Specifically, when considering the fuller range of covariates available 
in the Safe Passage data, ~30-50% of women with short intervals had unique sets of 




make causal inferences about the effect of short intervals for these women because there 
was no appropriate control group. Similarly, there were women with 18-23 months 
intervals that, based on measured characteristics, were unlikely to have <6 months 
intervals. Since there were almost no women with short intervals in the data with the 
same sets of characteristics, in our data 30-90% of women with 18-23 months intervals 
did not make appropriate counterfactuals. These findings could have large implications 
for interpregnancy interval research with causal questions. These data demonstrate the 
complexity of the processes that lead to interpregnancy interval length, which is perhaps 
to some degree deterministic based on contextual and biological factors. Findings of 
causal interpregnancy interval research may be generalizable to only a subset of women 
that have characteristics common between women with short and longer intervals. This 
issue may be difficult to identify without comprehensive confounder data, as we observed 
little non-overlap in the propensity scores when only select traditional covariates were 
used in the propensity score models.  
 Our ability to predict short interpregnancy intervals was better than has been 
observed in prior research. For instance, a study of >20,000 pregnancies from the 
Washington State Needs Assessment Database (1992-1999) found that maternal age, 
education, race, parity, and smoking were mildly predictive of interval length (C-
statistic=0.66).93 The addition of other individual socioeconomic factors and community 
level factors added little to the predictive accuracy of their model. Their sample was 
restricted to young, lower income women to meet eligibility for the program. Therefore, 




interpretation focused on identifying pregnancies within 2- and 5-years of the prior birth, 
rather than rapid repeat pregnancies within 6 months specifically. 
 
Differences between Populations  
We observed some differences with respect to strength of associations with short 
interpregnancy intervals across the three racial groups/study settings. Prior research has 
observed stronger associations in socioeconomically disadvantaged populations.27 We 
observed the highest association with intervals of <6 months among white women in the 
U.S. and the lowest, most attenuated associations among women of mixed ancestry in 
South Africa. We are not aware of other studies evaluating the associations between short 
interpregnancy intervals and preterm birth in this specific South African population for 
comparison. Our findings may have been due to chance, as the sample sizes were 
suboptimal, especially to study intervals of <6 months, which were rare in these groups, 
and preterm birth. Further, residual confounding is likely, given that covariate imbalance 
remained in the trimmed and weighted samples. Still, there are some potential effect 
modifiers that could be at play. Women in the white U.S. sample had higher rates of 
medical intervention at delivery, including Cesarean and induced deliveries. These 
factors might modify the associations. In addition, selection bias may have been a factor. 
Participation rates in the Safe Passage Study were lowest among white women from the 
U.S. Women who very recently had another baby may have been less likely to enroll in 
the study, given their current childcare burdens. Intuitively, one might suspect higher risk 




given the time commitment. Had this been the case, the expectation would be that the RR 
estimate would have been biased in a downward direction. This issue does not appear to 
explain what we observed, since the RR estimate was highest among white women. 
Alternatively, higher risk women may have been more likely to participate given the 
financial compensation. Lastly, while the RR estimate was higher among white U.S. 
women, the difference in absolute terms may be more minimal, given the rarity of short 
intervals among white women. Further, preterm birth was almost twice as common 
among American Indian women and women of mixed ancestry. If there is a causal 
association between short intervals and preterm birth, interventions targeted to 
populations with higher rates of preterm birth may result in the greatest absolute 
reduction. The American Indian population may be a group of particular need, given how 
common short intervals and preterm birth were.  
 Associations with intervals of 6-17 months were generally consistent with the null 
among women of mixed ancestry and white women. In contrast, these associations were 
elevated among American Indian women, although were attenuated in the propensity 
score trimmed and weighted results. In addition, for the 6-11 and 12-17 months 
comparisons, larger proportions of women in the index groups were trimmed among the 
American Indian sample compared with the other two groups. This suggests that 
confounding for the 6-11 and 12-17 months comparisons may have been strongest among 
the American Indian women. In addition, among white women, the lowest risk of preterm 
birth in the weighted data was in the 6-11 months group, compared with <6 and 12-23 




women in the white sample tended to be older at the time of their prior delivery, with 
>25% 30 years or older. Recent research suggests effect modification by maternal age. 
Specifically, associations between short intervals and spontaneous preterm birth were 
weaker among mothers ≥35 years compared with mothers 20-34 years.94 Similarly, in 
another analysis (unpublished to date) using data from the National Birth Defects 
Prevention Study, preterm birth risk was lowest with 6-17 months intervals among 
mothers who were 30 years or older at the time of the prior pregnancy. While our 
estimates were extremely imprecise, our findings add to accumulating research, 
suggesting that waiting 18 months or longer after the prior delivery may not be as 
beneficial for women of advanced maternal age.  
In interpregnancy interval research, study to study differences in estimates are 
often theorized to be explained by the presence of effect modifiers or residual 
confounding. However, there may also be differences in the actual cofounding structures 
(that is, which variables are confounders in each population and how strong the 
confounding is). In our study, we observed that aspects of the prior delivery (gestational 
age, outcome, and complications) were more important among women of mixed ancestry 
than the other two groups. For example, when the prior delivery was stillbirth or neonatal 
death, 17.7% of mixed ancestry women had short interpregnancy intervals and 30.8% of 
the subsequent deliveries were preterm. In contrast, when the prior delivery was live 
birth, only 3.7% had short interpregnancy intervals and 11.5% were preterm. Similar 
associations were observed with prior preterm birth; however, the association attenuated 




lower likelihood of short intervals but increased risk of preterm birth. These associations 
were not as apparent in the U.S. data because stillbirths and neonatal deaths were less 
common and the associations between prior term birth, uncomplicated pregnancies, and 
short intervals were weak or absent. In the U.S. data, unplanned pregnancy was an 
important predictor of short intervals, as well as certain behaviors, such as lower 
likelihood of smoking, alcohol consumption, and drug use in the prior year. The latter 
observation may be because for women with <6 months intervals the prior year 
overlapped with the previous pregnancy (and lactation if applicable). Maternal and 
paternal employment, and related factors, such as degree of educational attainment, were 
important in all three populations. Women with short intervals had higher unemployment, 
fewer working hours per week, and less education. The pattern differed for income 
however, with U.S. women with short intervals more likely to have lower income and be 
recipients of government support, whereas the opposite was observed in South Africa. In 
sum, our data suggest that confounding structures of short interpregnancy intervals and 
preterm birth and the strength of confounding may differ based on the population(s) 
under study. Future investigators would be prudent to consider the full array of factors 
contributing interpregnancy interval length, not just the traditional covariates, and how 
they may differ across populations. 
Our study highlights disparities in socioeconomic factors, reproductive autonomy, 
and perinatal outcomes among American Indian women in the U.S. and mixed ancestry 
women in South Africa. As we observed, U.S. preterm birth rates are higher among 




or Hispanic.95, 96 The rationale for the higher rates of preterm birth among American 
Indian women is multifaceted and includes: high rates of personal, structural, and 
intergenerational discrimination and racism, interpersonal violence including rape, 
behavioral risk factors such as poor nutrition, alcohol abuse, and tobacco use, maternal 
comorbidities including obesity, chronic hypertension, and diabetes, socioeconomic 
disparities, and barriers to quality care.97  With respect to women of mixed ancestry, a 
study of >500 pregnancies in the Cape Town area (2012-2015) found a similar although 
slightly higher prevalence of preterm birth (16%) compared to what we observed 
(13%).98 For the most part, their sample and ours were similar with respect to maternal 
characteristics (e.g., low maternal educational attainment; smoking and alcohol use were 
common, as was “unplanned” pregnancy), although they were less likely to be living with 
a partner (43% versus 62%). That study was not limited to subsequent births, like ours. 
That study identified food insecurity as a strong predictor of earlier delivery, whereas 
higher socioeconomic status was associated with longer gestations.  
The prevalence of short interpregnancy intervals <6 months among white women 
in our data (4.0%) was comparable to estimates among white women following prior 
singleton live birth based on 2014 U.S. birth certificate data (4.1%).99 In contrast, 
American Indian women had intervals that were much shorter than have been observed in 
U.S. estimates overall, with 14.8% occurring within <6 months. Research on 
interpregnancy intervals among American Indian women is more limited. An older report 
of U.S. women using data from the National Center on Health Statistics (1988-1991) 




and 25.9% had intervals <12 months (we observed 21.8%).100 A more recent report of 
>25,000 adolescent mothers in California found that women identifying as Native 
American, Pacific Islander, or Latina had lower odds of “optimally” spaced pregnancies 
compared with white women, controlling for demographic factors, length of 
contraception coverage, and contraceptive efficacy.101 In addition, women identifying as 
Native American were least likely to use any form of birth control, and oral 
contraceptives specifically, compared with all other racial groups.101 A recent report by 
the U.S. Centers for Disease Control and Prevention (CDC) found that the racial group 
with the highest proportion of repeat teen pregnancies was American Indian.102 There is a 
history of medical maltreatment of American Indians in the U.S., resulting in distrust of 
the care provided by Indian Health Services. In the 1960s and 1970s many American 
Indian women were coerced into sterilization.103 In the present day, many American 
Indian women face barriers to reproductive autonomy, including lack of availability of 
and time with knowledgeable providers,104 limited culturally-sensitive sex education and 
family planning services,104-106 discrimination, paternalism, and racism,107 and lack of 
access or cumbersome barriers to certain services and procedures, including emergency 
contraception, abortion, and postpartum sterilization.108 These barriers tend to be worse 
for women living in rural areas of the U.S., such as where our study was conducted, 
where there are fewer medical facilities, pharmacies, and providers, and women must 
travel further on average for services.104  
 The prevalence of short intervals observed in our study among women of mixed 




Demographic and Health Survey of 2003, 3.5% of women in the Western Cape and 4.4% 
of mixed ancestry women had birth intervals (time from one delivery to the next delivery) 
of <17 months (interpregnancy interval from prior outcome to start of the next pregnancy 
was not measured).109 One possible reason for the rarity of short interpregnancy intervals 
is that injectable contraceptives (which are highly effective) are common. According to 
the same survey, 70% of mixed ancestry women who are sexually active use any form of 
birth control, with the most common being 3-month injectable contraceptives, following 
female sterilization.109, 110 One reason why use of contraception is so high in this 
population is that modern contraceptive methods, like injections and oral contraceptives, 
are available for free at public health care facilities in South Africa.  Recent efforts have 
been made to promote the use of long-acting and reversible contraception (LARC).111 
However, the LARC implant was introduced in 2014, so it is unlikely to have much, if 




In our study, the propensity score weighted RR estimates controlling for a wide 
array of confounders were similar, though slightly lower, compared to those obtained in 
the full samples controlling for a smaller set of traditional covariates, suggesting a 20-
100% increase in preterm birth risk for women with <6 months intervals versus 18-23 
months intervals. The fact that the estimates in the full sample and weighted sample were 




several factors had non-overlap between women with <6 months versus 18-23 months 
interpregnancy intervals. Since the propensity scores only included factors that were 
related to both interpregnancy interval and preterm birth in our data, these findings 
suggest the possibility of strong confounding in all three populations. One might have 
expected that the relationship would be more attenuated after applying the propensity 
score trimming and weighting. However, confounding does not always result in 
downward attenuation; it can also be in an upward direction. Thus, the net upward and 
downward bias from all measured confounders combined may be close to 0. That said, 
there were some major drawbacks further hindering our ability to make more definitive 
conclusions. The propensity score weighted estimates were very imprecise, as many 
participants were excluded during the trimming process. Also, confounder control was 
not fully achieved after propensity score trimming and weighting, as several covariates 
remained imbalanced (although this may have been driven by the random confounding 
due to small numbers). The sample was insufficient after trimming to allow for further 
regression adjustment for the multiple covariates that remained imbalanced, as the 
multivariable models in the weighted data would not converge. We know that several of 
these covariates were associated with preterm birth, so residual confounding is suspected. 
In addition, while we may be getting closer to achieving exchangeability by applying 
propensity score methods to control for many measured covariates, there are still several 
unmeasured factors that could be important determinants of interpregnancy interval 
length, such as beliefs around contraception and reproductive autonomy, breastfeeding 




and underlying fecundability.43 Some of these factors may also be related to preterm birth 
risk. Propensity scores methods create balance only with respect to measured factors, and 
may exacerbate differences among unmeasured factors,112 or those measured but not 
included in the propensity score model. Thus, there is also potential for residual 
confounding by unmeasured factors. 
 
Misclassification  
Misclassification of interpregnancy interval length is expected to be minimal, as 
women should remember dates of prior live births. However, there may be issues with 
recall of exact stillbirth dates, as date of fetal demise is often unknown. The method of 
gestational age assignment for the pregnancy was standardized by study center. However, 
there may be issues with gestational age determination if last menstrual period was used 
among women with irregular cycles or if ultrasound was used and women were scanned 
after 22 weeks’, when dating by ultrasound tends to be less accurate.113 If a study 
pregnancy’s gestational age dating was off by only a few days or even weeks, it would 
have minimal impact on the interpregnancy interval categorization which was in months. 
Still, since interpregnancy interval is continuous, there may be benefit in evaluating the 
entire continuum, rather than separated into categories, as done in our study. The 
distributions of interpregnancy intervals and preterm birth were as expected based on 
prior research in these three populations. We suspect that we may be missing some early 
preterm births, especially among women in South Africa, due to left truncation, as 




pregnancy, except at admission for delivery. Given this, it was not that surprising that the 
preterm birth rate was slightly higher when restricting to women enrolled before 37 
weeks’.  
Bias due to misclassification from maternal report of covariates is possible, 
particularly due to social disability of certain responses. Great effort was made on the 
part of the original Safe Passage researchers to reduce the likelihood of this bias.47 
Several study staff were from the local community and built rapport and a sense of trust 
with the participants. Further, in the U.S., a certificate of confidentiality was obtained 
from the CDC to protect participants against reports of illegal behaviors. Simulation 
research has found that even if covariate misclassification is present, bias may be reduced 
during the propensity score trimming process.114  
An interesting aspect of this study is that the exposure, the outcome, and several 
covariates were measures of time (or were strongly correlated with time/age). Residual 
confounding may have affected our estimates since covariates were collected during the 
study pregnancy, instead of the former pregnancy. A recent study by Schummers et al. 
found that using data from the prior pregnancy compared to the study pregnancy made 
little difference in the adjusted estimates for preterm birth.115 Based on this, we would 
suspect it may not have much impact on our findings. This observation may be partly 
driven by the fact that some of these factors may not change much over a 2-year period, 
and those that do may be less important confounding factors, or may act entirely through 





Adjustment for Folate Antagonists 
The biological mechanism by which short intervals act on preterm birth is not 
fully understood. If we had a better understanding of the causal pathway, we may 
determine that it is not appropriate to control for certain behavioral/lifestyle factors (e.g., 
certain medical conditions, diet, alcohol and smoking), as adjustment may explain away 
some of the effect. Most of the behavioral/lifestyle factors were not retained in our 
propensity score models. However, the ones that were (i.e., alcohol consumption and 
smoking) may act as folate antagonists. However, it is important to note that these factors 
were assessed as use in the year prior to pregnancy, which may not be the relevant 
timeframe to interfere with folate levels during most of the pregnancy. In addition, as 
previously noted, the association between folate (and nutrition in general) with preterm 
birth is not well-understood. Lastly, we aimed to understand whether short intervals have 
an independent effect on preterm birth risk. The study of whether short intervals only 
increase preterm birth in the presence of folate depletion would be a slightly different 
research question.  
 
Missing Data 
Missing data were minimal for determining interpregnancy interval length and 
preterm birth status. Missing data were more common for covariates, particularly among 
American Indian women because a proportion did not return until their delivery. We used 
imputation to replace missing covariate values. The validity of imputation may be 




Sample Size and Imprecision  
As already noted, our ability to make reliable inferences regarding the 
associations between short interpregnancy intervals and preterm after “comprehensive” 
confounder control was limited, as the estimates were very imprecise. The imprecision 
may have also affected our ability to evaluate which variables were true confounders and 
whether covariates were balanced, as observed associations may have been due to 
chance. We could not adjust for additional covariates using multivariable regression 
modeling due to convergence issues. Lastly, ideally we would have studied additional 
outcomes that have been associated with short intervals (e.g., early preterm birth, small-
for-gestational age, neonatal loss) and evaluated other potential effect modifiers (e.g., 
history of preterm birth). However, these outcomes are even less common than preterm 
birth, and the sample size of our study was not sufficient for further stratification.  
 
Generalizability 
The Safe Passage targeted populations are unique, with greater likelihood of 
antenatal drinking and smoking, which may affect generalizability. 
 
Conclusions 
The most important contribution of this study was highlighting the complexity of 
determinants of short interpregnancy interval length. This issue may have major 
implications for future interpregnancy interval research with causal questions. Such 




manipulated. To conduct valid observational research, the target trial framework has been 
emphasized.116 Certain analytic strategies, such as propensity scores,13 can be used in 
attempt to mimic certain aspects of a randomized trial, such as the covariate balance 
achieved through randomization. Still, it is challenging to conceptualize a randomized 
controlled trial whose resulting estimand would theoretically correspond with the one 
obtained through our observational study. One can counsel women regarding clinical 
recommendations, increase access to postpartum contraception, or change policies related 
to the two. Further, if the mechanism(s) by which short interpregnancy intervals affect 
the next pregnancy’s outcome become known in the future, there may be further 
opportunities for intervention. For instance, if short intervals increase risks for certain 
birth defects or other adverse outcomes in the presence of folate depletion, then 
increasing folic acid intake postpartum to reach a non-deplete level could be a public 
health strategy to prevent outcomes that would otherwise be attributed to short 
interpregnancy intervals. Still, there are factors of birth spacing that are beyond our 
control—not the least of which is the fact that nearly half of U.S. pregnancies are 
unplanned.117 There may be factors (e.g., religious views on contraception) that may 
deem certain interventions ineffective among some women within the population. Even 
when pregnancies are being planned and such planning practices can be influenced, one 
should be careful to promote unnecessary increased spacing between pregnancies because 
it could have implications for the total number of pregnancies a woman has and/or the 
outcome of those pregnancies, given reduced fecundability associated with advancing 




COVID-19 pandemic may translate to delayed childbearing for some women,118 
increasing the need for attention on this research area. Future interpregnancy researchers 
would be prudent to acknowledge and carefully consider these complexities when aiming 
to make causal statements and clinical recommendations regarding impact of short 







Table 2.1 Characteristics of Multigravada Women by Self-Reported Racial Group/Study Setting and Interpregnancy Interval 
Category, Safe Passage Cohort (2007-2015) 


























  186 211 177 119 54 203 253 218 35 119 292 337 
DEMOGRAPHIC AND SOCIAL FACTORS 
Maternal Age             
  <20 18.8 26.5 19.2 26.9 7.4 3.9 3.6 3.7 25.7 16.8 23.3 23.2 
  20-24 47.3 38.4 36.7 36.1 25.9 26.6 21.7 19.7 28.6 32.8 34.3 38.9 
  25-29 19.4 22.8 33.3 28.6 40.7 41.9 49.0 45.9 28.6 27.7 24.7 26.4 
  ≥30 14.5 12.3 10.7 8.4 25.9 27.6 25.7 30.7 17.1 22.7 17.8 11.6 
Hispanic 5.9 5.7 6.2 5.9 5.6 3.5 1.6 0.9     
Partnered and Living 
Together 60.2 65.4 58.8 58.0 94.4 94.1 98.4 94.5 60.0 64.7 63.4 60.5 
Maternal Education             
  <HS 55.4 50.7 42.4 37.8 9.3 5.9 2.4 2.8 91.4 84.0 82.9 83.7 
  HS 26.3 26.1 26.6 28.6 25.9 18.2 10.3 13.8 8.6 14.3 15.1 14.2 
  >HS 18.3 23.2 31.1 33.6 64.8 75.9 87.4 83.5 0.0 1.7 2.1 2.1 
Partner Education             
  <HS 34.4 37.4 35.0 29.4 3.7 4.9 4.7 1.4 68.6 68.9 71.6 77.2 
  HS 45.2 44.6 41.2 46.2 40.7 21.2 20.2 17.9 31.4 24.4 23.6 19.3 
  >HS 20.4 18.0 23.7 24.4 55.6 73.9 75.1 80.7 0.0 6.7 4.8 3.6 
Employed (Mother) 25.8 28.9 37.9 37.8 63.0 73.9 77.5 84.9 11.4 23.5 24.0 22.3 
  Number of hrs 
worked/wk (Mother) 22.6 24.6 24.1 27.7 22.6 24.6 24.1 27.7 22.6 24.6 24.1 27.7 






  Number of hrs 
worked/wk (Father) 33.0 33.6 37.3 37.3 33.0 33.6 37.3 37.3 33.0 33.6 37.3 37.3 
Household Income / 
Person             
  Quartile 1 29.0 34.6 26.6 34.5 48.2 32.0 26.5 20.2 20.0 26.1 26.4 24.6 
  Quartile 2 28.5 26.5 31.1 27.7 25.9 21.7 25.7 30.3 25.7 24.4 26.7 27.6 
  Quartile 3 22.0 15.6 14.7 15.1 16.7 24.1 26.9 24.8 22.9 23.5 19.5 21.1 
  Quartile 4 20.4 23.2 27.7 22.7 9.3 22.2 21.0 24.8 31.4 26.1 27.4 26.7 
People Contributing to 
Income 1.7 1.6 1.4 1.3 1.7 1.6 1.4 1.3 1.7 1.6 1.4 1.3 
People Supported by 
Income 5.1 5.2 5.0 4.7 5.1 5.2 5.0 4.7 5.1 5.2 5.0 4.7 
Receiving 
Government Support 96.2 95.3 93.8 91.6 48.2 27.1 22.5 18.8 25.7 43.7 43.5 41.8 
  Food Stamps (U.S. 
only) 84.4 86.3 83.6 83.2 29.6 17.7 11.1 8.7     
  TANF (U.S. only) 10.8 13.7 14.1 10.1 3.6 0.0 0.0 0.9     
  WIC (U.S. only) 91.4 85.8 83.1 76.5 44.4 23.2 22.1 16.1     
Alimony or Child 
Support     5.5 5.8 3.1 4.1 8.6 13.5 9.6 13.1 
Other Financial 
Support     5.5 8.7 3.1 1.8 40.0 37.8 39.7 41.8 
Privately Insured 1.1 0.5 1.1 5.0 51.9 68.0 71.5 78.4 0.0 0.0 0.0 0.0 
Living in an apartment 
or house 73.1 68.7 70.1 68.9 92.6 82.8 85.8 89.0 34.3 26.1 25.0 21.4 
Electricity 99.5 99.1 98.9 98.3 100.0 99.5 99.6 100.0 100.0 95.8 99.0 96.5 
Phone Service 96.8 98.1 95.5 97.5 100.0 99.5 99.6 100.0 71.4 79.0 83.2 80.4 
Running Water 99.5 98.2 95.7 96.0 100.0 99.5 99.6 100.0 71.4 80.7 77.4 72.4 
Toilet Inside Home 98.9 98.6 96.8 96.0 100.0 99.5 99.6 100.0 54.3 60.5 65.1 60.8 
Number of People 
Living in Home 5.5 5.1 4.7 4.0 5.5 5.1 4.7 4.0 5.5 5.1 4.7 4.0 






Moved in Past Year 55.9 53.6 54.8 54.6 46.3 26.6 24.9 18.4 45.7 27.7 32.9 27.6 
REPRODUCTIVE HISTORY 
Parity >1 in Prior 
Pregnancy 72.0 68.3 71.2 62.2 51.9 48.8 42.3 39.9 65.7 63.0 61.6 58.2 
Gravidity >1 in Prior 
Pregnancy 76.3 71.1 74.6 64.7 63.0 61.1 50.2 48.6 68.6 66.4 65.1 60.5 
Planned Pregnancy 27.4 35.6 48.6 46.2 75.9 85.2 89.3 91.7 17.1 9.2 14.0 13.1 
History of Preterm 
Birth 16.1 14.2 15.8 15.1 13.0 14.3 17.8 16.5 37.1 20.2 18.8 16.0 
History of Miscarriage 
or Stillbirth 28.0 19.4 21.5 10.9 37.0 31.0 25.7 25.2 48.6 28.6 19.9 18.7 
Previous Outcome 
Live Birth 97.3 98.6 96.6 98.3 90.7 96.6 98.8 100.0 68.6 82.4 91.4 93.8 
Gestational Age Prior 
Delivery             
  <32 3.2 1.0 1.7 0.8 5.6 3.0 2.0 1.8 25.7 5.9 4.1 4.5 
  32-36 8.1 9.0 6.2 7.6 5.6 7.4 14.2 9.2 8.6 9.2 8.2 6.8 
  37+ 88.7 90.1 92.1 91.6 88.9 89.7 83.8 89.0 65.7 84.9 87.7 88.7 
Complications in Prior 
Pregnancy 5.4 4.7 5.1 6.7 16.7 17.7 21.0 18.4 5.7 8.4 12.0 8.9 
MEDICAL HISTORY 
History of Anxiety 8.1 11.9 12.4 9.2 24.1 12.8 14.2 8.3 0.0 0.0 0.0 0.6 
History of Depression 27.4 29.4 28.3 23.5 37.0 25.6 28.1 26.6 5.7 4.2 3.8 4.5 
History of Diabetes 
(Type I or II) 2.7 1.4 5.7 5.9 5.6 7.4 5.9 6.4 2.9 2.5 1.0 0.9 
History of 
Hypertension 3.8 2.8 5.1 4.2 7.4 7.9 3.2 7.8 5.7 6.7 4.5 5.0 
History of Anemia 38.7 32.2 31.1 27.7 22.2 12.3 18.6 11.5 5.7 4.2 12.0 9.8 
History of Heart 
Disease 0.5 1.9 1.1 1.7 1.9 2.5 1.2 1.8 2.9 0.8 1.7 0.0 
History of 







Hypothyroid 0.0 1.0 1.7 1.7 9.3 10.3 9.9 8.3 0.0 0.8 0.0 0.0 
History of Cancer 0.5 0.5 0.6 2.5 3.7 1.5 0.4 1.8 0.0 0.0 0.0 0.0 
HEALTH RELATED BEHAVIORS 
Drug Use in the Year 
Prior 19.4 27.0 24.3 26.1 5.6 2.0 2.0 1.8 17.1 14.3 15.1 17.8 
Smoking Frequency 
Year Prior             
  Never 34.4 30.8 36.7 41.2 70.4 75.9 85.4 89.0 28.6 31.9 33.9 26.7 
  <Daily 37.1 35.1 33.3 35.3 16.7 11.3 6.7 5.5 11.4 10.9 7.9 10.7 
  Daily 28.5 34.1 29.9 23.5 13.0 12.8 7.9 5.5 60.0 57.1 58.2 62.6 
Drinking Frequency 
Year Prior             
  Never 40.9 29.9 27.7 16.0 27.8 17.7 11.9 7.3 28.6 37.0 36.6 41.3 
  <Monthly 46.2 52.1 45.8 58.0 51.9 53.2 59.7 57.3 51.4 33.6 37.0 36.5 
  Several Days/Month 12.9 18.0 26.6 26.1 20.4 29.1 28.5 35.3 20.0 29.4 26.4 22.3 
Secondhand Smoke in 
Home/Work 73.7 77.7 79.1 68.1 25.9 19.7 16.6 13.3 97.1 97.5 95.9 97.9 
Periconceptional 
Supplementation 19.9 16.1 18.6 18.5 53.7 58.6 59.3 59.2 5.7 2.5 2.1 3.0 
hrs hours, HS high school, mo months, SA South Africa, TANF Temporary Assistance for Needy Families, US United States, WIC 







Table 2.2 Absolute Standardized Differences of Maternal Characteristics for Each Interpregnancy Interval Contrast, Before and 
After Applying Propensity Score Trimming and Weighting, Safe Passage Cohort (2007-2015) 
 Overall (pooled)          
 0-5 mo vs 18-23 mo 6-11 mo vs 18-23 mo 12-17 mo vs 18-23 mo 
  before PS after PS before PS after PS before PS after PS 
DEMOGRAPHIC AND SOCIAL FACTORS  
Maternal Age 0.21 0.08 0.09 0.06 0.11 0.03 
Racial Group 1.22 0.03 0.66 0.04 0.22 0.02 
Hispanic 0.21 0.10 0.14 0.03 0.06 0.01 
Partnered and Living Together 0.09 0.17 0.12 0.13 0.08 0.07 
Maternal Education 0.20 0.04 0.16 0.08 0.11 0.00 
Partner Education 0.39 0.08 0.26 0.04 0.11 0.04 
Employed (Mother) 0.29 0.06 0.01 0.00 0.02 0.05 
  Number of hrsworked/wk (Mother) 0.59 0.25 0.36 0.11 0.19 0.05 
Employed (Father) 0.36 0.08 0.13 0.07 0.06 0.04 
  Number of hrsworked/wk (Father) 0.45 0.03 0.15 0.01 0.03 0.09 
Household Income / Person 0.20 0.19 0.16 0.04 0.03 0.06 
People Contributing to Income 0.22 0.02 0.14 0.03 0.11 0.10 
People Supported by Income 0.02 0.08 0.06 0.09 0.00 0.00 
Receiving Government Support 0.40 0.13 0.30 0.06 0.11 0.01 
  Food Stamps (U.S. only) 0.76 0.02 0.53 0.04 0.17 0.01 
  TANF (U.S. only) 1.04 0.05 0.18 0.02 0.08 0.00 
  WIC (U.S. only) 0.26 0.16 0.54 0.02 0.22 0.01 
Alimony or Child Support 1.22 0.15 0.06 0.04 0.14 0.13 
Other Financial Support 0.11 0.04 0.17 0.05 0.06 0.02 
Privately Insured 0.28 0.01 0.00 0.03 0.02 0.01 
Living in an apartment or house 0.43 0.02 0.26 0.02 0.11 0.03 
Electricity 0.16 0.06 0.04 0.06 0.10 0.06 






Running Water 0.37 0.12 0.32 0.19 0.13 0.04 
Toilet Inside Home 0.41 0.04 0.31 0.05 0.14 0.02 
Number of People Living in Home 0.16 0.05 0.02 0.05 0.01 0.02 
Crowding Index >1 0.12 0.00 0.18 0.01 0.06 0.01 
Moved in Past Year 0.49 0.22 0.17 0.01 0.13 0.04 
Study Center 1.21 0.07 0.69 0.16 0.29 0.08 
REPRODUCTIVE HISTORY  
Parity >1 in Prior Pregnancy 0.30 0.10 0.14 0.01 0.09 0.03 
Gravidity >1 in Prior Pregnancy 0.33 0.11 0.18 0.01 0.10 0.02 
Planned Pregnancy 0.18 0.02 0.08 0.01 0.09 0.02 
History of Preterm Birth 0.03 0.30 0.02 0.20 0.04 0.05 
History of Miscarriage or Stillbirth 0.30 0.06 0.15 0.05 0.07 0.01 
Previous Outcome Live birth 0.19 0.01 0.11 0.04 0.07 0.02 
Prior Delivery Preterm 0.15 0.08 0.02 0.09 0.06 0.02 
Complications in Prior Pregnancy 0.13 0.21 0.03 0.03 0.06 0.02 
Prior Delivery Year 0.61 0.62 0.46 0.22 0.28 0.02 
MEDICAL HISTORY  
History of Anxiety 0.21 0.07 0.19 0.02 0.14 0.01 
History of Depression 0.29 0.01 0.19 0.03 0.09 0.08 
History of Diabetes (Type I or II) 0.02 0.24 0.02 0.11 0.02 0.06 
History of Hypertension 0.05 0.09 0.01 0.03 0.08 0.11 
History of Anemia 0.44 0.02 0.13 0.08 0.15 0.07 
History of Heart Disease 0.02 0.14 0.08 0.11 0.05 0.00 
History of Hyperthyroid 0.01 0.17 0.01 0.08 0.03 0.09 
History of Hypothyroid 0.08 0.05 0.08 0.05 0.05 0.02 
History of Cancer 0.01 0.06 0.03 0.06 0.09 0.09 
HEALTH RELATED BEHAVIORS 
Drug Use in the Year Prior 0.06 0.08 0.02 0.10 0.04 0.08 
Smoking Frequency Year Prior 0.43 0.06 0.23 0.13 0.10 0.06 






Secondhand Smoke in Home/Work 0.04 0.08 0.11 0.10 0.03 0.02 
Folic Acid Intake from Diet 0.03 0.04 0.00 0.04 0.02 0.02 
Periconceptional Supplementation 0.02 0.11 0.12 0.06 0.05 0.02 
 American Indian (US)          
 0-5 mo vs 18-23 mo 6-11 mo vs 18-23 mo 12-17 mo vs 18-23 mo 
  before PS after PS before PS after PS before PS after PS 
DEMOGRAPHIC AND SOCIAL FACTORS  
Maternal Age 0.38 0.11 0.18 0.08 0.21 0.07 
Racial Group 
   
  
  
Hispanic 0.00 0.16 0.01 0.08 0.01 0.05 
Partnered and Living Together 0.05 0.18 0.15 0.30 0.02 0.06 
Maternal Education 0.38 0.03 0.28 0.09 0.08 0.02 
Partner Education 0.12 0.03 0.21 0.23 0.13 0.15 
Employed (Mother) 0.26 0.07 0.19 0.05 0.00 0.09 
  Number of hrsworked/wk (Mother) 0.39 0.40 0.18 0.19 0.15 0.19 
Employed (Father) 0.11 0.03 0.20 0.05 0.20 0.09 
  Number of hrsworked/wk (Father) 0.13 0.05 0.10 0.05 0.04 0.07 
Household Income / Person 0.19 0.37 0.04 0.22 0.16 0.34 
People Contributing to Income 0.06 0.08 0.09 0.05 0.03 0.13 
People Supported by Income 0.31 0.04 0.32 0.15 0.16 0.05 
Receiving Government Support 0.20 0.01 0.15 0.01 0.08 0.04 
  Food Stamps (U.S. only) 0.03 0.00 0.09 0.06 0.01 0.02 
  TANF (U.S. only) 0.02 0.06 0.11 0.10 0.12 0.06 
  WIC (U.S. only) 0.42 0.39 0.24 0.07 0.16 0.02 
Alimony or Child Support 0.13 0.18 0.12 0.16 0.24 0.18 
Other Financial Support 0.22 0.06 0.27 0.05 0.31 0.04 
Privately Insured 0.23 0.13 0.28 0.09 0.23 0.05 
Living in an apartment or house 0.09 0.10 0.00 0.01 0.03 0.14 






Phone Service 0.04 0.09 0.04 0.01 0.11 0.17 
Running Water 0.24 0.24 0.17 0.26 0.02 0.07 
Toilet Inside Home 0.20 0.24 0.21 0.26 0.04 0.01 
Number of People Living in Home 0.33 0.12 0.32 0.01 0.23 0.01 
Crowding Index >1 0.07 0.08 0.08 0.04 0.20 0.12 
Moved in Past Year 0.03 0.14 0.02 0.05 0.00 0.04 
Study Center 0.50 0.17 0.40 0.06 0.27 0.14 
REPRODUCTIVE HISTORY  
Parity >1 in Prior Pregnancy 0.21 0.16 0.13 0.04 0.19 0.06 
Gravidity >1 in Prior Pregnancy 0.26 0.17 0.14 0.05 0.22 0.03 
Planned Pregnancy 0.40 0.05 0.22 0.05 0.05 0.09 
History of Preterm Birth 0.02 0.40 0.05 0.33 0.01 0.18 
History of Miscarriage or Stillbirth 0.44 0.03 0.24 0.02 0.29 0.03 
Previous Outcome Live birth 0.07 0.08 0.02 0.05 0.11 0.08 
Prior Delivery Preterm 0.10 0.07 0.05 0.13 0.02 0.09 
Complications in Prior Pregnancy 0.06 0.07 0.09 0.09 0.07 0.08 
Prior Delivery Year 0.66 0.70 0.49 0.48 0.18 0.09 
MEDICAL HISTORY  
History of Anxiety 0.04 0.04 0.08 0.04 0.10 0.04 
History of Depression 0.09 0.06 0.13 0.12 0.11 0.05 
History of Diabetes (Type I or II) 0.16 0.27 0.24 0.26 0.01 0.03 
History of Hypertension 0.02 0.00 0.07 0.06 0.04 0.03 
History of Anemia 0.23 0.02 0.10 0.00 0.07 0.05 
History of Heart Disease 0.11 0.06 0.02 0.12 0.05 0.18 
History of Hyperthyroid 0.16 0.26 0.17 0.23 0.11 0.21 
History of Hypothyroid 0.18 0.23 0.06 0.09 0.00 0.07 
History of Cancer 0.16 0.16 0.17 0.16 0.16 0.03 
HEALTH RELATED BEHAVIORS  
Drug Use in the Year Prior 0.16 0.05 0.02 0.05 0.04 0.12 






Drinking Frequency Year Prior 0.60 0.16 0.35 0.10 0.31 0.07 
Secondhand Smoke in Home/Work 0.12 0.03 0.22 0.05 0.25 0.06 
Folic Acid Intake from Diet 
   
  
  
Periconceptional Supplementation 0.04 0.06 0.06 0.12 0.00 0.18 
 White (US)          
 0-5 mo vs 18-23 mo 6-11 mo vs 18-23 mo 12-17 mo vs 18-23 mo 
  before PS after PS before PS after PS before PS after PS 
DEMOGRAPHIC AND SOCIAL FACTORS  
Maternal Age 0.21 0.16 0.17 0.19 0.08 0.08 
Racial Group 




Hispanic 0.26 0.10 0.17 0.22 0.06 0.04 
Partnered and Living Together 0.00 0.37 0.02 0.05 0.21 0.26 
Maternal Education 0.43 0.29 0.19 0.07 0.14 0.07 
Partner Education 0.58 0.24 0.26 0.06 0.25 0.09 
Employed (Mother) 0.52 0.19 0.27 0.05 0.19 0.10 
  Number of hrsworked/wk (Mother) 0.46 0.07 0.29 0.06 0.24 0.05 
Employed (Father) 0.23 0.11 0.08 0.06 0.16 0.24 
  Number of hrsworked/wk (Father) 0.20 0.07 0.12 0.09 0.17 0.22 
Household Income / Person 0.68 0.17 0.29 0.09 0.17 0.06 
People Contributing to Income 0.33 0.28 0.13 0.02 0.12 0.06 
People Supported by Income 0.15 0.07 0.04 0.04 0.05 0.02 
Receiving Government Support 0.65 0.20 0.20 0.14 0.09 0.04 
  Food Stamps (U.S. only) 0.55 0.04 0.27 0.07 0.08 0.18 
  TANF (U.S. only) 0.08 0.01 0.14 0.18 0.14 0.02 
  WIC (U.S. only) 0.65 0.05 0.18 0.11 0.16 0.02 
Alimony or Child Support 0.07 0.18 0.08 0.03 0.05 0.14 
Other Financial Support 0.11 0.01 0.28 0.26 0.06 0.00 
Privately Insured 0.58 0.02 0.24 0.06 0.16 0.02 






Electricity 0.00 0.00 0.10 0.10 0.09 0.09 
Phone Service 0.00 0.00 0.10 0.10 0.09 0.09 
Running Water 0.00 0.00 0.10 0.10 0.09 0.09 
Toilet Inside Home 0.00 0.00 0.10 0.10 0.09 0.09 
Number of People Living in Home 0.08 0.24 0.11 0.17 0.01 0.08 
Crowding Index >1 0.14 0.04 0.21 0.20 0.00 0.00 
Moved in Past Year 0.63 0.39 0.20 0.11 0.16 0.02 
Study Center 0.36 0.38 0.18 0.36 0.22 0.17 
REPRODUCTIVE HISTORY  
Parity >1 in Prior Pregnancy 0.24 0.05 0.18 0.09 0.05 0.01 
Gravidity >1 in Prior Pregnancy 0.29 0.07 0.25 0.11 0.03 0.07 
Planned Pregnancy 0.44 0.11 0.21 0.01 0.08 0.02 
History of Preterm Birth 0.28 0.23 0.06 0.10 0.03 0.06 
History of Miscarriage or Stillbirth 0.26 0.22 0.13 0.10 0.01 0.02 
Previous Outcome Live birth 0.45 0.41 0.27 0.21 0.15 0.16 
Prior Delivery Preterm 0.00 0.12 0.02 0.06 0.15 0.15 
Complications in Prior Pregnancy 0.04 0.58 0.02 0.03 0.07 0.02 
Prior Delivery Year 0.65 0.24 0.46 0.04 0.40 0.01 
MEDICAL HISTORY  
History of Anxiety 0.44 0.19 0.15 0.02 0.19 0.06 
History of Depression 0.23 0.28 0.02 0.17 0.03 0.13 
History of Diabetes (Type I or II) 0.04 0.38 0.04 0.09 0.02 0.12 
History of Hypertension 0.01 0.26 0.00 0.04 0.20 0.23 
History of Anemia 0.29 0.12 0.03 0.11 0.20 0.18 
History of Heart Disease 0.00 0.23 0.04 0.09 0.05 0.06 
History of Hyperthyroid 0.08 0.17 0.01 0.01 0.05 0.05 
History of Hypothyroid 0.04 0.16 0.07 0.09 0.06 0.06 
History of Cancer 0.11 0.10 0.03 0.03 0.14 0.16 
HEALTH RELATED BEHAVIORS  






Smoking Frequency Year Prior 0.48 0.25 0.35 0.12 0.13 0.04 
Drinking Frequency Year Prior 0.62 0.11 0.34 0.09 0.22 0.06 
Secondhand Smoke in Home/Work 0.32 0.21 0.17 0.19 0.09 0.05 
Folic Acid Intake from Diet 




Periconceptional Supplementation 0.11 0.21 0.01 0.01 0.00 0.03 
 Mixed Ancestry (SA)          
 0-5 mo vs 18-23 mo 6-11 mo vs 18-23 mo 12-17 mo vs 18-23 mo 
  before PS after PS before PS after PS before PS after PS 
DEMOGRAPHIC AND SOCIAL FACTORS  
Maternal Age 0.22 0.15 0.30 0.14 0.18 0.03 
Racial Group 




   
  
  
Partnered and Living Together 0.01 0.01 0.09 0.04 0.06 0.04 
Maternal Education 0.26 0.07 0.00 0.02 0.03 0.02 
Partner Education 0.39 0.07 0.19 0.05 0.12 0.01 
Employed (Mother) 0.29 0.22 0.03 0.03 0.04 0.01 
  Number of hrsworked/wk (Mother) 0.07 0.15 0.02 0.03 0.02 0.06 
Employed (Father) 0.24 0.58 0.12 0.05 0.04 0.10 
  Number of hrsworked/wk (Father) 0.27 0.42 0.08 0.16 0.04 0.01 
Household Income / Person 0.15 0.37 0.10 0.11 0.04 0.08 
People Contributing to Income 0.25 0.55 0.07 0.15 0.07 0.15 
People Supported by Income 0.02 0.27 0.01 0.10 0.04 0.05 
Receiving Government Support 0.35 0.50 0.04 0.01 0.03 0.04 
  Food Stamps (U.S. only) 
   
  
  
  TANF (U.S. only) 
   
  
  
  WIC (U.S. only) 
   
  
  
Alimony or Child Support 0.14 0.41 0.01 0.02 0.11 0.11 
Other Financial Support 0.04 0.44 0.08 0.01 0.04 0.04 
Privately Insured 








Living in an apartment or house 0.29 0.27 0.11 0.05 0.09 0.04 
Electricity 0.27 0.16 0.03 0.14 0.17 0.14 
Phone Service 0.21 0.16 0.04 0.01 0.07 0.00 
Running Water 0.02 0.12 0.20 0.33 0.12 0.09 
Toilet Inside Home 0.13 0.37 0.01 0.01 0.09 0.03 
Number of People Living in Home 0.11 0.08 0.06 0.05 0.01 0.01 
Crowding Index >1 0.31 0.36 0.09 0.01 0.05 0.05 
Moved in Past Year 0.38 0.52 0.00 0.06 0.12 0.11 
Study Center 
   
  
  
REPRODUCTIVE HISTORY  
Parity >1 in Prior Pregnancy 0.16 0.29 0.10 0.12 0.07 0.05 
Gravidity >1 in Prior Pregnancy 0.17 0.23 0.12 0.08 0.09 0.08 
Planned Pregnancy 0.11 0.34 0.12 0.11 0.03 0.00 
History of Preterm Birth 0.49 0.28 0.11 0.12 0.07 0.02 
History of Miscarriage or Stillbirth 0.67 0.01 0.23 0.02 0.03 0.02 
Previous Outcome Live birth 0.68 0.03 0.36 0.01 0.09 0.02 
Prior Delivery Preterm 0.57 0.25 0.11 0.11 0.03 0.03 
Complications in Prior Pregnancy 0.12 0.16 0.02 0.02 0.10 0.10 
Prior Delivery Year 0.32 0.56 0.51 0.08 0.27 0.00 
MEDICAL HISTORY  
History of Anxiety 0.11 0.00 0.11 0.08 0.11 0.10 
History of Depression 0.06 0.00 0.01 0.02 0.03 0.07 
History of Diabetes (Type I or II) 0.15 0.25 0.13 0.13 0.01 0.00 
History of Hypertension 0.03 0.29 0.07 0.03 0.03 0.06 
History of Anemia 0.15 0.03 0.22 0.24 0.07 0.05 
History of Heart Disease 0.24 0.35 0.13 0.14 0.19 0.19 
History of Hyperthyroid 0.00 0.00 0.13 0.14 0.00 0.00 
History of Hypothyroid 0.00 0.00 0.13 0.14 0.00 0.00 







HEALTH RELATED BEHAVIORS  
Drug Use in the Year Prior 0.02 0.32 0.10 0.17 0.07 0.07 
Smoking Frequency Year Prior 0.05 0.16 0.11 0.29 0.17 0.14 
Drinking Frequency Year Prior 0.32 0.28 0.14 0.13 0.09 0.03 
Secondhand Smoke in Home/Work 0.05 0.35 0.03 0.01 0.12 0.08 
Folic Acid Intake from Diet 0.03 0.02 0.00 0.04 0.02 0.02 
Periconceptional Supplementation 0.14 0.26 0.03 0.02 0.06 0.06 
hrs hours, mo months, PS propensity score trimming and weighting, SA South Africa, US United States, vs versus, wk week 
Light gray shaded cells are standardized differences >0.2 for comparisons of index and reference interpregnancy intervals 
Dark gray shaded cells are standardized differences >0.2 for comparisons of index and reference interpregnancy intervals and standardized 














Figure 2.2 Distribution of Interpregnancy Intervals Following Pregnancies ≥20 Weeks’ Gestation by Self-Reported Racial 
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Figure 2.3 Propensity Score Distributions for Interpregnancy Intervals of <6 Months, 6-11 Months, and 12-17 Months versus 18-





































































Figure 2.4 Crude and Adjusted Risk Ratio Estimates for Short Interpregnancy Interval Comparisons (<6 months, 6-11 month, 
and 12-17 months, versus 18-23 months) and All Preterm Birth by Racial Group/Study Setting and Overall, Safe Passage Cohort 
(2007-2015) 
 






Figure 2.5 Crude and Adjusted Risk Ratio Estimates for Short Interpregnancy Interval Comparisons (<6 months, 6-11 month, 
and 12-17 months, versus 18-23 months) and Spontaneous Preterm Birth by Racial Group/Study Setting and Overall, Safe 
Passage Cohort (2007-2015) 
 






Figure 2.6 Directed Acyclic Graphs Depicting Associations between a Confounder of Short Interpregnancy Intervals and Preterm 
Birth and Timing of Collection 
 




CHAPTER THREE: Timing and Amount of Gestational Weight Gain and Risks for 
Small-and Large-for-Gestational Age Infants among Women with Prepregnancy 
Obesity 
INTRODUCTION 
 The U.S. Centers for Disease Control and Prevention estimate that from 2011 to 
2015 the relative increase in the prevalence of prepregnancy obesity (≥30 kg/m2) was 
8%.119 Moreover, the prevalence of class III obesity (≥40 kg/m2) increased more than 
classes I (30-34.9 kg/m2) and class II (35-39.9 kg/m2).119 By 2015, a quarter of U.S. 
women started pregnancy with obesity.119 Women with obesity are at increased risk for 
many obstetric complications, including gestational diabetes, gestational hypertension 
and preeclampsia, Caesarean delivery, and large for gestational age (LGA) infants.16, 120 
Further, evidence suggests offspring are more likely to have obesity in childhood.121, 122 
Absolute risks tend to be higher with increasing obesity classes. Given these data, there is 
urgent need to understand how to optimize pregnancy outcomes among women with 
obesity.16  
Gestational weight gain—that is, weight gain during pregnancy—is a potentially 
modifiable risk factor for several adverse pregnancy outcomes. The current U.S. 
recommendations for gestational weight gain were established in 2009 by the Institute of 
Medicine (IOM) (now the National Academy of Medicine) and are specific to 
prepregnancy BMI category (Table 3.1).123 According to the guidelines, women with 
obesity are recommended to gain between 5 and 9 kg during the pregnancy.123 More 




trimester and 0.17 to 0.27 kg per week during trimesters 2 and 3.123  There are not 
separate recommendations by class of obesity. The 2009 guidelines are similar to those 
put forth in 1990, when the IOM recommended that women with BMI >29.0 kg/m2 gain 
at least 6.8 kg during their pregnancy.124 It is speculated that obstetricians at the time 
would put an upper bound of 11.34 kg, since that was the upper bound of the 1990 IOM 
recommendations for women with a BMI between 26.1 and 29.0 kg/m2.124   
When the guidelines were first established, the primary focus was improving 
immediate survival of the infant, with less focus on long-term child health outcomes or 
those related to the mother.125 Limited data existed to inform guidelines for women with 
prepregnancy obesity, in part because obesity was less common at the time, and there was 
less information available on maternal outcomes and long-term outcomes for the infant. 
Given the recent trends, further tailoring of the weight gain guidelines to address a 
broader range of outcomes may be warranted for more optimal pregnancy health.  
One pregnancy outcome of interest is infant birthweight percentile, specifically 
small-for-gestational age (SGA, often defined as <10th percentile for birthweight given 
gestational age) and large-for-gestational age (LGA, often defined as >90th percentile for 
birthweight given gestational age). LGA in particular is a concerning outcome for women 
with prepregnancy obesity, as they are at higher risk than women in other BMI 
categories.126, 127 LGA infants are more likely to be born by Cesarean section, to be 
affected by shoulder dystocia and neonatal hypoglycemia, and to have longer 
hospitalizations.128-130 Even though women with obesity tend to be lower risk for SGA,126, 




healthcare services in the first year of life and are at increased risk of dying 
prematurely.128, 131  
Historically, it has been thought that a certain degree of gestational weight gain is 
needed to achieve optimal infant birthweight, but the same degree of weight gain may not 
be necessary for all women.132 Many clinicians think that the IOM guidelines for women 
with obesity are too high.133, 134 Recent studies support that weight gain below the 
recommendations—or even loss—may led to more favorable outcomes among some 
women with obesity.135-138 A review by Goldstein et al. reported that for women with 
obesity, gain below the recommendations resulted in moderately higher risk of SGA (OR 
1.5, 95% CI 1.4-1.6]) but lower risk of LGA (OR 0.6, 95% CI 0.6-0.6).139 A sibling 
comparison analysis, which may have had better control of non-time-varying 
confounders,140 found similar though slightly attenuated patterns.141 Based on the 
accumulating research, the American College of Obstetricians and Gynecologists 
(ACOG) states that obese women who gain less than the IOM recommendations do not 
need to increase rate of gain if fetal growth appears to be adequate.142  
Until recently, data have been lacking to establish separate recommendations by 
obesity class. However, studies are increasingly being conducted to study the influence of 
gestational weight gain on maternal and child health within each obesity class. 
Differences in risks and benefits at the same weight gain values might suggest that 
separate recommendations are required for each class of obesity. A recent review by 
Faucher et al. found that the associations between gestational weight gain and SGA were 




consistent.143  The authors suggested changing the guidelines to recommend that women 
with class III obesity (the highest grade) gain no weight in pregnancy.143 This implies that 
these women would actually need to lose body fat to maintain a constant weight, as 
gestational weight—particularly in the latter half of pregnancy—represents a 
combination of maternal and fetal components.144 Very low gain or weight loss needs to 
be monitored closely, as it can lead to ketonemia, which increases risks for pregnancy 
complications and abnormal fetal development.16  
 Historically, studies of gestational weight gain primarily examined total gain 
(weight change from start to end of pregnancy). Total weight is the simplest and most 
readily interpreted method to model gain. When total weight gain is used, investigators 
usually adjust for gestational weight gain, as pregnancies that are longer in duration have 
more opportunity for maximum weight gain or loss. However, there is concern that 
adjustment for gestational age at delivery may result in collider bias, a form of systematic 
error that occurs when one adjusts for certain factors that are not confounders.145-148 
Extreme estimated fetal weight in utero may prompt medical intervention to deliver the 
infant(s) earlier in gestation. For instance, ACOG suggests that scheduled Cesarean 
delivery at 37 weeks’ or earlier may be beneficial for fetuses with suspected fetal growth 
restriction and other clinical findings.149 In such an instance, gestational age at delivery 
may be a common effect of gestational weight gain and extreme infant size. Gestational 
age could also be conceptualized as a mediator on the causal pathway to infant size at 
birth, because had the infant been born at a later gestational age, the fetal growth 




new delivery gestational age.150 In addition, when studying pregnancy outcomes the 
appropriateness of the denominator after traditional multivariable adjustment for 
gestational age remains a concern.140, 151 If a woman is only at risk while pregnant, the 
correct denominator is the number of ongoing pregnancies at the time of her delivery. 
However, traditional multivariable regression adjustment modifies the denominator to be 
the number of deliveries occurring at the gestational age that the pregnancy outcome 
occurred. Thus, other methods would need to be used if one wanted to adjust for 
gestational age, such as the fetuses-at-risk approach.152 
Another issue that is not always taken into account in this area of research is 
specific timing of gain. Most women do not enter antenatal care until mid-to-late in the 
first trimester (8-10 weeks’), and some women, such as those with public insurance,153, 154 
tend to enter antenatal care later in pregnancy. It would be informative to better 
understand the impact of early versus late weight gain and the extent to which outcomes 
could be improved by modifying gain trajectory after the first trimester. In addition, 
certain causal mechanisms leading to adverse outcomes may be particularly sensitive to 
deviations from weight gain recommendations during specific timeframes.140  
Latent class modeling, such as group-based trajectory models (GBTM),18 have not 
been commonly used and can take advantage of serial antenatal measurements across 
pregnancy, when available. GBTM is a data-driven method to classify trajectories of 
weight gain over time based on latent patterns detected in the serial measurements and 
assign probabilities of membership to each participant for each trajectory identified. 




subgroups, rather than a single homogenous group.155 A benefit of GBTM is that it 
accounts for patterns of weight gain across gestation without adjustment for gestational 
age, avoiding the aforementioned issues encountered with using total gestational weight 
gain in traditional regression models. In addition, classification based on GBTM may also 
be less prone to bias from random measurement error, since the trajectories are 
determined by the pattern observed over several measurements, not only start and end 
weight as is the case when using total gestational weight gain. 
One study that applied GBTM to investigate associations between gestational 
weight gain and infant size was the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) Fetal Growth Study. In their multi-center 
cohort of U.S. singletons (n=2802), Pugh et al. classified rates of weight gain during the 
first trimester versus the second and third trimesters, and combined, using GBTM.156 
Women in the lowest trajectories throughout the entire pregnancy had the highest risk of 
SGA outcomes. In comparison, women who changed from low early gain to more rapid 
gain later on were at lower risk for SGA. Women who were in the highest trajectories 
throughout pregnancy had the highest risk of having an LGA infant. Risk was lower 
among women who started in the highest trajectory but shifted to a more moderate 
trajectory in trimesters 2 and 3.  
Despite measurement of serial weights and use of GBTM, several aspects of the 
Pugh et al. study156 limited inference for women with obesity specifically. First, the study 
excluded women with risk factors for poor fetal growth, including chronic hypertension, 




which would have excluded some women with obesity and potentially make their study 
findings not generalizable to the general population of women with obesity. This 
exclusion likely narrowed the observed ranges of gestational weight gain. Second, Pugh 
et al. did not build their models by prepregnancy BMI categories, which could have 
affected the trajectories identified, since the majority of the women in their sample were 
of normal weight. For the second and third trimesters, the reference group [i.e., 0.48 
kg/week (95% CI 0.47-0.48)] and the group below the reference [i.e., 0.29 kg/week (95% 
CI 0.28-0.30)] more closely approximated what would be considered within and below 
the IOM recommendations for women of normal weight (i.e., 0.35-0.50 kg/week) but 
were both higher than the recommendations for women with obesity (0.17-0.27 kg/week). 
Third, Pugh et al. evaluated effect modification by prepregnancy BMI using a statistical 
interaction term in the multivariable regression models. The authors concluded that there 
was no interaction since the term was not statistically significant. A non-significant 
product term in a regression model does not necessarily mean that there is no effect 
modification or biologic interaction.157 Biologic interaction refers to two causal agents 
coming together (here, prepregnancy BMI and gestational weight gain) to produce a 
different effect than would be expected based on the additive independent effects of the 
two agents in isolation.158-160  In contrast, statistical interaction is based on mathematical 
model (typically a product term for two variables in a multivariable regression model), 
rather than a natural phenomenon.158 Further, the focus on the p value (which is based on 
both the magnitude of the coefficient and the sample size), rather than the magnitude of 




would be to focus on the proportion of cases attributed to biologic interaction (i.e., 
interaction contrast).161 However, when that is not possible, or if it is unclear if the 
second agent is causal, stratification by the other variable (here, prepregnancy BMI) may 
be helpful for determining whether effect modification is present on the scale of 
interest.158 Effect modification is a difference in the magnitude of associations (between 
gestational weight gain and infant size) based on the value of another variable 
(prepregnancy BMI), regardless of whether or not that other variable is a causal risk 
factor of the outcome.158 Stratified results were not presented in the NICHD Fetal Growth 
Study, and BMI categorization did not include delineation by obesity class. 
In the present study, we estimated the associations between maternal weight gain 
during pregnancy, based on degree and timing (trimester 1, trimesters 2 and 3) and small- 
and large-for-gestational age at birth among women with prepregnancy obesity. We 
explicitly evaluated effect measure modification by conducting all analyses stratified by 
prepregnancy obesity class. We hypothesized that the trajectory of gestational weight 
gain in the second and third trimesters would be more indicative of these two outcomes 
than gain in the first trimester. Further, we hypothesized that the associations between 
gestational gain and these two outcomes would be strongest among class I and weakest 







We used data from a case-cohort of pregnant women who delivered at Magee-
Womens Hospital in Pittsburgh, Pennsylvania (1998-2010). The case-cohort design saved 
on resources (e.g., time to abstract medical records) while maintaining precision and 
enabling investigation of multiple outcomes.162 From a cohort of approximately 112,000 
deliveries, women were randomly sampled based on prepregnancy BMI (including 
separate categories for obese I-III) so each subcohort had 1,411 women. For our analysis, 
we focused on the three subcohorts of women with obesity class I (30-34.9 kg/m2), class 
II (35-39.9 kg/m2), and class III (≥40 kg/m2). From the original cohort, a minimum of 
150 to at most 400 pregnancies with outcomes of interest (here, SGA and LGA) were 
randomly selected from each obesity class and served as the cases. The original research 
protocol was approved by the local institutional review board (IRB) at the University of 
Pittsburgh. Our research was reviewed by the Boston Medical Center / Boston University 
Medical Campus IRB and deemed “not human subjects research” since the data were 
already collected and the participating women could not be identified. 
Our study was restricted to women with liveborn singleton pregnancies with at 
least two antenatal visit weight measurements during the second and (if the pregnancy 
continued) third trimesters. We excluded women with no medical records available, one 
or no measurements in the second and third trimesters, and missing data on potential 





Modeling Gestational Weight Gain 
Prepregnancy BMI was derived from the woman’s height and weight and 
calculated as weight (kg)/height (m2). Height was measured at the first antenatal visit. 
Prepregnancy weight was obtained from either the most recent weight measured at the 
clinic prior to the start of pregnancy, or if not available, based on maternal recall at the 
first antenatal visit. Maternal weight was measured by a nurse at each clinical antenatal 
visit and recorded in the medical records. All of these measurements were abstracted 
from the medical record for the study. Total weight gain in the first trimester gain was 
calculated as weight at 14 0/7 weeks’ gestation minus the prepregnancy weight. First 
trimester weight gain was categorized as: below, as recommended, or above the IOM 
guidelines.   
Since weight was not always measured at exactly 14 0/7 weeks’, we estimated 
weight at this time point based on linear change in weight between the last measurement 
taken in the first trimester and the first measurement taken in the second trimester, or if 
there were no first trimester weight measurements available, based on the first two 
weights in the second trimester. We excluded women whose estimated weight change at 
the end of the first trimester was >1.81 kg lost or gained per week. This exclusion was 
done because of concerns that these were measurement errors that would greatly impact 
the end weight for first trimester gain category and the starting point for the creation of 
the second and third trimester trajectories. Even if not errors, these women had such 





To categorize gain in the second and third trimesters, we used GBTM to identify 
3-4 distinct latent groups. We opted to estimate at least 3 groups, so that we could attempt 
to identify at least one trajectory below and at least one above the reference. The sample 
size was insufficient to evaluate more than 4 groups (encountered convergence issues, 
sample size calculations not shown). These trajectories were based on (estimated) weight 
at 14 0/7 weeks’ and all subsequent antenatal measured weights. Most women in the 
subcohorts had far more weight measurements than the minimum requirement of two to 
develop the trajectories [median 9 (interquartile range [IQR] 7-11)]. We modeled all 
trajectories as linear following a cumulative normal distribution 1) for ease of 
interpretation and 2) to mimic the current IOM recommendations as closely as possible—
both of which we believed would facilitate translation to clinical practice. The trajectory 
models were weighted by the inverse of the sampling fractions for each obesity class. In 
the primary analysis, we modeled all women at once (as opposed to separate models by 
obesity class) to facilitate comparison of the results from the associational SGA/LGA 
models across the obesity classes. We were concerned the groups might look slightly 
different if created within each obesity class, given the data-driven nature of the GBTM 
technique. We descriptively reviewed the distribution of the posterior probabilities for 
each trajectory. For the primary analysis, we assigned women to the trajectory for which 
they had the highest posterior probability. To visually evaluate how individual data over 
time mapped to the data-derived assigned linear trajectory, we selected a random sample 





Definitions for Small-and Large-for-Gestational Age 
Gestational age at delivery was ascertained from medical records and determined 
clinically by ultrasound and menstrual dating.163 The two outcomes, SGA and LGA, were 
defined as birthweight <10th and >90th percentile for gestational age, respectively, based 
on fetal growth standards developed by Hadlock.164, 165  
 
Covariates 
 Data were available on a wide array of potential confounders. These included 
maternal age (which we categorized as <25, 25-34, ≥35 years), maternal race (which, due 
to sparse data in the minority racial groups, was reduced to two categories: white, non-
white), maternal education [less than high school, high school or general educational 
development (GED), some college or associate’s degree, college graduate], insurance 
(private, other), marital status (married, not married), and parity (0, 1, 2 or more). Even 
though we stratified by maternal BMI category, we further adjusted models for 
continuous prepregnancy BMI to control for any residual confounding within categories. 
For associational models with SGA outcomes, we also adjusted for chronic hypertension 
(yes, no). For associational models with LGA outcomes, we also adjusted for pre-existing 
diabetes (yes, no). For the models evaluating associations with second and third trimester 
weight gain trajectories, we also adjusted for first trimester weight gain category (below, 
within, above the IOM recommended range). In the event of possible time trends, we 
considered control for delivery year. Since the amount of weight a woman gained and her 




(continuous). Lastly, we further controlled for infant sex because male infants tend to be 
slightly larger and Hadlock’s fetal growth standard is not sex-specific.   
 
Statistical Analysis 
 We generated contingency tables between the weight groups (first trimester 
weight gain categories, second-third trimester weight gain trajectories) and outcomes 
(SGA and LGA). We also generated descriptive statistics of the aforementioned 
covariates by these variables. These exercises were performed to understand the 
distribution of these variables, how strong crude associations were, and where data were 
sparse. 
We then estimated crude and adjusted risk ratios (RRs) using modified Poisson 
regression with robust 95% confidence intervals (CIs) for the associations between 
gestational weight gain groups and SGA/LGA outcomes.79 Women in the groups that 
most closely aligned with the current IOM recommendations served as the reference. 
Specifically, for the models of first trimester weight gain, the reference group was 
women whose total gain in the first trimester fell within the recommended range of 0.2 to 
2 kg. For second and third trimester gain, we selected the trajectory that most closely 
reflected the recommended gain of 0.17 to 0.27 kg per week. The models were weighted 
by the inverse of the selection fractions, given the case-cohort design. In the main 
analysis, the adjusted models controlled for all of the aforementioned covariates. The 
only exception was maternal BMI, maternal height, and delivery year, as control for these 




precision. We noted that, on their own, nearly all covariates resulted in <10% change to 
the crude models. Thus, based on these data, confounding by any given individual factor 
was not very strong.  
Some participants had no antenatal weight measurements taken during the first 
trimester. Therefore, for the associations with first trimester weight gain, we used inverse 
probability of censoring weights based on maternal age, race, education, marital status, 
insurance, pre-existing diabetes, chronic hypertension, smoking, parity, and delivery year 
to reweight the estimates so that the sample characteristics among women with first 
trimester data looked more similar to those among the full sample. 
 
Sensitivity Analyses 
We conducted several sensitivity analyses of the trimester 2 and 3 trajectory class 
assignments. First, for each woman we included the probability of being in each 
trajectory, rather than assigning each woman to only one category, and recomputed the 
RR estimates. Second, we included higher order terms in the GBTM model and evaluated 
improvement in model fit compared with our linear models based on the Akaike's 
Information Criteria (AIC) and the Bayesian Information Criteria (BIC). Third, we 
removed the estimated contribution of fetal weight from antenatal weight measurements, 
to see if this component entirely explained observed associations. We did not have the 
estimated fetal weight measured during pregnancy during obstetric ultrasound to directly 
subtract fetal weight. Instead, we used a proxy. We estimated linear rate of fetal weight 




and birth date. We chose 14 weeks’ since this is about when the fetal component starts to 
contribute to gestational weight. We then subtracted the estimated current fetal weight 
from each antenatal weight measurement, recomputed the second and third trimester 
trajectories, re-estimated the associational models, and compared the new results to the 
conventional findings. Fourth, we removed women with >10 measurements during the 
second and third trimester. These women contributed more data points to creation of the 
trajectories. It is possible that these women were more closely monitored during their 
pregnancies (possibly due to having more pregnancy complications or risk factors), or 
these women were simply more adherent to antenatal care. Once we removed women 
with >10 measurements, we recomputed the second and third trimester trajectories, reran 
the associational models, and compared the new results to the conventional findings. 
Fifth, we built the second and third trimester trajectory models within obesity classes to 
evaluate how much the class-specific trajectories differed from those identified using the 
collapsed model in the main analysis. Lastly, in an attempt to isolate the influence of 
weight loss versus weight maintenance, we created new trajectories among women who 
were assigned to the below recommended category. We then generated separate RR 
estimates and 95% CIs for the below and maintenance groups. We did not report 







We conducted an exploratory analysis by calculating the proportions in each 
subcohort with certain pregnancy complications [i.e., gestational diabetes meninges 
(GDM) and preeclampsia] according to combinations of first and second/third trimester 
weight gain categories by each obesity class. Women with associated preexisting 




Among the original 1411 women sampled from each cohort, there were ultimately 
1290, 1247, and 1198 women in the final analytic subcohorts for classes I, II, and III, 
respectively (Figure 3.1). These sampled subcohorts represented 12.8% of the 10067 
women in the full class I cohort, 28.4% of the 4389 women in the class II cohort, and 
46.6% of the 2569 women in the class III cohort. The analytic samples contained 262, 
171, and 123 SGA cases among classes I, II, and III, respectively, representing 30.6%, 
41.9%, and 50.6% of all SGA outcomes in each of the three full cohorts. The analytic 
samples contained 353, 286, and 257 LGA cases among classes I, II, and III, respectively, 
representing 28.4%, 45.5%, and 58.7% of all LGA outcomes in each cohort. Among 
women who were originally sampled, the most common reasons for exclusion from the 
analytic sample were no medical records available (percent excluded from the subcohorts 
and case groups ranged from 3.1% to 6.9%) and having only one or no antenatal weight 





After reweighting the data, the prevalence of SGA and LGA births within each 
obesity class reflected that in each full cohort, prevalences increased with higher classes 
of obesity. Specifically, SGA births occurred in 8.5% of class I, 9.3% of class II, and 
9.5% of class III, and LGA births occurred in 12.3% of class I, 14.1% of class II, and 
17.1% of class III.   
Covariate patterns differed between the cases and the subcohorts but were fairly 
consistent across the obesity classes (Table 3.2). In comparison to the subcohorts, 
mothers of SGA births were shorter, younger, more likely to self-identify as minority 
race (mostly Black), less educated, more likely to have public insurance or pay out-of-
pocket for the pregnancy, less likely to be married, more likely to be nulliparous, more 
likely to be smokers, and more likely to have chronic hypertension. SGA births were also 
more likely to be female. LGA births exhibited the opposite patterns. Specifically, 
mothers of LGA births were taller, older, more likely to self-identify as white, more 
educated, more likely to have private insurance, more likely to be married, less likely to 
be nulliparous, less likely to be smokers, and more likely to have pre-existing diabetes. 
LGA cases were also more likely to be male. There were no clear differences with respect 
to delivery year.  
 
First Trimester Weight Gain  
The median (IQR) weight change during the first trimester was 2.27 kg (0.07-




When broken into categories, the recommended amount of total weight gain (0.2 to 2.0 
kg) was the least common category for all three classes of obesity (20% to 23%, Table 
3.3), potentially reflecting the narrow range of this category. Gain above the 
recommended range was most common for women in classes I and II (53% and 41%, 
respectively), whereas gain below the recommended range (most of whom lost weight) 
was most common for women with class III obesity (43%). The maximum weight 
changes in the first trimester were -14.06 kg lost and 18.6 kg gained, corresponding to 
approximately 1 kg/week and 1.32 kg/week, respectively. The mean total amount of 
weight gained in the recommended and above recommended categories was similar 
across obesity classes (~1.04 and 4.54 kg, respectively). However, the amount lost in the 
below recommended category was slightly greater with increasing obesity classes (-1.04, 
-1.50, and -1.81 kg for classes I, II, and III, respectively).  
 
Characteristics of Women with First Trimester Data 
Upon creating the censoring weights (based on women with first trimester data 
available versus those with only second and third trimester data), we found that the 
factors most related to not having first trimester data were higher parity, not being 
married, younger age, having less than a high school education, and having no insurance 
coverage during the pregnancy (data not shown). Women in classes I and II without first 
trimester data had higher risk for SGA and lower risk for LGA than those with first 
trimester data. SGA and LGA risks were similar among women with first trimester data 




Associations with SGA Outcomes 
 For classes I and II, SGA births were more common among women who gained 
below the recommended range in the first trimester (10.7% and 10.9% among classes I 
and II, respectively) (Table 3.3). For class I, SGA births were least common (7.0%) 
among women who gained above the recommend range. For class II, SGA births were 
comparable for women who gained below and within the recommended range (8.7% and 
8.2%, respectively). A different pattern emerged for class III. SGA prevalence was 
highest among women who gained above the recommended range (11.2%) and 
comparable for women who gained below and within the recommended range (8.6% and 
8.2%, respectively).  
 After adjustment for confounders and weighting for sampling, the RR estimates 
suggested no increase to a slight increase in SGA with gain below compared with within 
the recommended range for all obesity classes (RR estimates ranged 1.0 to 1.3; Table 
3.3). For gain above the recommended range, SGA risk was moderately reduced for 
obesity class I (RR=0.7), compatible with the null for classes II (RR=0.9), and slight 
increased for obesity class III (RR=1.2). Some estimates shifted slightly downward upon 
further weighting for censoring and control for infant sex, but the interpretation was 
largely unchanged.  
 
Associations with LGA Outcomes 
 For classes I and II, LGA outcomes were most common among women who 




respectively) and were least common among women who gained below the recommend 
range (10.1% and 11.7%, respectively) (Table 3.3). For class III, LGA prevalence was 
similar across all categories of first trimester weight gain, although the prevalence was 
slightly higher among women who gained below (17.7%) or above (16.8%) versus within 
the recommended range (16.3%). 
 After adjustment for confounders and weighting for sampling, the RR estimates 
suggested no notable decrease in LGA with gain below compared to within the 
recommended range for all obesity classes (RR point estimates ranged 0.9 to 1.1; Table 
3.3). For gain above the recommended range, the estimates suggested no to slight 
increase in LGA risk (RR ranged 1.1 to 1.2). Estimates were unchanged or slightly 
attenuated upon further weighting for censoring and control for infant sex. 
 
Second and Third Trimester Weight Gain 
 From the start of the second trimester (14 0/7 weeks’) through delivery, women 
with class I obesity tended to gain more weight in total compared with women in classes 
II and III, whereas women with class III obesity gained the least [median (IQR) for class 
I 9.66 kg (6.19-13.5), class II 8.61 kg (4.55-12.70), class III 6.90 kg (3.04-11.80)]. 
Assuming a linear rate of gain, the median amounts gained were 0.39 (0.25-0.54) 
kg/week, 0.34 (0.19-0.52) kg/week, and 0.28 (0.12-0.47) kg/week for classes I, II, and III, 
respectively. In each obesity class, 4.2%, 8.3%, and 11.6% of women appeared to lose 
weight during this timeframe, as their estimated starting weight at 14 0/7 weeks’ was 




 A 4-group linear trajectory model was selected over a 3-group model because the 
4-group model included a category that best reflected the recommendations (slope 
0.27±0.01 kg/week) (Figure 3.2, Table 3.4). The other three categories included one 
below recommended (generally women maintaining their weight, slope -0.05±0.03 
kg/week) and two categories above (higher: slope 0.54±0.01 kg/week, highest: slope 
0.91±0.02 kg/week). The trajectory that most closely aligned with the recommendations 
was the most frequent category for all classes of obesity, except for class I where the two 
most frequent categories were within the recommended range and the next higher 
trajectory. As seen with first trimester gain, gain below the recommendations was more 
common among women with class III obesity (32%, versus 12% and 21% for classes I 
and II), and gain above the recommendations was most common among women in class I 
(49% for class I, versus 36% and 28% for classes II and III). The posterior probabilities 
for the trajectory that each individual was assigned in the main analysis were very high 
(median values 1.00, IQR 0.99 to 1.00). Plots of the individual raw trajectories from the 
25 women randomly sampled from each latent trajectory group are provided in Figure 
3.3. They appeared to closely follow the slope of the trajectory group to which they were 
assigned, with the exception of the low group which appeared to comprise a combination 
of women who maintained their weight and women who lost weight.  
 
Associations with SGA Birth 
 For all obesity classes, the prevalence of SGA birth was highest among women 




Specifically, depending on the class of obesity, the prevalence of SGA ranged from 11% 
to 16% among women who gained less than recommended, whereas SGA prevalence 
ranged 7% to 10% among women who gained within or higher than the 
recommendations.  
 After adjustment for measured confounders and weighting for sampling, low gain 
in the second and third trimester was associated with increased risk of SGA for women 
with obesity classes I and II (RR point estimates were 1.5 and 2.4, respectively; Table 
3.4). Low gain was not associated with SGA risk among women in class III (RR=1.0). 
Highest gain in trimesters 2 and 3 was associated with slightly reduced risk of SGA for 
classes I and II (RRs=0.8) but not class III (RR=1.0). Interpretation remained largely 
same upon further adjustment for infant sex and upon applying probabilistic trajectory 
group assignments, although the reduced SGA risk observed with highest gain for classes 
I and II attenuated in some models. 
 
Associations with LGA Outcomes 
 Consistently across all obesity classes, the prevalence of LGA increased as second 
and third trimester weight gain trajectory increased (Table 3.4). Specifically, LGA 
prevalence was always the lowest among women in the lowest trajectory group (6% to 
12%, depending on the obesity class), and prevalence was always highest (20% to 24%) 
among women in the highest trajectory group. 
 After adjusting for measured confounders and weighting for sampling, the crude 




with gain below the recommendations (RR point estimates ranged 0.6 to 0.8, depending 
on the obesity class). LGA birth risk increased with increasing amounts of second and 
third trimester weight gain. Specifically, the RRs ranged 1.3 to 2.0, depending on the 
obesity class and how high the gain was. The magnitude of the relative risks for LGA 
birth tended to be greater among classes I and II compared with class III. Interpretation 
was unchanged upon further adjustment for infant sex and using probabilistic trajectory 
assignment.  
 
Overlap between First Trimester and Second/Third Trimester Weight Gain 
 Weight gain in the first trimester was significantly predictive of weight gain 
trajectory for trimesters 2 and 3 (Wald chi-square statistic p value <0.0001). For instance, 
among women with class III obesity, a greater proportion of women who had low first 
trimester weight gain (<0.02 kg) had low weight gain in the second and third trimesters 
(23%), compared with women who had first trimester gain within the recommended 
range of 0.2 to 2 kg (15%) or above 2 kg (17%) (Table 3.5). Similarly, a greater 
proportion (11%) of women with first trimester weight gain above the recommendations 
were in highest trajectory for second and third trimester weight gain, than women with 
low or as recommended first trimester weight gain (3% and 2%, respectively). Still, the 
association was not entirely deterministic as there were women with all possible 
combinations of first and second/third trimester weight gain. For almost all combinations 
of prepregnancy obesity class and first trimester weight gain, the most frequent second 




most common combinations by class were above first + higher second-third trimester 
weight gain for class I and below first + recommended second-third trimester weight gain 




When we included higher order terms, model fit based on AIC and BIC only 
slightly improved, and the assignment of individual women to each group was largely 
unchanged (data not shown). 
 
Subtracting Estimated Fetal Weight 
 Without the contribution of estimated fetal weight, roughly the same four 
trajectory groups for second and third trimester gain were identified (Figure 3.4). 
Overlap between the original and the new trajectory assignments was very high (91%-
96%). Without estimated fetal weight, the slope for each trajectory decreased (equating to 
approximately 0.14 kg less per week) (Table 3.6). The posterior probabilities were 
slightly lower, and the standard error for the two lowest trajectories was about 3x greater 
than in the main analysis. The associations with SGA and LGA were largely unchanged, 
although SGA associations for class I and the LGA associations for classes II and III 
were slightly attenuated. In addition, the associations between low gain and LGA for 
class I were now null instead of protective, and the associations between highest gain and 




Excluding Women with Many Measurements 
 Excluding women with >10 antenatal weight measurements in the second and 
third trimesters had minimal impact on the trajectories (Figure 3.5). The majority (88-
100%) of the women in the original groups were contained within the corresponding 
trajectories from the new model. The associations with SGA and LGA were largely 
unchanged (Table 3.6), although associations with SGA for classes I and II were slightly 
attenuated. In addition, the RR point estimate for the association between low gain and 
LGA for class I was flipped—i.e., increased instead of protective; however, the 95% CIs 
around the estimate was very wide, including values above and below the null. 
Associations between highest gain and SGA for class III were now slightly protective 
instead of null. 
 
Development of Trajectories by Obesity Class  
 For class I, the 4-group model for second and third trimester weight gain was 
essentially identical to that based on trajectories for all obese women combined from the 
main analysis (data not shown). For class II, all four trajectories had lower slopes, with 
0.09-0.14 fewer kg gained per week (low: -0.08±0.10 kg/week, recommended: 0.18±0.03 
kg/week, higher: 0.45±0.01 kg/week, highest 0.82±0.02 kg/week). Lastly, for class III, 
the slope for the lowest trajectory was the same as the main model, and the slopes for the 
other three trajectories were slightly lower (low:  -0.18±0.08 kg/week, recommended: 






 We attempted to look at weight loss by creating sub-trajectories among women 
originally classified as having gain below the recommended amount for the second and 
third trimester. The GBTM procedure identified two trajectories—i.e., a weight 
maintenance group (93.2%) and a weight loss trajectory (estimated loss of about 0.73 
kg/week, 6.8%) (Figure 3.6). The crude and adjusted RR point estimates for weight 
maintenance were nearly identical to those computed for the below recommended gain 
trajectory in the main analysis (Table 3.7). Due to small numbers, inferences could not 
be drawn for the associations with the weight loss trajectory.  
 
Secondary Analysis 
Gestational Diabetes Mellitus 
 GDM was more common as obesity class increased. Specifically, GDM 
developed among 9.2% of women with class I obesity, 10.6% of women with class II 
obesity, and 14.4% of women with class III obesity. For classes I and II, the proportion of 
women with GDM was lowest among women with low first trimester weight gain (i.e., 
7.0% and 7.4%) (Figure 3.7). Among class I, the prevalence of GDM continued to 
increase with increasing first trimester weight gain. Among class II, the proportion of 
women with GDM was the same with recommended and higher first trimester weight 
gain. In contrast, among women with class III obesity, proportions with GDM were 




 The mean gestational age at first glucose screen were 24.0, 23.7, and 22.8 weeks’ 
for classes I, II, and III, respectively. The data suggested that weight gain patterns may 
shift after diagnosis of GDM (Figure 3.7). Specifically, women with GDM diagnosis 
were more likely to have low or recommended weight gain in second and third trimester, 
compared with women without GDM. This pattern held for all classes of obesity 
regardless of amount of weight gain in the first trimester. For instance, for women with 
class III obesity and high first trimester weight gain, 26.7% of those with GDM had low 
second and third trimester weight gain and 46.7% had weight gain within the 
recommendations. In contrast, 16.1% of women without GDM had low second and third 
trimester weight gain and 39.1% had weight gain within the recommendations. The only 
exception was for women with class I obesity whose first trimester weight gain was less 
than recommended. For them, weight gain patterns in the second and third were nearly 
identical between women with and without GDM. 
 
Preeclampsia 
 Preeclampsia was more common as obesity class increased. Specifically, 
preeclampsia occurred in 10.3% in class I, 10.7% in class II, and 13.0% in class III. There 
was not a clear pattern between first trimester gain and preeclampsia (Table 3.8), 
although the group with the highest prevalence of preeclampsia (16.1%) was class III 
women who gained above the recommended amount during the first trimester. With 
respect to second and third trimester weight gain, preeclampsia prevalence was lowest 




11%) and was highest among women who gained the most weight for all obesity classes 




In our study, gestational weight gain during the first trimester had fairly minimal 
influence on small-and large-for-gestational age birth. All adjusted RR point estimates 
fell between 0.71 and 1.2. For classes I and II, weight gain below the recommended 
amount of 0.02 kg in the first trimester was associated with a minimal increase in SGA 
birth risk and slight decrease in LGA risk, and weight gain above the recommended 2 kg 
was associated with slight decrease in SGA risk and no-to-slight increase in LGA risk. In 
contrast, for class III, weight gain outside of the recommended range of 0.02-2 kg was 
associated with no-to-slight increase in both SGA and LGA risk.  
Our finding that first trimester gain may have minimal influence on risk of SGA 
and LGA birth is encouraging from a clinical care perspective since nearly half of U.S. 
pregnancies are unplanned and pregnancy may not be recognized until weeks into the 
first trimester.117 Further, many women do not enter antenatal care until the latter part of 
the first trimester—or later—leaving little room for clinical intervention during the first 
trimester.153, 154  
Trajectory of weight gain during the second and third trimesters tended to be 
more influential than first trimester weight gain. For classes I and II, SGA risk increased 




maintaining their weight during this latter part of pregnancy. The observed association 
was stronger among women in class II than in class I but the 95% confidence intervals 
had a fair amount of overlap. In contrast, for women with class III obesity, SGA risk did 
not appear to decrease with weight maintenance. With respect to LGA births, across all 
obesity classes, LGA risk was lowest with lower weight gain and increased as second and 
third trimester weight gain trajectory increased. Associations tended to attenuate or 
remain the same upon applying several sensitivity analyses, although these sensitivity 
analyses had limitations. For instance, we removed estimated fetal weight to understand 
if the fetal component of weight gain was driving the associations; however, we modeled 
fetal growth during trimesters 2 and 3 as linear, but actual fetal growth is not exactly 
linear.164, 165  
Our findings support that high gain among obese women—particularly gain as 
high as 0.9kg or more per week—during the second and third trimester should be avoided 
for LGA prevention. For women with class III obesity, low gain appears to help to 
decrease LGA risk while not increasing SGA risk. This is important since women with 
class III obesity are at highest risk for having an infant born LGA. Taken together, lower 
than currently recommended gain or weight maintenance may lead to more optimal 
outcomes with respect to infant size among women with class III obesity. Our research 
supports several recent studies using other methodologies suggesting that lower than 
currently recommended gain might be beneficial for women with class III obesity, 
especially for LGA risk reduction.139, 143, 166, 167  




trajectories were lower among women with GDM than those without this condition 
within all three obesity classes.  Although screening for gestational diabetes typically 
occurs late in the second trimester (between 24 and 28 weeks’), the American College of 
Obstetricians and Gynecologists (ACOG) recommends that women at higher risk 
(including women with a history of gestational diabetes, known impaired glucose 
metabolism, and obesity) be screened earlier.168 We observed that most women with 
GDM were initially screened mid-to late in the second trimester. Thus, these women 
contributed several weeks of data to the second and third trimester trajectories before 
diagnosis. Still, the lower trajectories of second and third trimester weight among women 
with GDM raise the possibility that clinical intervention may have impacted weight gain 
during the latter part of pregnancy. Physicians may advise their patients with gestational 
diabetes to eat healthier, increase exercise, and/or limit weight gain during the remainder 
of their pregnancy. A recent meta-analysis of weight gain among women with gestational 
diabetes found that excessive weight gain was associated with increased risks for 
pharmacological treatment, hypertensive disorders of pregnancy, caesarean section, LGA, 
and macrosomia, compared with recommended or below recommended gain.169  In 
contrast, lower than recommended gain was protective against LGA and macrosomia, 
and did not substantially increase the risk of SGA.169 Since we observed minimal 
association between first trimester weight gain and LGA, we speculate that efforts to 
decrease the rate of gain in the latter part of pregnancy among women whose gain was 
more than recommended in the first trimester may help to reduce LGA risk. However, 




of such an intervention.   
We also observed that preeclampsia was high among women with class III obesity 
who gained above the current recommendations in the first trimester. This may partly 
explain why we observed no decrease in SGA—an outcome associated with 
preeclampsia—with high weight gain in the first trimester for women with class III 
obesity. Further, across all obesity classes, risk of preeclampsia increased with increasing 
weight gain during the second and third trimesters, serving as another reason for women 
with obesity to avoid high weight gain during pregnancy. This exploratory analysis was 
limited, as we lacked information on timing of onset and severity, which are important 




Some estimates were imprecise. We had originally aimed to look at combinations 
of first and second/third trimester weight gain to investigate whether combinations of 
early and later gain act synergistically. Unfortunately, we had insufficient data to 
rigorously evaluate such combinations with a reliable degree of precision. In addition, we 
had insufficient data on women who lost weight during pregnancy to make a comment. 
Thus, based on these data the impact of weight loss remains unclear. 
 
Misclassification of Prepregnancy Weight 




Some of the prepregnancy weight data were self-reported. There is potential for recall 
errors, particularly for women who did not weigh themselves frequently prior to the 
pregnancy. Unfortunately, we do not know which participants had reported versus 
measured prepregnancy weight. Even among women with measured prepregnancy 
weight, their weight may have fluctuated between the last clinic visit and the start of the 
pregnancy leading to incorrect estimates of starting weight. Such fluctuations may be 
more common among women with obesity than women of lower BMI categories.170, 171 
Another issue is that calibration can vary slightly from scale to scale, and weight may be 
influenced by other factors such as time since last meal, weight of clothing, etc. Errors, if 
present, even if only 0.5 kg, could have shifted classification of a woman’s first trimester 
weight gain category, given how narrow the recommended range is. Indeed, we found 
some participants with extreme weight changes in the first trimester (~0.91-1.36 kg/wk). 
However, these extremes are not entirely implausible. Lastly, we did not have many 
measurements during the first trimester, so we could not evaluate trajectories like we did 
in trimesters 2 and 3. It would be helpful to understand the impact of first trimester 
trajectories, particularly non-linear ones. For instance, some women may lose weight in 
early pregnancy (e.g., due to reduced appetite from morning sickness) and then start to 
gain towards the end of the first trimester (when morning sickness tends to dissipate).   
We have no reason to believe that the classification errors would be differential 
with respect to the study outcome, given that outcomes occurred after the prepregnancy 
weight data were recorded. Sometimes nondifferential misclassification can lead to a bias 




may be stronger than we observed. However, the direction of nondifferential 
misclassification bias is not always predictable. The bias can be affected by random error, 
categorization of an underlying continuous variable when there is a dose-response 
relationship (as suspected with weight gain and SGA/LGA), and when using more than 
two categories.172-176 Thus, we cannot make the assumption that the true associations are 
stronger than we observed. In addition, biological plausibility would point to second and 
third trimester weight gain being more important than first trimester weight gain, as the 
range of embryotic/fetal growth deviations are minimal during the first trimester, which 
is why obstetric ultrasound estimates of crown-rump length are considered very reliable 
for determining gestational age in the first trimester.177 Furthermore, several other studies 
have similarly observed weak or no associations between first trimester weight gain and 
SGA and LGA.178-180 However, these studies did not focus specifically on women with 
obesity. 
 In an attempt to correct for potential misclassification, in a bias analysis 
prepregnancy weight was imputed based on the linear rate of weight change between the 
first measured weight in the first trimester and the next available measurement.  With the 
new prepregnancy weight, weight change in the first trimester was re-calculated and 
categorized. This imputation resulted in even more extreme estimates of first trimester 
loss and gain (data not shown). One potential explanation is that measurements taken 
during pregnancy are still prone to some degree of measurement error. Further, rates of 
gain close to the end of the first trimester may be more substantial, not reflective of 





Few women were excluded from the second and third trimester trajectory 
analyses. However, ~18% of women did not have any measurements in the first trimester, 
leading to concerns of selection bias in those data. Women in classes I and II who did not 
have first trimester measurements (those entering antenatal care later in pregnancy) were 
at higher risk for SGA and lower risk for LGA. In an attempt to overcome possible 
selection bias, we used inverse probability of censoring weights to reweight the first 
trimester results to reflect the distribution of covariates in the full sample. We assumed 
that the women without first trimester data followed similar first trimester weight gain 
patterns as women with first trimester data with similar demographic characteristics, so 
that the act of reweighting the data would adjust for this possible selection bias. We 
found that reweighting had little influence on the study results. However, we do not know 
if our assumption on which this analysis was based holds. Thus, the possibility of bias 
due to selection for the first trimester findings cannot be ruled out.  
 
Choice of Outcomes 
We focused on SGA and LGA for our study outcomes. LGA in particular has 
received heightened attention in recent years due to concerns over the growing childhood 
obesity epidemic.181, 182 However, research regarding birthweight and childhood obesity 
is conflicting,183-185 and gestational weight associations with childhood obesity appear to 
differ from those with birthweight.178-180, 186 Thus, SGA and LGA may not make the best 




obesity has been increasing in the U.S.,181, 182 birthweight has been decreasing.187-189 The 
birthweight time trend is thought to be related to earlier gestational age at delivery 
resulting from increased use of interventions like medically induced labor and Cesarean 
delivery. However, even after accounting for these factors, the increases in SGA and 
decreases in LGA still persist.187-191 Another contributing factor is that births to women of 
color are an increasing proportion of all U.S. births, and women who identify as non-
white are at higher risk for SGA births than white women.188, 190, 192  Lastly, at least one 
study has suggested that the increasing proportion of U.S. births among women ≥35 years 
may partly explain the uptick in SGA births.190 An added complication with using SGA 
and LGA births is that their classification can differ slightly based on the choice of 
growth chart.193 Studies of other important outcomes, such as stillbirth and neonatal 
death, maternal complications, and better determinants of long-term outcomes, are 
important to inform clinical guidelines for gestational weight gain. 
 
Inference from Observational Data 
Our study has several strengths including availability of antenatal weight 
measurements over time and using the GBTM approach, which capitalizes on such data. 
The GBTM approach may not be as susceptible to random measurement error as 
traditional approaches like total gestational weight gain, which is anchored by only two 
measurements, i.e., the starting and delivery weights. We also evaluated first versus 
second and third trimester weight gain separately and stratified all results by obesity 




aspects have been recommended to improve the quality of epidemiologic research 
evaluating gestational weight gain.140 Lastly, we had data on a variety of covariates, 
which some data sources do not have, although we cannot entirely rule out the possibly of 
residual confounding.  
While some may conceptualize diet quality or frequency of physical activity as 
confounders in the study of gestational weight gain and infant size, we did not. Instead, 
we conceptualized these factors to be contributors to antenatal weight gain. That said, 
there may be potential issues with consistency. How weight is achieved and maintained 
can vary (e.g., from diet and exercise) and whether these factors correspond to different 
outcomes is unknown. It is not entirely clear what intervention this observational study is 
reflecting, nor whether that intervention would have the same effects as what we 
observed. The effectiveness of weight loss interventions in reducing adverse pregnancy 
outcomes among women with obesity have been inconclusive.194 Further, such regimens 
can increase psychological stress, and stress has been found to increase risks for certain 
pregnancy complications.122 These inferential issues in the observational research of 
gestational weight gain have been discussed elsewhere.195  
 
Closing Comments 
Our study supports that second and third trimester weight gain may be more 
important for SGA and LGA birth than first trimester weight gain. This finding is 
meaningful because it signals potential for clinical intervention even several months into 




trimesters may reduce LGA risk while not substantially increasing SGA risk among 
women with class III obesity. Limiting excessive weight gain may aid in reducing 
adverse pregnancy outcomes, such as LGA, and may also be a strategy to prevent long-
term obesity in the general population of childbearing people, a growing public health 
concern.  
The time window for intervention on maternal weight during pregnancy is 
relatively brief. Even though women tend to be more motivated to have healthier 
lifestyles during pregnancy, behavioral changes can be challenging.196 Increasingly, U.S. 
mothers are gaining more weight than recommended. A meta-analysis by Goldstein et al., 
including >1 million pregnancies, found that while 23% of women gained less than the 
IOM recommendations, nearly half (47%) gained more,139 demonstrating poor adherence 
to the clinical guidelines. The likelihood of excessive weight gain tends to be more 
pronounced among women with overweight or obesity.197  
Since prepregnancy obesity is an important risk factor for subfertility198, 199 and 
adverse pregnancy outcomes,16, 120, 200 there is a great need to reduce the burden of 
obesity at the population-level prepregnancy. Targeted interventions prior to pregnancy 
have been recommended142, 201 but are difficult given the high occurrence of unintended 
pregnancy. For women who have already had a pregnancy, ACOG recommends 
interpregnancy clinical counseling to encourage women with obesity to return to their 
prepregnancy weight within 6 to 12 months postpartum, with the ultimate goal to achieve 
normal BMI.36 These women interact with the healthcare system more frequently in the 




baby visits) than then general population outside of pregnancy and postpartum. That said, 
interventions not directed to the individual, but rather an entire community (such as 
policy changes to increase access to low-cost, healthy foods), may be most effective and 









in Pregnancy  
Total Gain 
Trimester 1  
Gain per Week 
Trimesters 2-3  
Underweight 






(1.0-1.3 lbs)     
Normal  
  18.5-24.9 kg/m2 




0.35-0.5 kg  
(0.8-1.1 lbs)     
Overweight  
  25-29.9 kg/m2 





(0.5-0.7 lbs)     
Obese  
  >30 kg/m2 
5-9 kg  
(11-20 lbs) 








Table 3.2 Characteristics of Pregnancies among Women with Obesity in Case-Cohort Study by Prepregnancy Obesity Class, 
Magee-Womens Hospital, Pittsburgh, PA, 1998‒2011 
    
  
Obesity Class I 
    
  
Obesity Class II 
    
  



















  n=1290 n=262 n=353  n=1247 n=171 n=286  n=1198 n=124 n=257 
Prepregnancy BMI            






















Maternal Height (inches)           






















Maternal Age            
 14 to 24 years 24.0 34.4 15.9  22.1 28.1 13.6  22.0 25.8 12.1 
 25 to 34 years 56.4 50.4 58.1  56.9 52.6 56.3  58.8 58.9 66.5 
 35 to 46 years 19.6 15.3 26.1  21.0 19.3 30.1  19.2 15.3 21.4 
Maternal Race            
 White 75.7 62.2 83.6  72.1 63.7 86.0  67.7 55.7 82.1 
 Black 22.1 36.3 13.6  25.9 34.5 12.9  30.9 41.9 17.9 
 Other 2.2 1.5 2.8  2.0 1.8 1.1  1.4 2.4 0.0 
Maternal Education            
 Less than HS 7.5 13.4 4.0  8.1 11.7 5.2  7.7 8.1 3.1 
 High school 26.1 32.1 23.8  27.8 32.8 24.5  29.1 33.9 29.6 
 Some college 28.8 29.4 28.3  29.8 28.1 25.2  35.2 33.1 34.6 
 College graduate 37.5 25.2 43.9  34.4 27.5 45.1  28.1 25.0 32.7 
 





 Private 62.3 42.4 62.3  53.0 42.7 62.9  53.5 43.6 59.5 
 Public/OOP 37.7 57.6 37.7  47.0 57.3 37.1  46.5 47.5 40.5 
Married            
 Yes 61.5 40.1 71.1  57.0 41.5 71.0  57.2 39.5 68.1 
 No 34.7 59.9 28.9  38.3 58.5 29.0  39.6 44.6 31.9 
Parity            
 0 39.5 49.6 33.7  39.3 49.7 31.5  39.6 50.8 33.9 
 1 36.1 27.9 40.2  35.0 32.2 44.4  32.1 29.8 35.0 
 2+ 24.4 22.5 26.1  25.7 18.1 24.1  28.3 19.4 31.1 
Smoker            
 Yes 16.9 31.7 13.0  18.1 24.6 11.2  14.4 23.4 9.0 
 No 83.1 72.9 87.0  81.9 75.4 88.8  85.6 76.6 91.0 
Diabetes (I or II)            
 Yes 2.5 2.7 6.5  4.1 4.1 8.7  6.4 4.0 14.0 
 No 97.5 97.3 93.5  95.9 95.9 91.3  93.6 96.0 86.0 
Chronic Hypertension           
 Yes 7.4 16.8 6.2  11.6 16.4 13.6  16.7 21.8 18.7 
 No 92.6 83.2 93.8  88.4 83.6 86.4  83.3 78.2 81.3 
Delivery Year            
 1998-2004 40.3 43.3 44.5  40.1 43.3 40.2  39.9 37.9 42.0 
 2005-2011 59.7 56.7 55.5  59.9 56.7 59.8  60.1 62.1 58.0 
Infant Sex            
 Female 51.1 55.7 38.8  49.9 64.3 36.7  49.9 58.9 42.8 
  Male 48.9 44.3 61.2   50.1 35.7 63.3   50.1 41.1 57.2 
BMI body-mass-index, HS high school, IQR interquartile range, LGA large-for-gestational age, OOP out-of-pocket, PA Pennsylvania, 




Table 3.3 Description of First Trimester Weight Gain and Associations with SGA and LGA 
Outcomes by Prepregnancy Obesity Class, Magee-Womens Hospital, Pittsburgh, PA, 1998‒
2011 
Obesity Class I    
Description    
 Category Total T1 Gain % within  
  Mean (IQR) Subcohort  
Below <0.2 kg 
-1.09  
(-3.13 to -0.41) 27.0%  
Within 0.2 to 2.2 kg 
1.09  
(0.68 to 1.59) 20.3%  
Above  >2.2 kg 
4.54  
(3.13 to 6.80) 52.7%  
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Below 10.7% 1.1 (0.75 to 1.6) 1.1 (0.73 to 1.6) 1.1 (0.73 to 1.6) 
Within 9.3% 1 1 1 
Above  7.0% 0.71 (0.50 to 1.0) 0.70 (0.49 to 1.0) 0.70 (0.49 to 1.0) 
Associations with LGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Below 10.1% 0.86 (0.61 to 1.2) 0.87 (0.62 to 1.2) 0.90 (0.64 to 1.3) 
Within 12.6% 1 1 1 
Above  13.3% 1.1 (0.80 to 1.4) 1.1 (0.82 to 1.5) 1.1 (0.82 to 1.4) 
Obesity Class II    
Description    
 Category Total T1 Gain % within  
  Mean (IQR) Subcohort  
Below <0.2 kg 
-1.50  
(-3.63 to -0.50) 35.9%  
Within 0.2 to 2.2 kg 
1.00  
(0.68 to 1.50) 23.0%  
Above  >2.2 kg 
4.54  
(3.18 to 7.12) 41.0%  
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Below 10.9% 1.3 (0.82 to 2.0) 1.2 (0.80 to 1.9) 1.2 (0.77 to 1.9) 
Within 8.7% 1 1 1 
Above  8.2% 0.90 (0.57 to 1.4) 0.87 (0.55 to 1.4) 0.85 (0.54 to 1.3) 
Associations with LGA    
 
% with 




Below 11.7% 0.85 (0.61 to 1.2) 0.85 (0.61 to 1.2) 0.88 (0.63 to 1.2) 
Within 14.4% 1 1 1 
Above  16.4% 1.2 (0.90 to 1.6) 1.2 (0.90 to 1.6) 1.2 (0.90 to 1.6) 
Obesity Class III    
Description    
 Category Total T1 Gain % within  
  Mean (IQR) Subcohort  
Below <0.2 kg 
-1.81  
(-3.86 to -0.64) 43.4%  
Within 0.2 to 2.2 kg 
1.04  
(0.59 to 1.41) 21.0%  
Above  >2.2 kg 
4.85  
(3.31 to 6.80) 35.6%  
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Below 8.6% 1.0 (0.61 to 1.7) 0.96 (0.57 to 1.6) 0.95 (0.56 to 1.6) 
Within 8.2% 1 1 1 
Above  11.2% 1.2 (0.70 to 2.0) 1.2 (0.68 to 2.0) 1.1 (0.67 to 1.9) 
Associations with LGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Below 17.7% 1.1 (0.78 to 1.5) 1.1 (0.79 to 1.5) 1.1 (0.79 to 1.5) 
Within 16.3% 1 1 1 
Above  16.8% 1.1 (0.78 to 1.6) 1.1 (0.77 to 1.5) 1.1 (0.77 to 1.5) 
CI confidence interval, IQR interquartile range, kg kilograms, LGA large-for-gestational 
age, PA Pennsylvania, RR risk ratio, SGA small-for-gestational age, std standard, T1 first 
trimester 
RR1 Weighted by inverse sampling fractions and adjusted for maternal age, education, 
marital status, race, smoking, insurance, and chronic hypertension (SGA) and diabetes 
(LGA). 
RR2 Weighted by inverse sampling fractions and censoring weights and adjusted for 
maternal age, education, marital status, race, smoking, insurance, and chronic 
hypertension (SGA) and diabetes (LGA). 
RR3 Weighted by inverse sampling fractions and censoring weights and adjusted for 
maternal age, education, marital status, race, smoking, insurance, chronic hypertension 
(SGA) and diabetes (LGA), and infant sex. 





Table 3.4 Description of Second and Third Trimester Weight Gain Trajectories and Associations with SGA and LGA Outcomes 
by Prepregnancy Obesity Class, Magee-Womens Hospital, Pittsburgh, PA, 1998‒2011 
Obesity Class I         
Description     
 
Slope±std error 
(kg/week) Total T2-3 Gain Posterior Probabilities % within 
  Median (IQR) Median (IQR) Subcohort 
Low -0.05±0.03 0.0 (-2.27 to 1.36) 1.00 (0.99 to 1.00) 12.0% 
Recommended 0.27±0.01 6.53 (4.53 to 8.35) 1.00 (0.98 to 1.00) 38.8% 
Higher 0.54±0.01 12.25 (10.39 to 14.33) 1.00 (0.99 to 1.00) 39.0% 
Highest 0.91±0.02 19.64 (17.78 to 23.13) 1.00 (1.00 to 1.00) 10.2% 
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 14.5% 1.5 (0.94 to 2.5) 1.5 (0.94 to 2.4) 1.6 (0.98 to 2.7) 
Recommended 8.7% 1 1 1 
Higher 7.3% 0.86 (0.63 to 1.2) 0.86 (0.63 to 1.2) 0.86 (0.61 to 1.2) 
Highest 8.6% 0.84 (0.46 to 1.5) 0.92 (0.52 to 1.6) 0.90 (0.51 to 1.6) 
Associations with LGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 6.8% 0.79 (0.39 to 1.6) 0.80 (0.39 to 1.6) 0.82 (0.38 to 1.8) 
Recommended 9.7% 1 1 1 
Higher 13.9% 1.4 (1.1 to 1.8) 1.4 (1.1 to 1.7) 1.4 (1.1 to 1.9) 
Highest 19.6% 1.9 (1.3 to 2.8) 1.8 (1.2 to 2.6) 2.0 (1.4 to 2.9) 




Obesity Class II 
Description     
 
Slope±std error 
(kg/week) Total T2-3 Gain Posterior Probabilities % within 
  Median (IQR) Median (IQR) Subcohort 
Low -0.05±0.03 -0.27 (-2.27 to 1.36) 1.00 (1.00 to 1.00) 21.1% 
Recommended 0.27±0.01 6.21 (4.54 to 8.16) 1.00 (1.00 to 1.00) 43.5% 
Higher 0.54±0.01 12.25 (10.48 to 14.65) 1.00 (0.99 to 1.00) 39.0% 
Highest 0.91±0.02 20.05 (18.01 to 24.49) 1.00 (1.00 to 1.00) 8.8% 
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 16.2% 2.4 (1.6 to 3.7) 2.4 (1.6 to 3.7) 2.5 (1.6 to 3.9) 
Recommended 7.4% 1 1 1 
Higher 9.0% 1.2 (0.84 to 1.9) 1.3 (0.85 to 1.9) 1.3 (0.85 to 1.9) 
Highest 8.9% 0.80 (0.34 to 1.9) 0.85 (0.36 to 2.0) 0.76 (0.31 to 1.9) 
Associations with LGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 6.3% 0.60 (0.34 to 1.1) 0.63 (0.36 to 1.1) 0.59 (0.33 to 1.1) 
Recommended 12.5% 1 1 1 
Higher 18.0% 1.4 (1.1 to 1.8) 1.4 (1.1 to 1.8) 1.5 (1.1 to 1.9) 
Highest 19.6% 2.0 (1.3 to 3.0) 2.0 (1.3 to 3.1) 2.0 (1.3 to 3.1) 
Obesity Class III    
Description     
 
Slope±std error 
(kg/week) Total T2-3 Gain Posterior Probabilities % within 
  Median (IQR) Median (IQR) Subcohort 
Low -0.05±0.03 -0.18 (-2.72 to 1.45) 1.00 (1.00 to 1.00) 32.2% 




Higher 0.54±0.01 12.61 (10.43 to 14.79) 1.00 (0.98 to 1.00) 21.0% 
Highest 0.91±0.02 20.18 (18.60 to 24.40) 1.00 (1.00 to 1.00) 7.3% 
Associations with SGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 11.2% 1.0 (0.63 to 1.7) 0.96 (0.59 to 1.6) 0.96 (0.58 to 1.6) 
Recommended 9.7% 1 1 1 
Higher 8.3% 0.84 (0.53 to 1.4) 0.85 (0.53 to 1.4) 0.79 (0.48 to 1.3) 
Highest 8.7% 0.96 (0.46 to 2.0) 0.99 (0.47 to 2.1) 1.1 (0.51 to 2.2) 
Associations with LGA    
 
% with 
Outcome RR1 (95% CI) RR2 (95% CI) RR3 (95% CI) 
Low 11.6% 0.76 (0.51 to 1.1) 0.79 (0.53 to 1.2) 0.79 (0.52 to 1.2) 
Recommended 16.2% 1 1 1 
Higher 20.0% 1.3 (0.98 to 1.7) 1.3 (0.96 to 1.7) 1.4 (1.0 to 1.8) 
Highest 24.4% 1.6 (1.0 to 2.4) 1.6 (1.0 to 2.4) 1.6 (1.0 to 2.5) 
CI confidence interval, IQR interquartile range, kg kilograms, LGA large-for-gestational age, PA Pennsylvania, RR risk ratio, 
SGA small-for-gestational age, std standard, T2-3 second and third trimester 
RR1 Weighted by inverse sampling fractions and adjusted for maternal age, education, marital status, race, smoking, 
insurance, first trimester weight gain, and chronic hypertension (SGA) and diabetes (LGA). 
RR2 Weighted by inverse sampling fractions and censoring weights and adjusted for maternal age, education, marital status, 
race, smoking, insurance, first trimester weight gain, and chronic hypertension (SGA) and diabetes (LGA), and infant sex 
RR3 Weighted by inverse sampling fractions and censoring weights and adjusted for maternal age, education, marital status, 
race, smoking, insurance, first trimester weight gain, chronic hypertension (SGA) and diabetes (LGA), using probabilistic 
assignment. 






Table 3.5 Overlap between First Trimester Total Weight Gain and Second and Third 
Trimester Weight Gain Trajectories by Prepregnancy Obesity Class Subcohort, Magee-
Womens Hospital, Pittsburgh, PA, 1998‒2011 
  First Trimester Total Weight Gain 





Trajectory    
Class I     
 Low 7.0%, 1.9% 3.7%, 0.8% 4.5%, 2.4% 
 Recommended  52.5%, 14.2% 43.3%, 8.9% 36.5%, 19.3% 
 Higher 35.7%, 9.6% 47.9%, 9.7% 49.7%, 26.2% 
 Highest 4.9%, 1.3% 5.1%, 1.0% 9.3%, 4.9% 
     
Class II     
 Low 17.0%, 6.1% 9.0%, 2.1% 9.6%, 3.9% 
 Recommended  53.4%, 19.2% 50.0%, 11.5% 41.5%, 17.0% 
 Higher 26.3%, 9.5% 37.2%, 8.6% 38.4%, 15.8% 
 Highest 3.3%, 1.2% 3.9%, 0.9% 10.6%, 4.3% 
     
Class 
III     
 Low 22.9%, 9.9% 15.3%, 3.2% 17.4%, 6.2% 
 Recommended  53.1%, 23.1% 52.7%, 11.1% 40.1%, 14.3% 
 Higher 20.7%, 9.0% 30.1%, 6.3% 31.4%, 11.2% 
 Highest 3.3%, 1.5% 2.0%, 0.4% 11.1%, 3.9% 
Column percent, overall percent shown 
First trimester weight gain (start through 13 6/7 weeks’) categorized as below, within or 
above the IOM recommendation of 0.2 to 2 kg. 
Linear trajectories of gestational weight gain during the second and third trimesters (14 
0/7 weeks’ through delivery) based on the group-based trajectory models: low (slope -
0.05±0.03 kg/week), recommended (slope 0.27±0.01 kg/week), higher (0.54±0.01 
kg/week), and highest (0.91±0.02 kg/week). 







Table 3.6 Sensitivity Analyses of Second and Third Trimester Weight Gain Trajectories and 
Associations with SGA and LGA Outcomes by Prepregnancy Obesity Class, Magee-
Womens Hospital, Pittsburgh, PA, 1998‒2011 
  Low Recommended Higher Highest 
Without EFW     
Slope±std error -0.18±0.01 0.14±0.00 0.41±0.01 0.77±0.02 
Obesity Class I     
SGA RR  
(95% CI) 
1.2  
(0.66 to 2.2) 1 
1.1  
(0.78 to 1.5) 
1.1  
(0.65 to 2.0) 
LGA RR 
 (95% CI) 
1.0  
(0.54 to 1.9) 1 
1.2  
(0.95 to 1.6) 
1.5  
(1.0 to 2.3) 
Obesity Class II     
SGA RR  
(95% CI) 
2.1  
(1.3 to 3.3) 1 
1.2  
(0.79 to 1.7) 
0.78  
(0.33 to 1.9) 
LGA RR  
(95% CI) 
0.62  
(0.34 to 1.1) 1 
1.3  
(1.0 to 1.7) 
1.7  
(1.1 to 2.6) 
Obesity Class III     
SGA RR  
(95% CI) 
0.93  
(0.56 to 1.5) 1 
0.90  
(0.56 to 1.4) 
1.5  
(0.84 to 2.9) 
LGA RR  
(95% CI) 
0.88  
(0.60 to 1.3) 1 
1.1  
(0.82 to 1.5) 
1.3  
(0.76 to 2.1) 
Without Many Measurements    
Slope±std error -0.18±0.06 0.23±0.02 0.50±0.01 0.91±0.02 




(0.85 to 3.1) 1 
0.93  
(0.64 to 1.3) 
1.1  
(0.59 to 2.1) 
LGA RR  
(95% CI) 
1.5  
(0.62 to 3.4) 1 
1.5  
(1.1 to 2.0) 
2.1  
(1.3 to 3.3) 
Obesity Class II     
SGA RR  
(95% CI) 
1.6  
(0.84 to 2.9) 1 
1.3  
(0.83 to 2.0) 
0.90  
(0.32 to 2.6) 
LGA RR  
(95% CI) 
0.42  
(0.15 to 1.1) 1 
1.5  
(1.1 to 2.1) 
2.3  
(1.4 to 3.7) 
Obesity Class III     
SGA RR  
(95% CI) 
0.83  
(0.45 to 1.5) 1 
0.81  
(0.50 to 1.3) 
0.80  
(0.34 to 1.9) 
LGA RR  
(95% CI) 
0.74  
(0.42 to 1.3) 1 
1.3  
(0.95 to 1.9) 
1.7  
(1.0 to 2.9) 
CI confidence interval, EFW estimated fetal weight, LGA large-for-gestational age, PA 
Pennsylvania, RR risk ratio, SGA small-for-gestational age, std standard 
RR Weighted by inverse sampling fractions and adjusted for maternal age, education, marital 
status, race, smoking, insurance, first trimester weight gain, and chronic hypertension (SGA) and 
diabetes (LGA). 





Table 3.7 Description of Weight Loss and Maintenance Trajectories During the Second and 
Third Trimesters by Prepregnancy Obesity Class, Magee-Womens Hospital, Pittsburgh, 
PA, 1998‒2011 
  Weight Loss Weight Maintenance  
As 
Recommended 
 (n=39) (n=602) (n=2196) 
Description    
Slope±std error -0.45±0.06 -0.01±0.01 0.27±0.01 
Total T2-3 Gain 
Median (IQR) 
-11.43 
(-16.78 to -9.98) 
0.0  
(-1.86 to 1.50) 
6.21 
(4.26 to 8.16) 
    
Associations    
Obesity Class I    
SGA RR1 (95% CI) NC 1.8 (1.2 to 2.7) 1 
SGA RR2 (95% CI) NC 1.4 (0.91 to 2.1) 1 
LGA RR1 (95% CI) 1.5 (0.49 to 4.7) 0.60 (0.30 to 1.2) 1 
LGA RR2 (95% CI) NC 0.76 (0.36 to 1.6) 1 
Obesity Class II    
SGA RR1 (95% CI) NC 2.2 (1.5 to 3.3) 1 
SGA RR2 (95% CI) NC 2.2 (1.5 to 3.2) 1 
LGA RR1 (95% CI) NC 0.53 (0.31 to 0.89) 1 
LGA RR2 (95% CI) NC 0.61 (0.34 to 1.1) 1 
Obesity Class III    
SGA RR1 (95% CI) 0.93 (0.56 to 1.5) 1.1 (0.71 to 1.7) 1 
SGA RR2 (95% CI) NC 0.98 (0.63 to 1.5) 1 
LGA RR1 (95% CI) 0.79 (0.21 to 2.9) 0.71 (0.49 to 1.0) 1 
LGA RR2 (95% CI) NC 0.80 (0.54 to 1.2) 1 
CI confidence interval, EFW estimated fetal weight, IQR interquartile range, LGA large-
for-gestational age, NC not computed (due to small cell size or because model would not 
converge), PA Pennsylvania, RR risk ratio, SGA small-for-gestational age, std standard 
RR1 Weighted by inverse sampling fractions 
RR2 Weighted by inverse sampling fractions and adjusted for maternal age, education, 
marital status, race, smoking, insurance, first trimester weight gain (LGA only), and 
diabetes (LGA only). 






Table 3.8 Occurrence of Preeclampsia by First and Second/Third Trimester Weight Gain 
and Prepregnancy Obesity Class, Magee-Womens Hospital, Pittsburgh, PA, 1998‒2011 
 
  Obesity Class I Obesity Class II Obesity Class III 
First Trimester Weight Gain   
Below 9.1% 10.8% 12.9% 
Within 10.9% 12.0% 9.4% 
Above 8.7% 10.5% 16.1% 
Second and Third Trimester Weight Gain  
Low 4.3% 5.8% 11.0% 
Recommended 9.8% 8.9% 12.3% 
Higher 8.8% 13.1% 12.8% 
Highest 15.9% 16.9% 20.6% 
Linear trajectories of gestational weight gain during the second and third trimesters (14 
0/7 weeks’ through delivery) based on the group-based trajectory models: low (slope -
0.05±0.03 kg/week), recommended (slope 0.27±0.01 kg/week), higher (0.54±0.01 
kg/week), and highest (0.91±0.02 kg/week). 

















Figure 3.2 Trajectories of Second and Third Trimester Weight Gain in the Main Analysis 
 
The figure depicts the linear trajectories of gestational weight gain during the second and third trimesters (14 0/7 weeks’ 
through delivery) based on the group-based trajectory models used in the main analysis. There were 4 trajectories identified: 
low (slope -0.05±0.03 kg/week, red), recommended (slope 0.27±0.01 kg/week, green), higher (0.54±0.01 kg/week, blue), and 







Figure 3.3 Individual Raw Trajectories (Spaghetti Plots) of Weight Change in the Second and Third Trimesters 
 
Each plot contains n=25 women randomly sampled from each of the 4 trajectories used in the main analysis (low, 








Figure 3.4 Sensitivity Analysis - Trajectories of Second and Third Trimester Weight Gain without Estimated Fetal Weight 
 
The figure depicts the linear trajectories of gestational weight gain during the second and third trimesters (14 0/7 weeks’ 
through delivery) based on the group-based trajectory models derived in a sensitivity analysis excluding the estimated 
contribution of fetal weight. There were 4 trajectories identified: red (slope -0.18±0.01 kg/week), green (slope 0.14±0.00 
kg/week), blue (0.41±0.01 kg/week), and black (0.77±0.02 kg/week). Slopes represented by solid lines. Error bars represented 







Figure 3.5 Sensitivity Analysis - Trajectories of Second and Third Trimester Weight Gain without Many Measurements 
 
The figure depicts the linear trajectories of gestational weight gain during the second and third trimesters (14 0/7 weeks’ 
through delivery) based on the group-based trajectory models derived in a sensitivity analysis excluding women with >10 
measurements. There were 4 trajectories identified: red (slope -0.18±0.06 kg/week), green (slope 0.23±0.02 kg/week), blue 







Figure 3.6 Sensitivity Analysis – Sub-trajectories of Second and Third Trimester Weight Gain among Women in the Low Group 
 
The figure depicts the linear trajectories of gestational weight gain during the second and third trimesters (14 0/7 weeks’ 
through delivery) based on the group-based trajectory models derived in a sensitivity analysis of subgroups within the women 
identified as being in the low trajectory in the main analysis. There were 2 trajectories identified: weight loss (slope -0.45±0.06 
kg/week, red) and weight maintenance (slope -0.01±0.01 kg/week, green). Slopes represented by solid lines. Error bars 




Figure 3.7 Patterns of Gestational Weight Gain in the First and Second and Third 
Trimesters with Diagnosis of Gestational Diabetes, Restricted to Women in Each 

































CHAPTER FOUR: Placental Pathology Clusters, Growth, and Neonatal Outcomes 
INTRODUCTION 
Fetal growth restriction (FGR, also known as intrauterine growth restriction) is a 
complex condition where the fetus does not reach its innate growth potential.19, 203 FGR 
increases the risk of intrauterine demise and infant morbidity (e.g., hypoglycemia, 
hyperbilirubinemia, hypothermia, intraventricular hemorrhage, necrotizing enterocolitis, 
seizures, sepsis, respiratory distress syndrome) and mortality.204-210 Infants affected by 
FGR are also at increased risks for problems in childhood (including cognitive delay) and 
in adulthood (e.g., obesity, type II diabetes, coronary heart disease, stroke).211, 212  
 The term small-for-gestational age (SGA) is often used synonymously with FGR, 
but this is a misconception.19 SGA is defined based on a statistical threshold for small 
growth, often defined as birthweight (or estimated fetal weight) <10th percentile. Ideally, 
FGR classification would require serial obstetric ultrasounds, whereas SGA is based on 
measurement at one time point. SGA based on newborn birthweight is often used a 
proxy, since it is much easier to measure than true FGR. However, SGA may include 
constitutionally small but otherwise healthy and normal infants, in addition to those 
affected by FGR. In fact, it is suspected that up to 70% of SGA infants are 
constitutionally small but not growth restricted.213 Further, fetuses with growth restriction 
in utero may not meet the specific cut off of <10th percentile, excluding them from the 
definition of SGA. SGA alone is likely insufficient to study the etiology and 
consequences of FGR. Instead, there may be benefit in looking at the full spectrum of 




and placental information,217 to identify and understand the etiology of FGR and its 
consequences.    
 The placenta plays a major role in the interchange between the childbearing 
individual and the fetus,218 so not surprisingly placental abnormalities are etiologically 
linked to a variety adverse pregnancy outcomes.219-224 Poor placental perfusion, placental 
disorders like abruption, and umbilical cord abnormalities lead to inadequate fetal 
nutrition.20, 21  It is estimated that fetal growth restriction and/or placental insufficiency 
account for 26-32% of the stillbirths that occur in high-income settings.225 Some 
estimates are as high as 60% depending on the stillbirth classification system used.226  
 The suspected primary cause of FGR is placental insufficiency.20, 21 In addition to 
placental causes, other factors that may contribute to the development of FGR include 
maternal factors (e.g., comorbidities such as renal disease, cigarette smoking, infection) 
and fetal factors (e.g., genetic disorders, congenital malformations, multiple gestation 
pregnancies).20, 227-229    
 One approach to study the multifaceted causal pathways leading to fetal growth 
restriction and related disorders is hierarchical clustering—a type of unsupervised 
machine learning.230 This data-driven analytic technique has been used by Stanek et al. to 
identify latent groups of commonly co-occurring clinical risk factors, complications, and 
outcomes of pregnancy with placental pathological lesions.22-24 In brief, Stanek et al. 
found that the clusters—overall and among small infants specifically—formed around 
placental lesions more so than clinical phenotypes, supporting the “dimension and value” 




labeled the placental clusters as malperfusion (e.g., in severe preeclampsia), fetal 
thrombotic vasculopathy, severe ascending infection, chronic inflammation, and mixed 
etiology,22-24 the prevalences of which differed based on infant size and gestational age at 
birth.23, 24 The most frequent cluster among SGA infants born before 33 0/7 weeks’ was 
poor perfusion.23 The findings suggested that data-driven techniques may aid in 
retrospectively distinguishing between constitutionally small fetuses and those that are 
fetal growth restricted due to placental causes.23 
 There are, however, limitations of the Stanek et al. placental cluster studies. First, 
the placentas constituted convenience samples, with higher prevalence of adverse 
pregnancy outcomes. Second, the clustering technique was applied in a way where it 
assigned each placental and clinical feature to its own latent subgroup. Features grouped 
into the same cluster were those that often co-occurred across pregnancies. In this way, 
each feature was assigned to only one cluster, but an individual pregnancy could have 
been affected by more than one cluster. This application is similar to how clustering has 
been used in genomics studies to identify genes commonly responsible for certain 
phenotypes across samples,231 including breakthrough research in cancer.232, 233 An 
alternative approach would be to group together individuals, rather than features. 
Individuals in the same cluster would tend to have similar patterns across various 
features. Each individual would be assigned to only one cluster, but the features 
themselves could occur in more than one cluster. Third, the Stanek et al. clusters were 
created based on many types of clinical and placental data collected throughout 




type of data (e.g., placental pathology) or from one time point. Fourth, the pathologist 
reviewing each placenta was not blinded to clinical information at the time of 
examination. While this reflects clinical practice, it could introduce bias into the 
assessment. Lastly, while the researchers aimed to study FGR, they had data on SGA 
only (that is, birthweight <10th percentile).  
 In our exploratory study, we aimed to assess how underlying subgroups of 
placental pathology are associated with neonatal size at delivery and other pregnancy 
outcomes, such as stillbirth. In addition, we compared our data-derived placental clusters 
to the expert consensus-based Amsterdam criteria for placental lesions.234 Our 
overarching goal was to assess whether placental pathology, in addition the full spectrum 
of infant birthweight (not strictly SGA), may be beneficial to understanding pregnancies 
at high risk for adverse neonatal outcomes, some of whom may be affected by FGR. 
Evidence to this end would stress the importance of considering such information when 





Our study data were from the multi-center, prospective Safe Passage cohort (same data 
source as Chapter 2 Short Interpregnancy Intervals and Preterm Birth Risk: An 
Exploration of Confounding in Three Populations). The study design has been described 




the Western Cape, South Africa, enrolled as early as 6 weeks’ gestation and were 
followed through the child’s first year of life. As part of the main study protocol, 
participants attended up to three in-person study visits during pregnancy. During the 
study visits, participants completed standardized questionnaires (collecting information 
on demographic characteristics, reproductive and medical history, and lifestyle and 
behaviors), mental health batteries, and physiological assessments. The main protocol 
also involved extensive medical record abstraction with details of the pregnancy, 
delivery, and child’s first year of life. The research was approved by IRBs affiliated with 
each study center and, in the U.S., by the local tribal research review boards.51  
Our analysis drew upon data from an embedded protocol of the Safe Passage 
Study. Approximately a third of the women enrolled in the Safe Passage Study prior to 24 
weeks’ gestation (target n=3,750) were invited at random to participate in an additional 
embedded protocol, which involved an extra study visit at 28-32 weeks’ gestation, 
placental collection, obstetric Doppler biometry, as well as other study components. The 
specific measures collected on women participating in the embedded protocol depended 
upon the study’s sampling protocol (based on a priori power calculations, not shown) and 
the resources available at each study center.  
 
Placental Collection 
For participants in the embedded study at the centers in Sioux Falls, South Dakota, and 
Stellenbosch, Western Cape of South Africa (target n=2,800), placental samples were 




allow for an adequate number of early deliveries, additional placentas were collected 
from births occurring before 32 weeks’. In addition, to allow for representation of 
placentas from the other study centers, a random sample of additional placentas were 
collected from deliveries occurring within specific gestational age windows from the 
other four U.S. study centers. Lastly, women whose pregnancies ended in stillbirth (fetal 
death ≥20 weeks’) were approached for consent to additional study components, 
including donation of placental tissue.  
 Clinical staff notified study personnel of each delivery in real time. Clinical staff 
placed the placenta in the refrigerator within 4 hours of delivery. Upon confirming 
consent to placental tissue donation for study purposes, study staff processed (or if 
consent was not given, discarded) the placenta, preferably within 48 hours of delivery 
(maximum 7 days).  The pathological evaluation was broken into two parts: macroscopic 
examination and microscopic examination.  
 
Macroscopic Examination 
The macroscopic examination was completed by local pathologists (or trained 
study staff) at the clinical centers. Macroscopic examination and sectioning was done in 
the fresh and unfixed state according to a standardized protocol. During examination, the 
following features were noted: placental weight and dimensions, presence or absence of 
meconium, abnormal cord insertion (circummarginate, circumvallate, and percentage), 
obstructive cord lesions (with type specified e.g., true knot), thrombosed chorionic plate 




percentage of disc volume), and infarction (including percentage of disc volume). The 
features were recorded on the study case report form.  
The placenta samples were prepared for shipment to the lead study pathologists. 
The samples included ambient cross-sections of the proximal (2 blocks) and distal (2 
blocks) umbilical cord, 1 block strip of membranes (2-5 cm wide) including the point of 
rupture and the nearest placental edge, and cross-sections of the parenchyma (2 blocks) 
from the central region of the placenta (near umbilical cord insertion). Staff also sent 




The microscopic examinations of placental samples from South Africa were 
completed at Tygerberg Hospital (Western Cape, South Africa). Samples from the U.S. 
participants were examined at Boston Children’s Hospital (Boston, Massachusetts). 
Boston Children’s Hospital was the primary affiliation for the majority of the study’s 
pathology investigators (including neuropathologists for the SIDS analysis). Upon receipt 
of the samples at their respective locations, histology slides were made from the blocks 
placental tissue by lab technicians in preparation for the microscopic examination. The 
examinations were completed by one of two study placental pathologists (one at each 
location) according to a standardized protocol. The features noted during the microscopic 






Published standards were used to assign gestational age-standardized percentiles 
for placental weight, as well as umbilical cord length and diameter.235-237 The published 
standards were based on normal placentas of deliveries that occurred at specific 
gestations. Measurements were considered small if the values were <10th percentile for 
gestational age and large if the values were >90th percentile for gestational age.  
 
Quality Assurance/ Quality Control 
Several procedures were put in place to support the quality and uniformity of the 
pathological examinations.238 During a pilot study (2005-2006), the study pathologists 
developed and piloted a set of diagnostic manuals for placental evaluation that were 
finalized and implemented for the Safe Passage Study. Along with the manuals, the 
pathologists established a “calibrating” set of classic placental pathology cases for 
reference. Pathologists completing the microscopic evaluations were blinded to the 
outcome of the pregnancy.239 (Given the close proximity to the delivery, blinding could 
not be guaranteed for those who did the macroscopic evaluations.)  
In summer 2010, once the first 10% of the target (~280 placentas) had been 
examined, 20% (n=43) were randomly selected for blinded re-review by both study 
placental pathologists. Following, interrater reliability kappa statistics were computed to 
estimate concordance240 between two pathologists with respect to 5 features on the 
microscopic examination that may be more prone to discordant diagnosis: 




location), chorionic plate/stem villus thrombosis, microscopic abruption, and villitis. 
Agreement was fair for meconium-laden macrophages (kappa=0.39), moderate for 
chorioamnionitis intensity and microscopic abruption (kappas 0.42 and 0.58, 
respectively), and substantial for chorioamnionitis present and chorionic plate/stem villus 
thrombosis (kappas were 0.61 and 0.62, respectively).  The two pathologists discussed 
the areas of discordance in an effort to unify diagnoses going forward.  
 
Growth Outcomes 
Infant weight and head circumference at delivery were measured by clinical staff, 
recorded in the medical record, and then abstracted for the purpose of the study. 
Gestational age was determined at enrollment and estimated based on standard local 
clinical practice (i.e., obstetric ultrasound in South Africa, a clinical evaluation based on 
clinical examination, obstetric ultrasound, and last menstrual period in the U.S.). Given 
our particular interest in birthweight percentiles, we excluded women who lacked 
information on gestational age or birthweight (<1%). We assigned percentile categories 
for these metrics given sex and gestational age at delivery based on the standards 
established by the World Health Organization (WHO).241 Birthweight and head 
circumference were categorized as <5, 5-<10, 10-<25, 25-<50, 50-<75, 75-<90, 90-<95, 
and ≥95 percentile. For head circumference, we also derived <2.5 and >97.5 percentile. 
SGA was defined as birthweight <10th percentile and LGA was defined as birthweight 
>90th percentile. The WHO charts cover gestational ages between 20 and 40 weeks’. 




occurring after 40 weeks’. These deliveries were excluded since a WHO percentile could 
not be assigned.   
 
Pregnancy Complications and Other Neonatal Outcomes 
 Several other neonatal outcomes were considered in our analysis. These included 
stillbirth (defined as fetal loss ≥20 weeks’ gestation), preterm delivery (<37 weeks’), 
early preterm delivery (<34 weeks’), and infant death during the first year of life. We 
evaluated preterm delivery among all pregnancies, as well as among live births only. 
Stillbirths were categorized according to the primary cause of death based on the 
Boyd/PASS stillbirth classification scheme.242 We also considered preeclampsia, 
gestational diabetes, medically-induced preterm delivery (that is, delivery occurring 
before 37 weeks’ and after induction of labor or Cesarean without spontaneous labor), 
Apgar score at 1 minute, infant resuscitation at birth, and neonatal intensive care unit 
(NICU) admission before delivery discharge. Since these pregnancy complications and 
outcomes may be affected by clinical practices, we stratified all of these results by study 
setting (Northern Plains, U.S., versus Western Cape, South Africa).  
 
Covariates  
We considered a number of previously suggested risk factors for FGR in the 
analysis. These included 1) maternal medical history, i.e., history of chronic 




pregnancy body-mass-index (BMI) and BMI at enrollment, various measures of smoking, 
alcohol, and drug use during the pregnancy (including trajectories of exposure throughout 
pregnancy that take into account timing and quantity243); and 3) conditions of the study 
pregnancy, i.e., use of fertility treatment for the pregnancy, vaginal bleeding during the 
pregnancy, hospitalization for vaginal bleeding, urinary tract infection during pregnancy, 
any type of infection during pregnancy, and oligohydramnios.  
 
Doppler Indices 
Women participating in the embedded protocol at the study centers in Sioux Falls, 
South Dakota, and Stellenbosch, Western Cape of South Africa, had Doppler ultrasound 
collected as part of the study at 20-24 weeks’, 28-32 weeks’, and 34-38 weeks’, in 
addition to any assessments done for clinical purposes. This additional study assessment 
was not performed on participants at the other study centers due to lack of availability of 
ultrasound equipment and trained research staff. The clinical and study data were 
combined for our analysis. 
 The study’s fetal biometry and Doppler assessments were performed according to 
a standard protocol developed for the Safe Passage Study based on clinical best practices. 
All sonographers participating in the study were certified ultrasonographer technologists 
and, prior to administering the research assessments, were trained according to the study 
data collection protocol to ensure uniformity across the sites. On-going quality 
monitoring was performed by the data coordinating and analysis center and a group of 




The Doppler study measures consisted of uterine artery pulsatility index (PI); 
umbilical artery PI, resistance index (RI), absent end-diastolic flow (AEDF), and systolic/ 
diastolic (SD) ratio; middle cerebral artery PI; and ductus venosus PI and A-wave. Most 
measures were collected as continuous variables which we then categorized for our 
analysis according to published normative percentiles for week of gestation. Umbilical 
artery PI,244 umbilical artery RI,245 umbilical artery SD ratio,245 uterine artery PI,246 and 
ductus venosus PI247 were flagged as abnormal if above the 95th percentile, whereas 
middle cerebral artery PI246 was flagged if below the 5th percentile.  
 
Statistical Analysis 
  We generated descriptive statistics of the placental features, birthweight, and 
birthweight percentiles overall and by study setting to review the data for plausibility and 
to visualize the distribution of the data and where the data were sparse. Because of the 
variety of possible mechanisms that could lead to missing data (e.g., under-diagnosis of 
certain conditions, refusals to answer, missed visits, missing at random), we decided to not 
use multiple imputation to replace missing values, but rather leave them missing. 
We decided to analyze the data from the two main study centers (Northern Plains, 
U.S., and Western Cape, South Africa) as one group for most of the analyses. Combining 
the samples seemed appropriate for several reasons. First, while the frequency of the 
biological mechanisms present in each population may differ based on maternal risk 
factors (e.g., smoking, comorbidities), the underlying biology (the potential for these 




study setting. Second, the study protocol, including placental evaluations, were 
standardized across all sites participating in the study. Lastly, one of the Stanek et al. 
investigations was also international and combined the data for analysis.23  
 
Hierarchical Clustering 
Supervised statistical learning methods aim to predict an observed outcome based 
on the data.230 In contrast, unsupervised approaches, like hierarchical clustering, aim to 
uncover the underlying structure of the data without specifying a particular outcome.230 
Clustering methods partition observations into distinct groups so that the observations 
within each group are similar to one another with respect to the input data and dissimilar 
to the observations contained within the other groups.  
We used hierarchical clustering, an unsupervised machine learning method, to 
identify latent groups based on placental features noted on the macro- and microscopic 
study evaluations. All variables were input into the model as indicator variables. We used 
Ward’s D linkage248 with Jaccard as dissimilarity measure.249 Jaccard is used when the 
inputs are dichotomous.  
 Hierarchical clustering does not involve pre-specification of the number of groups 
expected in the data. Rather, hierarchical clustering provides information on what the 
groupings would be for a variable number of groups. The observations are subdivided in 
a tree-based representation called a dendrogram (refer to example in Figure 4.1). The 
term “hierarchical” refers to the fact that when the dendrogram is cut at a given height, 




greater height in the dendrogram. The choice of number of clusters for our analysis was 
informed by two common statistical approaches, specifically the average silhouette 
method and the gap statistic.250, 251 The silhouette method is a measure of how well each 
observation fits into each cluster. A high silhouette value is good, so based on this 
method alone, one would select the number of clusters that corresponds to the highest 
silhouette. The gap statistic compares the intra-cluster variation for different numbers of 
clusters in comparison with the null (0 clusters). The optimal number of clusters 
maximizes the gap statistic. The elbow method was also considered but discarded. The 
elbow method is based on the total within-cluster sum of squares. One aims to have the 
within-cluster sum of squares be as small as possible. When one plots the number of 
clusters against the total within-cluster sum of squares, a bend (elbow) in the plot is 
considered an indicator of the appropriate number of clusters. In our data, there was no 
clear bend, so this method did not prove useful. In addition to these methods, we also 
took into account the number of observations within each cluster and knowledge of 
related pathologies.  
The procedure groups each participant into one cluster, but does not require 
features to occur exclusively within one group. Therefore, many features were present in 
more than one cluster but were most frequent in one cluster.  
The machine learning procedure requires no missing data and at least one feature 
be present. This meant that two small groups of participants were excluded from cluster 
procedure: 1) those without any abnormalities and 2) those with missing values for at 




These participants were subsequently added to the most appropriate cluster group, so that 
they were not excluded altogether from the analysis. Specifically, participants who had 
no abnormalities were grouped into the cluster that had the least number of abnormalities. 
Those missing values at random were grouped into a seemly normal, mixed etiology 
cluster, since the abnormalities that were observed among this missing group did not 
appear to occur a high frequency.  
 
Amsterdam Criteria 
The Amsterdam criteria were established in 2016 by an international expert panel 
of placental pathologists and include a consensus-based placental sampling protocol and 
diagnostic criteria for commonly co-occurring placental lesions with theorized clinical 
significance.234 The five groups of placental lesions defined by the Amsterdam criteria 
are maternal vascular malperfusion, fetal vascular malperfusion, delayed villous 
maturation, patterns of ascending intrauterine infection, and villitis of unknown etiology.  
We reviewed the distribution of the machine learning-based cluster groups 
according to the placental lesions under each category in the Amsterdam criteria. We 
chose labels for each cluster identified in our hierarchical clustering analysis based on the 
most common features as defined by the Amsterdam criteria groups. We collapsed across 
“similar” clusters (originating from same higher-level of the dendrogram) when there 
were not meaningful differences in the clinical significance or severity of the placental 
lesions based on the definitions provided in the Amsterdam criteria. For instance, two 







We randomly split the sample 50/50 and re-did the analysis to see how well the 
same conceptual clusters could be identified in each subsample.  
 
Associations with Neonatal Outcomes, Growth, and Other Factors 
We theorized that the identified clusters represent different underlying etiologies, 
some of which may result in greater risk of FGR. Therefore, once we settled on the final 
clusters, we descriptively assessed differences by cluster in terms of growth and other 
neonatal outcomes, pregnancy complications, potential FGR risk factors, and Doppler 
ultrasound indices. 
 
Variation in Neonatal Outcomes Explained by Growth and Placental Pathology Clusters 
We were interested in understanding how our ability to explain variation in select 
neonatal outcome might improve with the addition of placental pathology cluster 
information, in addition to infant birthweight. The neonatal outcomes modeled included 
head circumference < 10th percentile based on WHO, stillbirth, preterm birth, and infant 
death. Each outcome was modeled as the dependent variable, and we used combinations 
of the birthweight percentiles and placental clusters as the independent variables. 
Specifically, the sets of independent variables were: 1) WHO-based definition for SGA 




clusters, 4) SGA, the clusters, and an interaction term, 5) the full spectrum of birthweight 
percentile categories, 6) birthweight percentile categories and placental clusters, and 7) 
birthweight percentile categories, placental clusters, and an interaction term. Models were 
compared in terms of the c-statistic for discrimination, adjusted R-square for variance 
explained, and -2 log likelihood for maximizing the likelihood.  
 
Macroscopic Flag 
We used random forest machine learning models to identify macroscopic 
placental features that were important for classification of the abnormal placental 
clusters. Random forest is a supervised machine learning approach. The algorithm 
summarizes classification accuracy of an outcome across a set (forest) of individual 
trees.252, 253 Here the outcome modeled was abnormal (i.e., maternal vascular 
malperfusion, fetal vascular malperfusion, inflammation) versus normal placental 
clusters. Variable importance is a key metric generated by random forest that summarizes 
the degree to which each independent variable contributes to the model. We fit random 
forest models comprising 1,000 single classification trees, with 5 variables randomly 
sampled at each node with a minimum of 20 observations needed for a split. Model 
discrimination was evaluated using area under the curve (AUC). To determine variable 
importance, we used a method based on the AUC with out-of-tree bags.254 In brief, this 
method calculates the AUC for each individual tree and then recalculates it after the 
participant values for an individual covariate are randomly permutated so it is no longer 




by the variable importance. There is not a straightforward interpretation of the absolute 
values of variable importance. However, they can be helpful to rank variables, with larger 
values indicating greater importance. Unimportant values lie just above and below 0. 
Traditionally, factors are considered ‘important’ if their variable importance values are 
higher than the absolute value of the lowest ranked predictor.255 An individual 
classification tree subdivides the data based on probability of being classified as an event 





 The analytic sample included 2,005 singleton pregnancies (Table 4.2). Of the 2005 
pregnancies, 1.6% resulted in stillbirth, 12.5% were preterm deliveries, and 20.7% were 
born SGA according to the WHO percentiles.  
 
Maternal Characteristics 
 Roughly 38% (n=771) of the sample was from the Northern Plains, U.S., and the 
other 62% was from the Western Cape of South Africa (Table 4.2). The most frequent 
maternal age range was 25 to 29 years old (32.6%). A minority of pregnancies occurred 
among women <20 years (14.5%) or ≥35 years (7.5%). Just over one third (38.4%) of the 




among women who identified as white (n=649, 88.2%), and the remainder identified as 
American Indian (n=99, 12.8%) or other race (n=23, 3.0%). Essentially all women from 
the Western Cape, South Africa, identified as mixed ancestry. There were stark 
differences in education level based on the setting. Most women in South Africa did not 
have a high school education (73.4%), whereas most women from the U.S. at least some 
college education (79.8%). Most women were living with their partner (63.0%). A 
quarter received financial support from the government for their pregnancy.  
 
Gestational Age and Size at Delivery 
 The distributions of gestational age at delivery were similar between the two 
study settings, although deliveries in South Africa occurred an average of 2.6 [95% 
confidence interval (CI) 1.4 to 3.9] days earlier than in the U.S. (Figure 4.2). The 
distributions differed more for birthweight, with infants in South Africa being lighter by 
469 (95% CI 416 to 521) grams on average (Figure 4.3). Head circumference at birth 
tended to be 40 mm wider in the Northern Plains than in South Africa. However, the 
association between head circumference and study setting was no longer present after 
accounting for gestational age and weight at delivery. The WHO percentiles for 
birthweight and head circumference are presented in Table 4.3. As one might expect 
based on the aforementioned distributions, pregnancies in South Africa tended to be 
smaller, with 78.5% of birthweights falling below the 50th WHO percentile. The 
pregnancies from the Northern Plains, U.S., tended to follow a more normal distribution 




infants comprised >20% of the sample. The distributions for head circumference were 
more similar between the two study settings. For South Africa, 59.5% of head 
circumferences fell between the 25th and 75th percentile, and for the U.S., 52.6% fell 
between the 25th and 75th percentile. For both study centers, a large proportion of 
measurements fell just above the 95th percentile cut off, resulting in 16.8% and 33.1% 
>95th percentile for South Africa and the U.S., respectively. It is worth noting that 17.6% 
of the pregnancies had unknown head circumference in the U.S. sample, whereas data 
were missing in only 3.3% of the South African sample. 
 
Placental Clusters 
The average silhouette method suggested only 2 clusters, whereas the gap statistic 
recommended 47 clusters. Ultimately, a 7 group model was selected, as it seemed a 
reasonable compromise between number of clusters, size of clusters, and clinically 
meaningful differences in patterns of placental features. There was high overlap with the 
Amsterdam descriptors for various etiologies. Features associated with severe maternal 
vascular malperfusion were most common in cluster 2 (n=117), whereas features of fetal 
vascular malperfusion were more common in cluster 3 (n=222). Signs of inflammation 
were more common in two clusters, but since the slight differences in features between 
these two groups did not appear to be clinically meaningful in terms of severity, these 
two clusters were collapsed to create a single cluster 4 (n=444). Following, the other 3 
clusters (few-to-no abnormalities, not severe mixed etiology, and mild grade signs of 




used as the reference (refer to Figure 4.1 and Table 4.4).  
The most common features of the maternal vascular malperfusion cluster (cluster 
2) were retroplacental bleeding with hemorrhage (97%), microscopic signs of placental 
abruption (88%), retroplacental blood clot (78%), and a few nucleated fetal erythrocytes 
(72%), and chorioangiosis (55%). Among the fetal vascular malperfusion cluster (cluster 
3), the most common features were increased patchy perivillous fibrin (80%), a few 
nucleated fetal erythrocytes (67%), small placenta (60%), in utero underperfusion (4 or 
more features present) (59%), and short cord (56%). Among the inflammation cluster 
(cluster 4), the most common features were meconium-associated amnion necrosis 
(70%), meconium-laden macrophages in the amnion (50%), and acute chorioamnionitis 
(47%).  
 
Split Sample Validation 
Upon splitting the sample in half and re-doing the creation of the clusters, similar 
groups were identified in each half sample, with good overlap between the original and 
new clusters. The primary distinction in the split samples was that more placentas were 
identified as affected by fetal vascular malperfusion compared to the analysis using the 
whole sample. Since the method allowed for features to be overlapping (non-exclusive) 
between clusters, it is possible that some pregnancies were, for instance, categorized as 
normal in the main analysis but were also affected by some features of fetal vascular 





 In sample 1 (n=1002), 72% contained in the original normal cluster created on the 
entire sample fell within the newly derived normal cluster, 91% of the original maternal 
vascular malperfusion cluster were in the new maternal vascular malperfusion cluster, 
81% of the original fetal vascular malperfusion cluster were in the new fetal vascular 
malperfusion cluster, and 79% from the original inflammation cluster were in the new 
inflammation cluster (kappa = 0.61, 95% CI 0.57 to 0.65). In sample 2 (n=1003), the 
percentages of the new clusters contained within the original clusters were 73%, 73%, 
85%, and 74% for normal, maternal vascular malperfusion, fetal vascular malperfusion, 
and inflammation, respectively (kappa 0.59, 95% CI 0.55 to 0.64). The patterns of 
individual placental features observed in each split sample clusters were largely the same 
as those observed in the original overall sample (Table 4.5).  
 
Associations with Neonatal Outcomes and Growth 
 The maternal vascular malperfusion cluster had the highest prevalence of several 
neonatal outcomes, such as stillbirth and preterm birth (including early preterm and 
medical induced preterm birth) (Table 4.6). The growth outcomes (SGA and head 
circumference <10th percentile) were more common among all abnormal placental 
clusters, compared to the normal cluster, but were most common among the fetal vascular 
malperfusion cluster. The abnormal placental clusters also had higher likelihood of Apgar 
<7 at 1 minute, resuscitation at birth, and NICU admission, although patterns differed by 
study setting. For instance, NICU admissions were highest among the maternal vascular 




only outcomes that were as or more common among the normal cluster compared to the 
abnormal clusters were gestational diabetes and infant death during the first year of life.  
 
Variation in Neonatal Outcomes Explained by Growth and Placental Pathology Clusters 
Consistently, across all four selected outcomes, the models including the full 
spectrum of WHO birthweight percentiles and the placental clusters yielded the best 
discrimination (highest c-statistic), explained variance (highest max-rescaled R-square), 
and maximized likelihood (lowest -2 log likelihood) (Table 4.7). Further, all model 
statistics showed benefit of using the placental cluster information plus SGA, or the full 
spectrum of birthweight percentiles without placental data, over SGA alone. The c-
statistic for the model with preterm birth as the dependent variable and the full spectrum 
of WHO birthweight percentiles and the placental clusters as the independent variables 
had the best statistics in comparison to the preterm birth models using the other sets of 
independent variables but indicated poor explanatory ability (c-statistic=0.62). In 
contrast, the c-statistics were strong when modeling stillbirth, head circumference <10th 
percentile, and infant death using the full spectrum of WHO birthweight percentiles and 
the placental clusters as the independent variables (c-statistics >0.8). The adjusted R-
squared values were the best (>0.2) for the head circumference <10th percentile and 
stillbirth models using the full spectrum of WHO birthweight percentiles and the 
placental clusters as the independent variables. These findings suggest a benefit of 
studying the full distribution of birthweight, as well as placental pathology if available, as 




alone, in our sample.  
 
Macroscopic Flag 
 The random forest model using the 25 placental features available from the 
macroscopic evaluation was fairly good at distinguishing between placentas contained 
within any of the abnormal clusters (identified via our hierarchical clustering procedure) 
versus those within the normal cluster (AUC=0.65). The variable importance plot is 
shown in Figure 4.4. Fourteen variables were identified as important. Based on these 14 
macroscopic features, we generated a single classification tree (Figure 4.5). We then 
created a dichotomous flag variable based on the features in the single classification tree 
that were present in 50% or more of the abnormal placentas. Specifically, placentas met 
the criteria for this flag if they had: macroscopic abruption OR placental weight <10th 
percentile and marginal infarction OR placental weight <10th percentile and cord 
diameter ≤90th percentile and central infarction OR placental weight <10th percentile and 
meconium present in cord but normal insertion OR placental weight between 10th and 
90th percentile and marginal infarction. The flag had moderate positive and negative 
predictive values (62.4% and 65.4%, respectively) when used to identify abnormal versus 
normal placentas (based on our placental clusters identified in the hierarchical clustering 
procedure). The flag captured 47.0% of placentas within the maternal vascular 
malperfusion cluster, 27.0% of placentas in the fetal vascular malperfusion cluster, 18.9% 
of placentas in the inflammation cluster, and 9.8% of normal placentas. The neonatal 




flag variable as the independent variables were not as strong as using the full spectrum of 
birthweight percentiles plus the four placental clusters but still demonstrated 
improvement over using SGA alone (Table 4.8).  
 
Antenatal Risk Factors and Doppler Measures  
With respect to antenatal risk factors (Table 4.9), a few findings were common 
across both study settings. Marijuana use during pregnancy was more common among 
the inflammation clusters. Hospitalization for vaginal bleeding was more common among 
the maternal vascular malperfusion clusters. Lastly, oligohydramnios was most common 
in the maternal vascular malperfusion cluster (as well as the fetal vascular malperfusion 
cluster in South Africa).  
That said, most findings with suspected antenatal risk factors were study setting-
specific (Table 4.9). In the Northern Plains, U.S., BMI tended to be lower among the 
fetal vascular malperfusion cluster and higher among the normal and inflammation 
clusters. In South Africa, BMI was lower among the maternal vascular malperfusion and 
inflammation clusters and was higher among the fetal vascular malperfusion cluster. 
Moderate-to-high continuous smoking during pregnancy and environmental smoking 
exposure was more common among the maternal vascular malperfusion cluster in the 
Northern Plains, whereas moderate-to-high continuous smoking was higher among the 
fetal vascular malperfusion and inflammation clusters in South Africa. Alcohol 
consumption throughout pregnancy was highest among the fetal vascular malperfusion 




South Africa. Any infection diagnosis during pregnancy was more common among the 
inflammation cluster in the Northern Plains, whereas diagnosed infection was most 
common among the fetal vascular malperfusion cluster in South Africa.  
 Abnormal Doppler indices were fairly uncommon, but some patterns were noted 
(Table 4.10). Low middle cerebral artery PI occurred more often among the maternal 
vascular malperfusion cluster in both study settings. With respect to site-specific 
findings, abnormal umbilical artery PI and RI were more common among the maternal 
vascular malperfusion cluster in the Northern Plains and among the fetal vascular 
malperfusion cluster in South Africa. Findings may be due to chance, especially in the 
Northern Plains where few individuals were in the vascular malperfusion cluster. Lastly, 
estimated fetal weight <10th percentile was most common among the maternal vascular 
malperfusion cluster in the Northern Plains and among the inflammation cluster in South 
Africa. The degree of missing data varied for the Doppler indices (for some nearly 30%), 




 Our study of two settings (i.e., Northern Plains, U.S. and Western Cape of South 
Africa) demonstrated that hierarchical clustering—a data-driven approach—can be used 
to group pregnancies based latent patterns of placental features. We identified one cluster 
with low prevalence of abnormalities that we considered normal (60.9% of the analytic 




expert consensus-based Amsterdam criteria.234 Specifically, there was a severe maternal 
vascular malperfusion cluster (5.8%) characterized by retroplacental bleeding with 
hemorrhage, microscopic signs of placental abruption, and retroplacental blood clot. 
There was also a fetal vascular malperfusion cluster (11.1%) characterized by increased 
patchy perivillous fibrin, small placenta, and four or more features of in utero 
underperfusion, and an inflammation cluster (22.1%) characterized by meconium-
associated amnion necrosis, meconium-laden macrophages in the amnion, and acute 
chorioamnionitis. Some investigator manipulation was involved to collapse conceptually-
like clusters (to limit data from being too sparsely subdivided), but the degree of 
investigator-manipulation was minimal—only to collapse groups that had already 
identified, not to re-categorize. Upon splitting the sample, the same conceptual clusters 
were identified, with moderate agreement.  
 The clusters were weakly-to-moderately associated with certain antenatal risk 
factors, pregnancy complications, and neonatal outcomes. The strongest associations 
were observed between the maternal vascular malperfusion cluster and preeclampsia, 
stillbirth, and preterm birth (including medically induced preterm birth). The growth 
outcomes (SGA and head circumference <10th percentile) were more common among all 
abnormal placental clusters, compared to the normal cluster, but were most common 
among the fetal vascular malperfusion cluster. Maternal BMI tended to be lower among 
the fetal vascular malperfusion cluster in the Northern Plains and in all abnormal clusters 
in the Western Cape. Infection during pregnancy was more common among the 




consideration of the full spectrum of birthweight percentiles—not just SGA versus non-
SGA—as well as placental pathology findings improve the variability explained for 
select neonatal outcomes (stillbirth, preterm birth, head circumference at birth <10th 
percentile, and infant death in the first year of life).  
 Given that a comprehensive clinical pathology is usually only conducted on 
selected placentas with suspected problems, it is important to understand whether certain 
macroscopic features can be used to screen placentas that are likely to have microscopic 
lesions, as a clinical flag that further microscopic evaluation is warranted and to be an 
indicator of placental abnormalities in etiologic research when only macroscopic details 
are available. The flag we created for being in any of the three abnormal placental 
clusters based on macroscopic information alone did not yield high accuracy (positive 
and negative predictive values were 62% and 65%, respectively). Still, the macroscopic 
flag had some improvement to explain the variance of select neonatal outcomes, 
compared to using SGA alone. This may be because the placentas with the most severe 
lesions tend to be identifiable macroscopically. The cluster that was best identified based 
on macroscopic features only was maternal vascular malperfusion. Depending on the 
setting (resources available, prevalence of abnormalities), this type of macroscopic flag 
may have clinical utility, but more work is needed. More than half of abnormal placentas 
would be missed based on this initial screen because their abnormalities are only 
detectable through microscopic evaluation. The cluster that was most often missed by the 
macroscopic flag were placentas with inflammation-related lesions. Conversely, ~10% of 




Difficulty with Identifying Fetal Growth Restriction  
 Ideally, we would have evaluated the relation between the placental clusters and 
intrauterine growth restriction,149 instead of SGA, given that FGR was our primary 
conceptual outcome of interest. However, FGR is much more challenging to identify than 
SGA.256 For one, there is not a gold standard method for classification of FGR. Since 
FGR relates to a period of suboptimal fetal growth, in theory one would track fetal 
growth over time and identify whether the fetal growth trajectory ever flattens relative to 
normative growth in the absence of FGR.257, 258 A recent expert consensus paper 
proposed a classification scheme for identifying FGR in neonates,216 but to our 
knowledge, this method has yet to be validated. One study that closely approximated the 
fetal growth trajectory ideal was the NICHD Fetal Growth Study, where an algorithm 
was developed to compute fetal growth velocity percentiles based standardized serial 
fetal biometry collected across pregnancy.259 The data were drawn from a U.S.-based 
sample of uncomplicated pregnancies (n=2,802).259 Growth velocity <10th percentile was 
used to identify suspected cases of FGR. In most research settings, however, the serial 
data needed to identify FGR are lacking. In clinical practice, serial ultrasounds are only 
performed on pregnancies flagged as being potentially worrisome, such as those with 
lower than expected fundal height (the distance between the pubic bone to the top of the 
uterus).149, 260, 261 Even when serial ultrasound data are available, the accuracy of interval 
growth assessment can be affected by certain factors, such as interrater reliability and 
machine calibration.262-266 Further, the variability of fetal growth increases over time, an 




measurements taken to develop the reference charts to assign percentiles and to determine 
the gestational age of the pregnancy (when last menstrual period is unknown or 
unreliable) are also affected by these issues. Lastly, there are debates about which growth 
charts are most appropriate to use given the population under study.193  
 
Limitations 
Misclassification and Model Misspecification  
There was potential for misclassification of our placental clusters. The placental 
lesions which were used to identify the clusters were assessed according to standardized 
criteria. However, the placental inter-rater placental concordance findings from the Safe 
Passage Study may seem suboptimal, especially compared to other areas of study. Inter-
rater agreement is a known issue in pathological examinations, particularly when raters 
are blinded to clinical information.268 Practice guidance for placental examination was 
presented by the College of American Pathologists in the late 1990s,269 but over the 
years, definitions have been refined and additional lesions have been noted. Thus, while 
our agreement statistics may not seem great, they are in line with what would be 
expected. In fact, inter-rater agreement with a kappa of 0.5 or more has been considered 
high for placental pathology.270 Further, it is important to keep in mind that the sample 
size for the inter-rater evaluation was small. Also, this assessment was done in the early 
years of the Safe Passage Study. Concordance may have improved over time, after the 
findings were discussed among the pathology team. Still, there may be some subjectivity 




pregnancy could not be guaranteed, given the proximity to the delivery, which could have 
resulted in bias.  
In addition to the complications of pathological evaluation, there were a number 
of modeling decisions that needed to be made to determine the hierarchical clusters (e.g., 
(dis)similarity measure, type of linkage, number of clusters). We reported the results 
using Ward’s linkage with Jaccard dissimilarity because these parameters were used in 
the studies by Stanek et al.22-24 In sensitivity analysis, Stanek et al. applied other methods 
and found the results were similar, with high overlap.22 We also found similarities when 
attempting complete and average data linkage; however, the data tended to be more 
sparsely divided (results not shown).  We applied subject knowledge to determine which 
clusters were clinically distinct. Each of these decisions could have affected the final 
classification of the placental clusters. With these machine learning methods there is no 
single “right” answer.230 The best one can do is modify parameters, assess how aspects of 
the data are being exposed, and attempt to validate the clusters.230 We had no gold 
standard for comparison. Our split sample analysis identified similar conceptual clusters. 
However, the actual classifications were not entirely overlapping with the main analysis.  
Given all this, we caution that our study was an exploratory and highly data-
driven. Our results should not be over-interpreted but rather considered more of a proof-
of-concept study, demonstrating that machine learning approaches may be useful to 
identify clinically meaningful latent patterns in high dimensional placental data. Some 
investigator manipulation was involved to collapse conceptually-like categories. In 




learning—to build robust, dependable, and data-efficient models—and oversight from 
content-area experts—who have an understanding of context and who can hone in on the 
results of greatest clinical relevance.271  
 
Selection, Missing Data, and Representativeness  
Most placental studies comprise retrospective pathological evaluations recorded 
in medical records. While the sample sizes are sometimes larger than ours, the samples 
often include overrepresentation of complicated pregnancies, since clinical pathology 
examinations are usually done only when problems are suspected. We assume that our 
sample contained a more representative sample, including uncomplicated pregnancies, 
since the participants were randomly selected for placental collection prior to 24 weeks’. 
In addition, we had data from additional sources, other than simply the medical record, so 
we could look at a variety of covariates. Still, these data had limitations. We did not have 
information on certain potentially important risk factors, like nutrition and environmental 
toxins. We also lacked data on long-term outcomes. We had considered evaluating 
relationships with growth over the first year of life but found that a high proportion of the 
infants had incomplete or temporally-sporadic information. Under-diagnosis of certain 
medical conditions may have also been an issue, particularly in South Africa, which 
could partly explain why we did not observe stronger associations with specific abnormal 
placental clusters. A possible explanation for why we did not see clearer associations 
with prenatal smoking, alcohol, and drug use in South Africa was that these exposures 




placental clusters. While the distributions of these exposures in the Northern Plains data 
were more approximate to the general U.S. population, the abnormal placental clusters, 
particularly the vascular malperfusion ones, were relatively rare in the U.S. data, making 
it hard to identify clear patterns.  
 
Comment 
 Our study serves as proof-of-concept of the potential of data mining tools to aid 
epidemiologists in the etiologic study of elusive pregnancy conditions like FGR. We 
made note of a few other studies that applied analytic techniques common to our study 
for prediction of fetal size272, 273 and severe neonatal morbidity274 and identification of 
high risk subgroups of early preterm birth.275 Still, these types of methods remain 
uncommon in perinatal epidemiologic research. In addition, our study highlights the 
potential benefit of including placental data, even if only crude macroscopic observations 
are available (e.g., placental weight, signs of abruption). The placenta is known play a 
vital role in pregnancy. Yet, there is much to learn about how studying the placenta may 
improve our understanding of the etiology of suboptimal growth and other adverse 
neonatal outcomes. Our study focused on placental information that is not available until 
delivery. However, clinical practice may be best aided by early risk prediction in 
utero.276, 277 Placental screening tools, such as estimation of placental volume and 
detection of placental lesions through obstetric imaging, are still in early development 
and are not yet ready for widespread clinical use but have demonstrated promising 




given that many other approaches for fetal growth screening (e.g., universal third 
trimester ultrasound, certain Doppler metrics, pregnancy associated plasma protein A) 






Table 4.1 Description of Placental Pathology Features 
Location Feature Definition 
Umbilical 
cord 
Vasculitis Inflammation within umbilical vessel wall(s) 
Funisitis Inflammation extending to Wharton’s jelly 
Thrombosis Thrombus within umbilical vessel(s), seen as fibrin 
thrombus adherent to umbilical vessel wall, or thrombus 
incorporation into umbilical vessel wall 
Meconium vascular 
necrosis 
Meconium laden macrophages apposed to vascular wall, 
with myocyte nuclear pyknosis and rounding up or 





Chorioamnionitis Inflammation of the extraplacental membranes and/or 
membranes of the chorionic plate 
Meconium-laden 
macrophages 












Inflammation within chorionic vessel walls 
Chorionic plate/stem 
villus thrombosis 
Thrombus within chorionic vessel(s), seen as fibrin 
thrombus adherent to chorionic vessel wall, or thrombus 
incorporation into chorionic vessel wall 
Amnion nodosum Nodular collections of fetal squames and/or vellus hairs 
adherent to the amnion surface 
Hemosiderin Refractile irregular brown pigment within macrophages  
Decidual arteriopathy Persistence of smooth muscle of decidual arterioles, and/or 
replacement of arteriolar walls with bright eosinophilic 
matrix material / with or without foamy macrophages  
Parenchyma Maturation Modeling of terminal chorionic villi appropriate for 
gestational age 
Infarct(s) Old: Ischemic necrosis of chorionic villi  
Recent: Crowding of chorionic villi with loss of 
intervillous space with or without loss of nuclear staining 




Excessive blood behind the placental disc 
Microscopic 
abruption 
Retroplacental blood and placental infarction and/or blood 
tracking into the intervillous space 
Villitis Inflammatory cells within chorionic villi 






Extravasation of intact fetal red cells within villous stroma 
Villous-stromal 
karyorrhexis 
Extravasation of fragmented fetal red cells/ nuclear debris 
within villous stroma 
Avascular villi Clusters of villi devoid of fetal capillaries 
Villous edema Clearing of villous stroma or separation of villous 




Fetal red cells with retained nucleus 
Chorangiosis Terminal villi with an excess of capillary profiles and 
consequential enlargement of villous size for gestational 
age 10 villi with >10 capillary profiles in > 10 fields  




Terminal chorionic villi that are hypermature and 
diminished in density, resulting in excessive intervillous 
space; must involve full thickness area(s) of the placental 
disc 
Extravillous fibrinoid 
/ trophoblast islands 










Table 4.2 Maternal and Pregnancy Characteristics of Analytic Sample of 2005 Singleton 
Placentas, Safe Passage Study (Northern Plains, U.S., and Western Cape, South Africa, 
2007-2015) 
Characteristic N (%) 
Study Center Northern Plains, U.S. 771 (38.5) 
 Western Cape, South Africa  1234 (61.6) 
Stillbirth  27 (1.6) 
Gestational Age 20-33 Weeks 67 (3.3) 
 34-36 Weeks 184 (9.2) 
 ≥37 Weeks 1754 (87.5) 
Small-for-Gestational Age 415 (20.7) 
Large-for-Gestational Age 224 (11.2) 
Maternal Age <20 Years 290 (14.5) 
 20-24 Years 506 (25.2) 
 25-29 Years 654 (32.6) 
 
29-34 Years 404 (20.2) 
 
≥35 Years 151 (7.5) 
Nulliparous  770 (38.4) 
Race American Indian 99 (4.9) 
 
Mixed Ancestry 1233  (61.5) 
 
White 649 (32.4) 
 
Other 24 (1.2) 
Education Less than High School 963 (48.0) 
 High School 364 (18.2) 
 Beyond High School 676 (33.7) 
Partnered and Living Together 1261 (63.0) 




Table 4.3 Distribution of WHO Percentiles for Birthweight and Head Circumference 











Birthweight    
<5th Percentile 11.7 16.3 4.4 
5th to <10th Percentile 9.0 12.6 3.1 
10th to <25th Percentile 19.8 25.1 11.2 
25th to <50th Percentile 21.0 21.6 20.0 
50th to <75th Percentile 17.1 13.5 22.8 
75th to 90th Percentile 10.3 6.7 16.0 
90th to <95th Percentile 4.6 1.5 9.5 
95th or Greater Percentile 6.6 2.5 13.1 
Head Circumference    
<5th Percentile 5.8 8.1 1.4 
5th to <10th Percentile 1.7 1.6 1.9 
10th to <25th Percentile 10.3 13.1 5.0 
25th to <50th Percentile 21.2 26.4 11.3 
50th to <75th Percentile 17.0 12.2 26.0 
75th to 90th Percentile 18.9 20.9 15.3 
90th to <95th Percentile 2.7 0.9 6.0 
95th or Greater Percentile 22.4 16.8 33.1 





Table 4.4 Description of Placental Pathology Clusters by Amsterdam Criteria, Safe Passage Study (n=2005 singleton pregnancies 
from Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 
      Cluster 1 Cluster 2 Cluster 3 Cluster 4 








Placental Feature Description n=1222 n=117 n=222 n=444 
Maternal Vascular Malperfusion     
-Placental Hypoxia      
 Small Placenta* <10th percentile for gestational age 35.5 46.2 59.9 48.0 
 Thin cord* <10th percentile for gestational age 2.9 3.4 3.2 4.3 
 Short cord <10th percentile for gestational age 48.0 40.2 55.9 48.2 
-Infarctions      
 Microinfarcts present*  11.2 23.1 41.9 15.8 
 Multiple old infarcts*  3.0 12.0 10.4 5.9 
 Multiple recent 
infarcts* 
 2.6 8.6 2.3 2.3 
 Macroscopic 
pathological infarction 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 
1.4 10.3 3.6 1.4 
 Microscopic 
pathological infarction* 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 
5.6 18.0 14.9 7.4 
-Retroplacental 
Hemorrhage 
     
 Retroplacental Blood 
Clot (macro) 
Macroscopic evidence that bleeding 
occurred (indicator of possible 
abruption) but clotted between the 
placenta and the wall of the uterus 





bleeding - old 
 3.0 6.0 2.7 4.7 
 Retromembranous 
bleeding - recent 





Bleeding behind the placenta upon 
microscopic evaluation, with 
infarction 





Bleeding behind the placenta upon 
microscopic evaluation, with 
intervillous hemorrhage 
7.2 97.4 3.6 7.0 
 Recent intervillous 
hemorrhage* 
Placental hemorrhage involving one 
of the larger veins of the villous 
vascular axis 
6.0 44.4 3.2 5.0 
 Indentation 
(abruption)* 
 2.3 16.2 3.2 1.6 
 Placental abruption 
(macro)* 
Macroscopic evidence of abruption 
(detachment from uterine wall, either 
partial or total) 
2.9 31.6 5.9 1.8 
 Placental abruption 
(micro)* 
Microscopic evidence of abruption 
(detachment from uterine wall, either 
partial or total) 
3.0 88.0 1.4 1.6 
-Villous Development      
 Distal Villous 
Hypoplasia* 
Abnormal development of placental 
villi with an apparent increase in 
intervillous space associated with 
low placental weight and growth 
restriction 
2.4 8.6 27.5 7.4 
 Accelerated 
Maturation* 
Hypervascularity due to maternal 




 Decidual Arteriopathy* 
Abnormal / incomplete remodeling 
of the spiral arteries resulting in 
necrosis 
3.8 16.2 9.0 5.2 
 Chorioangiosis (Focal) 
More than 10 terminal villi with 
more than 10 capillaries in several 
areas, with at least 15 vessels in 
occasional villi  
29.9 54.7 23.0 34.0 
       
Vascular Damage      
 Chronic Villitis  19.1 11.1 27.0 18.9 
 Patchy Villous Edema  20.1 27.4 23.0 23.9 
 Nucleated fetal 
erythrocytes (Few) 




chorionic plate vessels 
 8.9 15.4 12.2 9.7 
       
Fetal Vascular 
Malperfusion 
     
 Thrombosis*  0.8 1.7 0.9 2 
 Avascular villi 
(Regional)* 
One or more foci of avascular villi 
without an identified large-vessel 
thrombus 
16.5 16.2 40.5 17.3 
 Increased perivillous 
fibrin (Patchy)* 
Small amounts of fibrin are 
commonly scattered throughout the 
normal placenta 




 Increased perivillous 
fibrin (Regional)* 
Diffusely increased amounts of 
perivillous fibrin are a significant 
pathologic finding because may 
impair gas exchange and lead to 
growth restriction, 
oligohydramnious, premature birth 





Precursor to avascular villi 11.2 16.2 47.3 21.2 
 Villous-stromal 
karyorrhexis (Diffuse)* 
 1.2 1.7 1.4 0.2 
 In utero Underperfusion At least 4 features present 6.6 18.0 58.6 18.0 
       
Delayed Villous 
Maturation 
     
 Abnormal Maturation 
(other) 
Also called also called defective 
villous maturation and distal villous 
immaturity. Includes delayed, 
variable, arrest.  
14.9 7.7 15.8 15.7 
       
Patterns of Ascending Intrauterine Infection     
-Maternal Inflammatory Response     
 Acute 
Chorioamnionitis* 
Evidence of intra-amniotic 
inflammation, and but not always 
intra-amniotic infection 
13.3 32.5 9.0 47.1 
 Severe 
Chorioamnionitis* 
Chorioamnion (furthest stage of 
microbial invasion of the amniotic 
cavity) and Confluent 
8.4 17.1 7.2 34.4 






 Chorionic Plate 
Vasculitis* 
 3.6 9.4 1.4 23.2 
 Vasculitis of the Cord* Inflammation of umbilical vessels in response to infection 2.2 3.4 1.8 15.1 
 Funisitis* Inflammation of cord substance in response to infection 1.2 1.7 0.9 9.2 
 Intervillositis  2.4 0.0 0.0 2.0 
-Evidence of Meconium      
 Meconium in 
Membranes (macro) 
Macroscopic evidence of meconium 
passage in utero 9.0 6.0 4.5 11.0 
 Meconium-associated 
amnion necrosis 
Cell death in the amnion associated 
with lack of blood supply and 
presence of meconium 
4.5 17.1 5.9 70.1 
 
Meconium-laden 
macrophages in the 
Chorion 
Microscopic evidence of meconium 
passage in utero 6.6 10.3 6.8 34.9 
 
Meconium-laden 
macrophages in the 
Amnion 
Microscopic evidence of meconium 
passage in utero, evidence of fetal 
exposure 
4.6 10.3 5.4 50.0 
       
Other      
-Cord      
 Abnormal Insertion Velamentous, marginal or furcate 13.3 27.4 19.8 16.7 
 Marginal Insertion  6.8 8.6 5.0 4.7 
 Velamentous Insertion  0.9 0.9 0.0 1.1 
 Furcate Insertion  1.4 3.4 0.5 1.8 
 Obstruction  5.4 3.4 1.8 6.1 





 Placenta large  >90th percentile for gestational age 11.2 12.0 4.1 4.3 
  Thick cord Cord diameter >90th percentile 50.2 46.2 41.9 43.7 
 Long cord Cord length >90th percentile  1.1 0.0 0.9 1.4 




Table 4.5 Description of Placental Pathology Clusters by Amsterdam Criteria, Safe Passage Study, 50/50 Split Samples (n=2005 
singleton pregnancies from Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 
    Sample 1 (n=1002) 
  Cluster 1 Cluster 2 Cluster 3 Cluster 4 








Placental Feature Description n=471 n=56 n=226 n=247 
Maternal Vascular Malperfusion       
-Placental Hypoxia       
Small Placenta* <10th percentile for gestational age 28.2 41.1 59.3 46.6 
Thin cord* <10th percentile for gestational age 1.9 7.1 7.1 4.1 
Short cord <10th percentile for gestational age 51.6 37.5 52.2 43.3 
-Infarctions      
Micro-infarcts present*  8.0 23.2 36.3 15.8 
Multiple old infarcts*  1.5 12.5 11.1 4.1 
Multiple recent infarcts*  1.1 12.5 5.8 2.8 
Macroscopic pathological 
infarction 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 
0.2 10.7 4.0 2.4 
Microscopic pathological 
infarction* 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 




-Retroplacental Hemorrhage     
Retroplacental Blood Clot 
(macro) 
Macroscopic evidence that 
bleeding occurred (indicator of 
possible abruption) but clotted 
between the placenta and the wall 
of the uterus 
22.1 75.0 32.7 24.7 
Retromembranous 
bleeding - old 
 2.3 8.9 4.9 4.1 
Retromembranous 
bleeding - recent 
 10.0 26.8 8.4 9.3 
Retroplacental bleeding 
with overlying infarction* 
Bleeding behind the placenta upon 
microscopic evaluation, with 
infarction 




Bleeding behind the placenta upon 
microscopic evaluation, with 
intervillous hemorrhage 
5.9 92.9 6.2 7.7 
Recent intervillous 
hemorrhage* 
Placental hemorrhage involving 
one of the larger veins of the 
villous vascular axis 
4.7 53.6 3.1 6.1 
Indentation (abruption)*  1.3 16.1 5.3 0.4 
Placental abruption 
(macro)* 
Macroscopic evidence of abruption 
(detachment from uterine wall, 
either partial or total) 
1.9 30.4 6.2 2.8 
Placental abruption 
(micro)* 
Microscopic evidence of abruption 
(detachment from uterine wall, 
either partial or total) 




-Villous Development     
Distal Villous Hypoplasia* 
Abnormal development of 
placental villi with an apparent 
increase in intervillous space 
associated with low placental 
weight and growth restriction 
0.6 10.7 21.7 4.9 
Accelerated Maturation* Hypervascularity due to maternal vascular malperfusion 1.6 10.7 6.2 3.2 
Decidual Arteriopathy* 
Abnormal / incomplete remodeling 
of the spiral arteries resulting in 
necrosis 
1.5 21.4 9.7 4.5 
Chorioangiosis (Focal) 
More than 10 terminal villi with 
more than 10 capillaries in several 
areas, with at least 15 vessels in 
occasional villi  
23.0 69.6 31.0 34.4 
      
Vascular Damage     
Chronic Villitis  16.5 10.7 23.0 27.5 
Patchy Villous Edema  17.1 37.5 18.6 32.8 
Nucleated fetal 
erythrocytes (Few) 
 20.1 73.2 59.3 47.8 
Indeterminate 
congested/thrombosed 
chorionic plate vessels 
 6.0 19.6 14.6 13.0 
      
Fetal Vascular Malperfusion     




Avascular villi (Regional)* 
One or more foci of avascular villi 
without an identified large-vessel 
thrombus 
11.6 14.3 33.2 25.1 
Increased perivillous fibrin 
(Patchy)* 
Small amounts of fibrin are 
commonly scattered throughout the 
normal placenta 
4.9 26.8 73.9 35.6 
Increased perivillous fibrin 
(Regional)* 
Diffusely increased amounts of 
perivillous fibrin are a significant 
pathologic finding because may 
impair gas exchange and lead to 
growth restriction, 
oligohydramnious, premature birth 
0.4 1.8 11.1 6.5 
Villous-stromal 
karyorrhexis (Regional)* Precursor to avascular villi 8.9 16.1 26.6 28.3 
Villous-stromal 
karyorrhexis (Diffuse)* 
 0.2 0.0 3.1 0.8 
In utero Underperfusion 4 features present 0.4 19.6 50.9 13.4 
      
Delayed Villous Maturation     
Abnormal Maturation 
(other) 
Also called also called defective 
villous maturation and distal 
villous immaturity. Includes 
delayed, variable, arrest.  
16.1 16.1 13.3 18.6 




Patterns of Ascending Intrauterine Infection     
-Maternal Inflammatory Response     
Acute Chorio-amnionitis* 
Evidence of intra-amniotic 
inflammation, and but not always 
intra-amniotic infection 
7.0 39.3 13.3 49.0 
Severe Chorio-amnionitis* 
Chorioamnion (furthest stage of 
microbial invasion of the amniotic 
cavity) and Confluent 
4.4 19.6 12.4 34.0 
-Fetal Inlammatory Response     
Chorionic Plate Vasculitis*  1.5 10.7 2.7 21.5 
Vasculitis of the Cord* Inflammation of umbilical vessels in response to infection 1.7 1.8 2.7 15.0 
Funisitis* Inflammation of cord substance in response to infection 0.6 0.0 2.2 7.3 
Intervillositis  1.7 0.0 0.9 4.9 
-Evidence of Meconium     
Meconium in Membranes 
(macro) 
Macroscopic evidence of 
meconium passage in utero 8.5 5.4 4.9 15.4 
Meconium-associated 
amnion necrosis 
Cell death in the amnion associated 
with lack of blood supply and 
presence of meconium 
2.4 16.1 8.4 57.9 
Meconium-laden 
macrophages in the 
Decidua 
Microscopic evidence of 





macrophages in the 
Chorion 
Microscopic evidence of 
meconium passage in utero 5.4 10.7 6.1 35.2 
Meconium-laden 
macrophages in the 
Amnion 
Microscopic evidence of 
meconium passage in utero, 
evidence of fetal exposure 
3.7 10.7 8.9 34.8 
      
Other      
-Cord      
Abnormal Insertion Velamentous, marginal or furcate 10.0 32.1 23.9 19.0 
Marginal Insertion  6.0 16.1 7.1 4.5 
Velamentous Insertion  0.2 0.0 0.0 1.6 
Furcate Insertion  1.7 1.8 1.3 2.0 
Obstruction  6.2 5.4 3.5 4.1 
-Size      
Placenta large  >90th percentile for gestational age 13.6 16.1 3.5 4.5 
Thick cord Cord diameter >90th percentile 54.6 50 39.8 40.1 







    Sample 2 (n=1003) 
  Cluster 1 Cluster 2 Cluster 3 Cluster 4 








Placental Feature Description n=494 n=65 n=229 n=215 
Maternal Vascular Malperfusion      
-Placental Hypoxia      
Small Placenta* <10th percentile for gestational age 32.4 49.2 61.6 44.2 
Thin cord* <10th percentile for gestational age 4.9 0.0 0.9 3.3 
Short cord <10th percentile for gestational age 54.9 36.9 38.0 46.5 
-Infarctions      
Micro-infarcts present*  6.9 26.2 30.6 15.8 
Multiple old infarcts*  2.8 16.9 7.0 4.7 
Multiple recent infarcts*  1.2 7.7 3.9 2.3 
Macroscopic pathological 
infarction 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 
1.5 13.9 1.8 0.5 
Microscopic pathological 
infarction* 
Localized area of coagulative 
necrosis in the parenchyma due to a 
compromised blood supply 




-Retroplacental Hemorrhage     
Retroplacental Blood Clot 
(macro) 
Macroscopic evidence that 
bleeding occurred (indicator of 
possible abruption) but clotted 
between the placenta and the wall 
of the uterus 
23.4 73.9 31.9 19.5 
Retromembranous 
bleeding - old 
 2.4 4.6 3.5 6.5 
Retromembranous 
bleeding - recent 
 9.5 18.5 10.5 10.2 
Retroplacental bleeding 
with overlying infarction* 
Bleeding behind the placenta upon 
microscopic evaluation, with 
infarction 




Bleeding behind the placenta upon 
microscopic evaluation, with 
intervillous hemorrhage 
4.9 95.4 10.5 8.4 
Recent intervillous 
hemorrhage* 
Placental hemorrhage involving 
one of the larger veins of the 
villous vascular axis 
5.3 35.4 7.4 6.5 
Indentation (abruption)*  2.5 15.4 3.1 1.9 
Placental abruption 
(macro)* 
Macroscopic evidence of abruption 
(detachment from uterine wall, 
either partial or total) 
3.9 21.5 3.5 2.3 
Placental abruption 
(micro)* 
Microscopic evidence of abruption 
(detachment from uterine wall, 
either partial or total) 




-Villous Development     
Distal Villous Hypoplasia* 
Abnormal development of 
placental villi with an apparent 
increase in intervillous space 
associated with low placental 
weight and growth restriction 
2.0 7.7 15.3 6.1 
Accelerated Maturation* Hypervascularity due to maternal vascular malperfusion 4.6 12.3 6.1 7.0 
Decidual Arteriopathy* 
Abnormal / incomplete remodeling 
of the spiral arteries resulting in 
necrosis 
3.1 20.0 6.6 6.1 
Chorioangiosis (Focal) 
More than 10 terminal villi with 
more than 10 capillaries in several 
areas, with at least 15 vessels in 
occasional villi  
24.5 47.7 38.4 40.9 
      
Vascular Damage     
Chronic Villitis  20.7 12.3 18.3 15.8 
Patchy Villous Edema  18.4 20.0 28.0 19.5 
Nucleated fetal 
erythrocytes (Few) 
 27.3 69.2 61.1 45.1 
Indeterminate 
congested/thrombosed 
chorionic plate vessels 
 6.8 9.2 15.3 8.4 




Fetal Vascular Malperfusion     
Thrombosis*  0.8 3.1 1.3 0.9 
Avascular villi (Regional)* 
One or more foci of avascular villi 
without an identified large-vessel 
thrombus 
17.8 23.1 24.5 13.0 
Increased perivillous fibrin 
(Patchy)* 
Small amounts of fibrin are 
commonly scattered throughout the 
normal placenta 
11.3 30.8 57.2 35.8 
Increased perivillous fibrin 
(Regional)* 
Diffusely increased amounts of 
perivillous fibrin are a significant 
pathologic finding because may 
impair gas exchange and lead to 
growth restriction, 
oligohydramnious, premature birth 
3.4 1.5 8.3 4.2 
Villous-stromal 
karyorrhexis (Regional)* Precursor to avascular villi 8.9 26.2 29.7 20.9 
Villous-stromal 
karyorrhexis (Diffuse)* 
 1.2 1.5 1.3 0.0 
In utero Underperfusion 4 features present 3.9 20.0 34.1 19.1 
      
Delayed Villous Maturation     
Abnormal Maturation 
(other) 
Also called also called defective 
villous maturation and distal 
villous immaturity. Includes 
delayed, variable, arrest.  
13.7 3.1 13.1 16.0 




Patterns of Ascending Intrauterine Infection     
-Maternal Inflammatory Response     
Acute Chorio-amnionitis* 
Evidence of intra-amniotic 
inflammation, and but not always 
intra-amniotic infection 
10.5 27.7 18.3 51.6 
Severe Chorio-amnionitis* 
Chorioamnion (furthest stage of 
microbial invasion of the amniotic 
cavity) and Confluent 
4.7 13.8 12.7 40.5 
-Fetal Inlammatory Response     
Chorionic Plate Vasculitis*  3.7 4.6 3.1 28.4 
Vasculitis of the Cord* Inflammation of umbilical vessels in response to infection 1.4 4.6 1.3 17.2 
Funisitis* Inflammation of cord substance in response to infection 1.0 1.5 0.9 11.6 
Intervillositis  2.8 0.0 0.0 0.9 
-Evidence of Meconium     
Meconium in Membranes 
(macro) 
Macroscopic evidence of 
meconium passage in utero 10.8 4.6 3.9 8.8 
Meconium-associated 
amnion necrosis 
Cell death in the amnion associated 
with lack of blood supply and 
presence of meconium 
6.6 13.9 3.5 77.7 
Meconium-laden 
macrophages in the 
Decidua 
Microscopic evidence of 





macrophages in the 
Chorion 
Microscopic evidence of 
meconium passage in utero 6.3 9.2 1.3 41.9 
Meconium-laden 
macrophages in the 
Amnion 
Microscopic evidence of 
meconium passage in utero, 
evidence of fetal exposure 
11.2 7.7 7.4 44.7 
Other      
-Cord      
Abnormal Insertion Velamentous, marginal or furcate 14.5 23.1 14.4 12.6 
Marginal Insertion  7.1 3.1 3.5 7.4 
Velamentous Insertion  1.6 0.0 0.0 1.9 
Furcate Insertion  1.4 4.6 0.9 0.5 
Obstruction  4.7 3.1 4.8 7.0 
-Size      
Placenta large  >90th percentile for gestational age 13.0 10.8 1.3 5.6 
Thick cord Cord diameter >90th percentile 48.0 50.8 54.6 39.1 
Long cord Cord length >90th percentile  0.8 0.0 0.9 1.9 
Light gray shaded cells represent the cluster with highest proportion of a given placental feature, when in agreement with the 
findings of the clusters used in the main analysis (overall sample). 
Dark gray shaded cells represent the cluster with the highest proportion of a given placental feature, when in disagreement with 





Table 4.6 Pregnancy Complications and Neonatal Outcomes by Placental Pathology 
Clusters, Safe Passage Study (n=2005 singleton pregnancies from Northern Plains, U.S., and 
Western Cape, South Africa, 2007-2015) 









Overall n=1222 n=117 n=222 n=444 
SGA (BW <10th percentile WHO) 17.5 23.1 32.0 23.2 
HC <10th Percentile WHO 5.8 9.6 10.7 9.9 
BW and HC <10th Percentile 3.7 6.4 9.7 3.9 
Preterm <37 weeks (all) 12.4 27.4 7.7 11.3 
Preterm <37 weeks (live birth only) 11.6 21.5 7.7 10.9 
Preterm <34 weeks (all) 3.0 14.5 1.8 2.0 
Preterm <34 weeks (live birth only) 2.3 7.5 1.8 1.8 
Stillbirth 1.2 8.6 0.0 0.7 
Stillbirth, infection 2/13 3/10 0/0 1/3 
Stillbirth, cord 5/13 1/10 0/0 1/3 
Stillbirth, placental underperfusion 6/13 6/10 0/0 1/3 
Infant Death During First Year 0.9 0.9 0.0 0.7 
     
Western Cape, South Africa, only n=595 n=106 n=200 n=333 
Gestational Diabetes 1.4 1.0 0.5 0.3 
Preeclampsia  2.4 3.8 2.5 2.7 
Medically Indicated Preterm  4.3 8.4 3.7 3.0 
1 Min Apgar <7  3.0 5.5 2.6 4.6 
Resuscitated at Birth  5.8 8.3 2.0 8.5 
NICU Admitted  7.9 14.4 5.2 5.4 
     
Northern Plains, U.S., only n=627 n=11 n=22 n=111 
Gestational Diabetes  6.2 0.0 4.6 7.4 
Preeclampsia  2.6 10.0 4.8 1.8 
Medically Indicated Preterm  3.9 18.2 0.0 0.9 
1 Min Apgar <7  7.4 10.0 13.6 14.4 
Resuscitated at Birth 14.9 20.0 27.3 23.4 
NICU Admitted  9.5 10.0 0.0 14.7 
BW birthweight, HC head circumference, Min minute, NICU neonatal intensive care unit, SGA 
small-for-gestational age, U.S. United States, WHO World Health Organization 





Table 4.7 Models for Select Adverse Outcomes by Weight Percentile at Birth and/or 
Placental Pathology Clusters, Safe Passage Study (n=2005 singleton pregnancies from 
Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 







Head Circumference <10th Percentile    
 SGA WHO 0.714 0.1452 853.206 
 Cluster 0.575 0.0157 949.399 
 SGA + Cluster 0.751 0.1528 840.425 
 SGA + Cluster + Interaction Term 0.769 0.1758 820 
 All WHO Percentile Categories 0.803 0.2037 794.416 
 All WHO Percentile Categories + Cluster 0.809 0.2075 784.914 
 
All WHO Percentile Categories + Cluster + 




 SGA WHO 0.695 0.0747 261.74 
 Cluster 0.717 0.1031 252.902 
 SGA + Cluster 0.838 0.183 230.333 
 SGA + Cluster + Interaction Term 0.83 0.1889 230.399 
 All WHO Percentile Categories 0.763 0.0997 251.058 
 All WHO Percentile Categories + Cluster 0.874 0.2087 219.678 
 
All WHO Percentile Categories + Cluster + 
Interaction Term 0.863 0.2238 241.08 
Preterm    
 SGA WHO 0.527 0.0038 1499.354 
 Cluster 0.566 0.0232 1473.144 
 SGA + Cluster 0.579 0.0277 1464.852 
 SGA + Cluster + Interaction Term 0.579 0.0346 1453.377 
 All WHO Percentile Categories 0.58 0.0184 1467.333 
 All WHO Percentile Categories + Cluster 0.616 0.043 1432.178 
 
All WHO Percentile Categories + Cluster + 
Interaction Term NC NC NC 
Infant Death    
 SGA WHO 0.53 0.003 172.592 
 Cluster 0.577 0.011 170.922 
 SGA + Cluster 0.576 0.0155 169.171 
 SGA + Cluster + Interaction Term 0.657 0.0307 170.03 
 All WHO Percentile Categories 0.784 0.0815 158.31 
 All WHO Percentile Categories + Cluster 0.816 0.1017 153.322 
 
All WHO Percentile Categories + Cluster + 
Interaction Term 0.834 0.1724 175.046 




Table 4.8 Models for Select Adverse Outcomes by Weight Percentile at Birth and/or 
Macroscopic Flag for Placental Pathology Clusters, Safe Passage Study (n=2005 singleton 
pregnancies from Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 




Head Circumference <10th Percentile    
 Macro Flag 0.543 0.009 958.951 
 SGA + Macro Flag 0.72 0.1472 849.058 
 SGA + Macro Flag + Interaction Term 0.72 0.1478 847.507 
 All WHO Percentile Categories + Macro Flag 0.803 0.2044 791.404 
 All WHO Percentile Categories + Macro Flag 
+ Interaction Term 
0.806 0.2032 791.709 
Stillbirth    
 Macro Flag 0.738 0.119 250.144 
 SGA + Macro Flag 0.817 0.1675 235.881 
 SGA + Macro Flag + Interaction Term 0.817 0.1738 234.404 
 All WHO Percentile Categories + Macro Flag 0.825 0.1809 228.504 
 All WHO Percentile Categories + Macro Flag 
+ Interaction Term 0.861 0.2094 228.026 
Preterm    
 Macro Flag 0.546 0.012 1490.844 
 SGA + Macro Flag 0.551 0.0141 1485.003 
 SGA + Macro Flag + Interaction Term 0.551 0.0175 1479.586 
 All WHO Percentile Categories + Macro Flag 0.591 0.0268 1455.045 
 All WHO Percentile Categories + Macro Flag 
+ Interaction Term 
0.609 0.0395 1436.755 
Infant Death    
 Macro Flag 0.547 0.0036 172.701 
 SGA + Macro Flag 0.586 0.0078 171.054 
 SGA + Macro Flag + Interaction Term 0.589 0.0092 171.592 
 All WHO Percentile Categories + Macro Flag 0.8 0.0876 156.476 
 
All WHO Percentile Categories + Macro Flag 
+ Interaction Term 0.776 0.0853 167.702 




Table 4.9 Possible Risk Factors for Placental Pathology Clusters, Safe Passage Study (n=2005 singleton pregnancies from 
Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 
   Cluster 1 Cluster 2 Cluster 3 Cluster 4 
  Statistic Normal Maternal Vascular Malperfusion 
Fetal Vascular 
Malperfusion Inflammation 
South Africa  n=595 n=106 n=200 n=333 
Hypertension Prior to Pregnancy % 4.4 3.8 4.5 2.1 
Parity median±std 1.0±1.1 1.0±1.1 1.0±1.1 1.0±1.1 
Gravidity median±std 2.0±1.2 2.0±1.2 2.0±1.3 2.0±1.3 
Prepregnancy BMI*      
  Underweight (<18.5) % 15.6 20.0 18.8 19.8 
  Normal (18.5-24.9) % 46.6 48.3 40.6 48.4 
  Overweight (25.0-29.9) % 21.2 16.7 17.7 14.7 
  Obesity (≥30.0) % 16.6 15.0 22.9 17.2 
Pregnancy BMI      
  Underweight (<18.5) % 6.7 8.6 8.1 11.9 
  Normal (18.5-24.9) % 49.8 58.1 49.8 52.6 
  Overweight (25.0-29.9) % 22.3 13.3 19.8 17.9 
  Obesity (≥30.0) % 21.1 20.0 22.3 17.6 
Moderate-High Continuous Smoking in Pregnancy % 41.5 40.6 46.0 47.5 
Environmental Smoking Exposure % 96.4 97.1 95.3 95.7 
Continuous Alcohol Use in Pregnancy % 36.8 43.4 38.0 33.9 
Marijuana Use in Pregnancy % 7.6 5.8 7.5 10.8 
Meth Use in Pregnancy % 6.6 2.9 1.5 4.8 
Fertility Treatment % 0.0 0.0 0.0 0.0 
Vaginal Bleeding in Pregnancy % 7.8 12.8 4.1 5.3 
Hospitalization for Vaginal Bleeding % 4.7 6.9 4.1 5.3 




Any Infection in Pregnancy % 31.8 34.3 36.0 29.7 
Oligohydramnios  % 0.7 2.9 3.1 1.2 
Northern Plains  n=627 n=11 n=22 n=111 
Hypertension Prior to Pregnancy %     
Parity median±std 1.0±1.1 0.0±0.9 0.5±1.0 1.0±1.3 
Gravidity median±std 2.0±1.5 1.0±1.2 2.0±1.4 2.0±1.6 
Prepregnancy BMI      
  Underweight (<18.5) % 3.6 0.0 5.0 1.9 
  Normal (18.5-24.9) % 49.0 44.4 60.0 49.1 
  Overweight (25.0-29.9) % 22.4 33.3 25.0 25.5 
  Obesity (≥30.0) % 25.1 22.2 10.0 23.6 
Pregnancy BMI      
  Underweight (<18.5) % 1.0 0.0 0.0 0.0 
  Normal (18.5-24.9) % 39.7 33.3 60.0 39.8 
  Overweight (25.0-29.9) % 29.7 44.4 30.0 32.4 
  Obesity (≥30.0) % 29.6 22.2 10.0 27.8 
Moderate-High Continuous Smoking in Pregnancy % 5.1 9.1 0.0 4.5 
Environmental Smoking Exposure % 27.3 30.0 22.7 26.1 
Continuous Alcohol Use in Pregnancy % 39.9 45.5 63.6 47.8 
Marijuana Use in Pregnancy % 4.7 0.0 0.0 5.5 
Meth Use in Pregnancy % 1.0 0.0 0.0 0.0 
Fertility Treatment % 6.1 0.0 0.0 3.6 
Vaginal Bleeding in Pregnancy % 11.8 9.1 0.0 12.6 
Hospitalization for Vaginal Bleeding % 7.7 9.1 0.0 6.3 
Urinary Tract Infection in Pregnancy % 18.0 18.2 4.6 18.9 
Any Infection in Pregnancy % 50.6 54.6 50.0 61.3 
Oligohydramnios  % 3.4 18.2 0.0 0.9 





Table 4.10 Abnormal Obstetric Doppler Ultrasound Metrics by Placental Pathology Clusters, Safe Passage Study (n=2005 
singleton pregnancies from Northern Plains, U.S., and Western Cape, South Africa, 2007-2015) 
  Cluster 1 Cluster 2 Cluster 3 Cluster 4 







South Africa n=595 n=106 n=200 n=333 
Umbilical Artery PI High 4.8 3.2 9.0 6.3 
Umbilical Artery RI High 5.7 4.4 6.6 4.3 
Umbilical Artery AEDF 0.5 1.0 1.0 0.3 
Umbilical Artery SD Ratio 0.0 0.0 0.0 0.0 
Middle Cerebral Artery PI Low 11.9 14.9 8.8 10.8 
Uterine Artery PI High 12.7 8.6 13.3 8.9 
Ductus Venous PI High* 2.9 6.3 2.4 3.6 
Ductus Venous Awave 0.6 1.1 0.6 0.6 
Estimated Fetal Weight <10th Percentile 9.7 8.2 10.3 14.2 
Northern Plains, U.S. n=627 n=11 n=22 n=111 
Umbilical Artery PI High 4.1 9.1 0.0 3.1 
Umbilical Artery RI High 2.6 11.1 0.0 1.1 
Umbilical Artery AEDF 0.4 18.2 0.0 0.0 
Umbilical Artery SD Ratio 24.1 0.0 0.0 0.0 
Middle Cerebral Artery PI Low 17.4 42.9 15.0 13.6 
Uterine Artery PI High 6.6 0.0 5.0 4.6 
Ductus Venous PI High* 12.4 0.0 28.6 14.6 
Ductus Venous Awave* 0.0 0.0 0.0 0.0 
Estimated Fetal Weight <10th Percentile 10.8 27.3 0.0 6.5 







Figure 4.1 Dendrogram 
 






















































































Figure 4.4 Variable Importance for Macroscopic Features Based on Random Forest Model 
 
 












CHAPTER FIVE: Final Comments 
SUMMARY OF FINDINGS 
 The overarching aim of this dissertation was to apply novel analytic strategies 
with close ties to causal inference and statistical learning theory to gain new insights into 
well-studied areas of perinatal epidemiology.  
 
Study 1: Short Interpregnancy Intervals and Preterm Birth Risk: An Exploration of 
Confounding in Three Populations 
 In Study 1, we explored whether the association between short interpregnancy 
intervals (i.e., timeframe from the end of one pregnancy to the start of the next) and 
increased risk of preterm birth may be due to residual confounding by applying 
propensity scores. We found some degree of non-overlap in the propensity scores of 
women with <6 months intervals compared to those with 18-23 months intervals in all 
three populations under study. This issue may have been difficult to identify without 
comprehensive confounder data and if we had used traditional methods such as 
regression adjustment. These findings suggest that the combination of factors that 
influence the length of time between pregnancies is complex and perhaps to some degree 
deterministic based on contextual and biological factors. Findings of causal 
interpregnancy interval research may be generalizable to only a subset of women with 





Study 2: Timing and Amount of Gestational Weight Gain and Risks for Small-and Large-
for-Gestational Age Infants among Women with Prepregnancy Obesity 
 In Study 2, we examined the relative importance of timing and degree of 
gestational weight gain in relation to infant size at birth among women with obesity. We 
operationalized serial antenatal weight measurements as above, below, or within the 
current recommended ranges for U.S. pregnancies by timing during pregnancy. We used 
group based trajectory models to operationalize weight gain in the second and third 
trimesters. Our findings supported the current clinical guidelines, except for women with 
class III obesity. Among women with class III obesity, low gain in the second and third 
trimesters was associated with decreased risk of having a large-for-gestational age (LGA) 
infant, while not increasing small-for-gestational age (SGA) risk. Our findings are in 
agreement with several recent studies using other methodologies, suggesting that lower 
than currently recommended gain might be beneficial for women with higher class 
obesity, especially for LGA reduction.139, 143, 166, 167  
 
Study 3: Placental Pathology Clusters, Growth, and Neonatal Outcomes  
 In Study 3, we used hierarchical clustering to explore latent clusters of placental 
pathology and investigated whether the full spectrum of infant weight percentiles (not 
strictly SGA), in addition to the placental clusters, may be beneficial to identify high risk 
pregnancies. We identified one cluster with low prevalence of abnormalities and three 
abnormal clusters that mapped well to the expert consensus-based Amsterdam criteria: 




The clusters were weakly-to-moderately associated with certain antenatal risk factors, 
pregnancy complications, and neonatal outcomes. The full spectrum of birthweight 
percentiles plus the placental clusters was better able to explain the variability for select 
adverse outcomes, compared to using SGA only. Our study serves as proof-of-concept of 
the potential of data mining tools to aid epidemiologists in the etiologic study of elusive 
pregnancy conditions like fetal growth restriction. In addition, our study highlights the 
potential benefit of including placental data, even if only crude macroscopic observations 
are available. The placenta plays a vital role in pregnancy, yet there is still much to learn 
about how studying the placenta may improve our understanding of the etiology of 
suboptimal growth and other adverse neonatal outcomes.  
 In sum, these studies support that the application of novel analytic methods to 
high-dimensional datasets may expand our understanding of certain causal questions, 
even ones that have been broached before. Although, as seen in Study 2, such research 
may not always yield novel insights.  
 
APPLICATION OF NOVEL METHODS 
While the goal of this dissertation was to apply novel methods, one should note 
that methods themselves should not drive one’s research. As discussed further below, 
novel methodologies do not allow us to evade the basic assumptions required for valid 
inference. There is no need to overcomplicate an analysis with a novel methodology, just 
for the sake of including it. In our studies, while some components of the work involved 




Novel and traditional methods may be employed in tandem and complement one another. 
Based on the question at hand, one should choose the methodology that will best enable a 
valid answer.  
 
ASSUMPTIONS NECESSARY FOR VALID INFERENCE 
No matter what methods are applied, one cannot escape the assumptions needed 
to make valid inferences. These assumptions include but are not limited to: 
exchangeability,61 consistency,287, 288 positivity,288, 289 no misclassification,290 and no 
interference.291 Each one of our studies had potential violations of one or more of these 
assumptions, which calls into question the validity of the inferences made. This is not to 
say that these studies do not add to the literature in their respective areas. However, it is 
important to keep these limitations in mind when interpreting our results, particularly to 
avoid over-interpretation of the findings, relative to other studies, simply because our 
studies employed novel methodologies.  
 
Study 1: Positivity and Exchangeability 
Positivity means that for every combination of observed confounders there are 
individuals in both the index and reference exposure groups.289 If positivity is violated 
(for instance, if there are only individuals in the index group with certain characteristics), 
we cannot know with certainty if the observed association between the exposure and 
outcome is attributed to the index state itself or whether it is due to the effect of the 




partnered women younger than 40 years who become pregnant following in vitro 
fertilization almost certainly will not have interpregnancy intervals of <6 months because 
such treatment is usually not clinically advised unless the couple has attempted natural 
conception for 6 months.292 Positivity violations can also be random, related to the 
sampling of participants in the study. For instance, by chance there could be no women in 
the observed data with prior stillbirth or neonatal death with interpregnancy intervals of 
18-23 months. The positivity assumption is sometimes overlooked in epidemiologic 
research.293 In Study 1, propensity scores enabled us to see positivity assumption 
violations. Specifically, we could observe non-overlapping regions of the propensity 
scores of women in the index group (<6 months) compared to the reference group (18-23 
months). In such instances, the combination of characteristics among women with very 
high propensity scores only existed among women with <6 months intervals. Similarly, 
the characteristics among women with very low propensity scores only existed among 
women with 18-23 months intervals. That said, while we could see these violations, the 
propensity scores themselves did not allow us to overcome this issue. Since there was no 
appropriate comparison group for these women in our data, we could not make causal 
inference about the effect of short intervals among these women. Ultimately, we excluded 
them from the analysis, leaving us with a much smaller sample. Even among women 
where there was some overlap in the propensity scores, sometimes the overlap was not 
great, leading to extreme weights, which we also trimmed. In the final sample, several 
covariates remained imbalanced between the index and reference groups, in part due to 




whether exchangeability had actually been achieved, even in the propensity score 
trimmed and weighted samples. Exchangeability refers to the assumption that the 
observed outcomes among our reference group can stand in for what would have 
happened to our index group had they, contrary to fact, instead had the reference 
exposure.61 In other words, the observed individuals within our reference group are 
exchangeable with those in our index group, for the purpose of making causal 
comparisons. Since we cannot rule out exchangeability violations in our Study 1, one 
should not over-interpret our propensity score-adjusted estimates, as they may be biased 
by residual confounding from observed and/or unobserved factors. In practice, there will 
often be a tradeoff between avoiding positivity violations and confounding bias.289 For 
instance, one may avoid positivity violations by collapsing the two highest education 
categories so that there are now both index and reference individuals in the newly-created 
collapsed highest education category, but one may incur some degree of confounding 
because the collapsed groups are not strictly exchangeable. The bias produced should be 
small if the factors are not strong confounders.289 In our Study 1, we aimed to reduce our 
propensity score model to a more restricted set of variables that appeared to be 
confounding factors and were not extremely rare (to avoid positivity violations by 
chance). Still, the non-overlap in propensity score distributions remained. Our study 
serves as warning of potential positivity and exchangeability violations in interpregnancy 
research. Future researchers would be prudent to interrogate such challenges to causal 





Study 2: Consistency and Interference 
Consistency means that an individual's observed outcome given their observed 
exposure group (index or reference) is the same outcome that would occur if one could 
directly manipulate their exposure assignment and set it to the exposure group they 
happened to have.288, 294 This assumption is usually easily met in randomized controlled 
trials but can be much harder for observational research. Another way of thinking about 
consistency, particularly in the context of observational studies, is that the various ways 
to achieve a given exposure status should correspond with the same potential outcomes. 
In this way, the consistency assumption steers us away from ambiguously defined 
exposures.287 For instance, an exposure status of “smoker” may suffer from consistency 
issues because some individuals may smoke only one cigarette occasionally, while others 
may smoke multiple packs a day. The potential outcomes under these two different 
scenarios are likely quite different. Still, even when there is a precise definition for the 
exposure, consistency is not guaranteed. Consistency is especially difficult when the 
exposure under investigation is a biological factor that cannot be directly manipulated.287 
In the instance of gestational weight gain, as we investigated in Study 2, we cannot know 
with certainty if the outcomes we observed for an individual woman would be the same if 
we had intervened at the onset of the pregnancy to set her weight gain to follow that 
particular trajectory. How would such an intervention occur? A change to clinical weight 
gain recommendations? Assignment to a specific diet and exercise routine? Each path to 
achieve a certain trajectory may lead to a different potential outcome. Consistency is a 




It is not to say that there is no value gained from observational research in this area. 
However, it is crucial that the field also draws upon evidence from actual intervention 
studies to inform how we ultimately take action to improve health outcomes at the 
population level. This is because it is likely that the “effect” we observed in our 
observational study will not directly translate what we would observe under a well-
defined intervention.195  
It is also important to note that provider experience with past patients may 
influence their recommendations for future patients. For instance, if a provider had a 
prior patient with class III obesity that developed gestational diabetes and later went on to 
have an LGA infant, they may recommend that future patients with the same profile not 
gain as much weight in an effort to prevent future LGA outcomes. Such an intervention 
may be good clinical practice but it results in interference of causal inference in 
observational study. Interference occurs when the treatment or outcome of one individual 
is affected by the outcome of another individual.291 Causal inference in the presence of 
interference is possible, but requires special analytic techniques not employed in our 
Study 2. Thus, potential interference is another reason to interpret our findings with 
caution.  
 
Study 3: Selection, Misclassification, and Validation 
Our Study 3 aimed to indirectly address some important unanswered questions in 
perinatal epidemiology, such as What explains high mortality in small babies born at 
term?295 Despite a wealth of research on small infants, we are no closer to understanding 




outcomes. Placental studies may bring some clarity, including our Study 3 despite it 
being more exploratory in nature. However, potential obstacles to valid inference remain. 
Our approach for identifying placental clusters was highly data-driven. Thus, validation 
of our findings in other settings is crucial.230 As reported in psychology and nutrition 
research, replication of cluster analysis can be notoriously challenging.296, 297 Often 
published studies lack sufficient details for replication.296, 297 In addition, factors like 
sampling procedures and classification accuracy may influence the patterns detected by 
machine learning algorithms.298 Our Study 3 drew upon a database where participants 
were flagged for placental collection early in pregnancy, and so contained a proportion of 
“normal” deliveries. For most clinically-based databases, this will not be the case, as 
detailed placental examination will only occur if further inspection is warranted based on 
the conditions leading up to the delivery. In addition, the pathologists completing the 
microscopic evaluations in our study were blinded to the pregnancy outcome, which we 
assume minimized bias in reporting of placental features. In contrast, such blinding 
would be challenging to guarantee in most clinical settings. Lastly, missing data and 
underdiagnoses of comorbidities in our South African sample may have affected cluster 
identification and observed associations. Taken together, all of these considerations may 
make it difficult to replicate our findings in clinical databases—the source of most 
placental studies. Still, it would be important to attempt such replication, as we do not 





COMPARISON TO OTHER STUDIES 
 Any differences when comparing our study findings with those obtained from 
other sources should not be attributed entirely to the novel methodology alone, given 
there will likely be other differences in the design and conduct of the studies. For 
instance, in Study 1, we used data from a prospective pregnancy cohort which collected a 
much wider array of covariates compared to other U.S.-based interpregnancy interval 
studies which have tended to draw upon vital records-based databases. Vital records, in 
comparison, contain more limited covariate data. Even when the types of available data 
overlap (e.g., smoking status), the data quality from our study may be better than the vital 
records-based sources since our data were collected via standardized questionnaire early 
in pregnancy, rather than after delivery. The accuracy of the reported demographic 
factors, reproductive history, and clinical information filed on birth and fetal death 
certificates has been called into question.299 Confounders that are mismeasured 
independently and non-differentially with respect to the exposure and/or outcome are 
only partially controlled in adjusted estimates.300 Post-hoc adjustment for covariate 
misclassification in vital records is not simple, as what is collected on the birth certificate 
has changed over time and how the information is ascertained may vary from state-to-
state.301 One other potential issue is sampling. The women who comprise the Safe 
Passage Study (used in Studies 1 and 3) are not representative of all women. We 
observed different distributions of interpregnancy intervals, preterm birth risk, and 
confounding structures in each of the three populations in our Study 1 (i.e., American 




South Africa). These populations were targeted for the Safe Passage study’s original aim, 
given their historically higher rates of prenatal alcohol and tobacco use as well as higher 
rates of SIDS.47 Certain minority racial groups, such as women who identify as Black or 
Asian, were not sampled as part of Safe Passage. One benefit of using vital records, over 
cohort data, is that such sources are known for their completeness of sampling relative to 
the general population. All this to say, each study has its own set of parameters 
(population, intervention, comparison, outcome, time period, study design)—any of 
which may explain differences in observations between studies.  
 
CONCLUSION 
 No matter the methods employed, most importantly, one’s research should 
address a well-defined and important research question using a thoughtful and 
appropriate design.6 The complexities described above may affect one’s ability to make 
valid and reliable inferences. While the examples discussed are from particular studies, 
these issues likely exist to some extent in all observational studies presented in (and 
outside of) this dissertation work. Fortunately, no study stands on its own. One must 
weigh the strength of the evidence based on all available literature, with full 
consideration of the strengths and limitations of each study, before making any definitive 
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